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Abstract	  
The	  focus	  of	  my	  PhD	  has	  been	  two-­‐fold:	  	  
First,	   to	   improve	   the	   understanding	   of	   the	   biology	   behind	   a	   well-­‐known	  
cardiovascular	  disease	  (CVD)	  risk	  factor	  -­‐	  left	  ventricular	  mass,	  by	  identifying	  novel	  
genetic	   loci	  associated	  with	  this	  risk	  factor.	  A	  large-­‐scale	  association	  meta-­‐analysis	  
in	   over	   10,000	   individuals	   identified	   four	   novel	   loci	   associated	   with	  
electrocardiographically-­‐determined	  left	  ventricular	  mass.	  	  
	  
Second,	   to	   explore	   the	   application	   of	   known	   genetic	   determinants	   of	   the	   main	  
blood	   lipid	  fractions,	   the	   latter	  being	  well-­‐known	  CVD	  risk	  factors	  and	  therapeutic	  
targets.	   I	  assess	   the	  use	  of	  genetic	  variants	  associated	  with	  total	  cholesterol,	   low-­‐
density	  lipoprotein-­‐cholesterol	  (LDL-­‐C),	  high-­‐density	  lipoprotein-­‐cholesterol	  (HDL-­‐C)	  
and	  triglycerides	  for	  discriminating	  healthy	  individuals	  from	  those	  that	  have	  a	  high	  
absolute	   risk	  of	  CVD,	   those	   that	   require	   lipid-­‐lowering	  medication,	  and	  those	   that	  
have	  a	  coronary	  event.	  The	  lipid	  genetic	  variants	  showed	  poor	  discriminatory	  ability	  
for	   all	   three	  outcomes	  and	  provided	  no	   improvement	  over	   the	  widely-­‐used,	   non-­‐
genetic	  Framingham	  10	  year	  CVD	  risk	  score.	  Lipid-­‐associated	  genetic	  variants	  were	  
also	   used	   to	   generate	   genetic	   risk	   score	   instruments	   for	   LDL-­‐C,	   HDL-­‐C	   and	  
triglycerides,	   which	   were	   applied	   in	   a	   Mendelian	   randomisation	   analysis	   to	  
determine	   their	   causal	   relationship	   with	   carotid-­‐intima	   media	   thickness	   (CIMT).	  
CIMT	  has	  been	  a	  widely	  used	  surrogate	  outcome	  measure	   in	  clinical	   trials	  of	  CVD	  
drugs.	  LDL-­‐C-­‐lowering	  drugs	  have	  shown	  to	  reduce	  CIMT	  progression	  and	  CHD	  risk	  
in	   clinical	   trials.	  However,	   the	  extent	  of	   any	   causal	   association	  between	  HDL-­‐C	  or	  
triglycerides	  and	  CIMT	  is	  unclear.	  The	  results	  from	  this	  MR	  analysis	  support	  a	  casual	  
relationship	  with	   LDL-­‐C,	  but	  not	  with	  HDL-­‐C	  and	   triglycerides,	  which	  may	   indicate	  
that	  CIMT	  is	  a	  less	  useful	  surrogate	  end	  point	  in	  clinical	  trials	  of	  primarily	  HDL-­‐C	  or	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1 Introduction	  
1.1 Background	  
Cardiovascular	   disease	   (CVD)	   is	   the	   main	   cause	   of	   death	   in	   the	   UK.	   The	   World	  
Health	  Organisation	   (WHO)	  has	  predicted	   that	  23	  million	  people	  per	   year	  will	   die	  
from	  CVD	  globally	  by	  2030	  (World	  Health	  Organisation	  2012).	  CVD	  encompasses	  a	  
wide	   range	   of	   Mendelian	   and	   complex	   disorders,	   including	   diseases	   of	   the	  
vasculature,	  diseases	  of	   the	  myocardium,	  diseases	  of	   the	  heart's	  electrical	   circuit,	  
and	  congenital	  heart	  disease	  (Table	  1.1)	  	  
	  
Table	  1.1	  	  Cardiovascular	  disorders.	  
CVD	  Group	   Description	  
Coronary	  heart	  disease	  
(CHD)	  or	  coronary	  artery	  
disease	  	  (CAD)	  
Disease	  of	  the	  blood	  vessels	  supplying	  the	  heart	  muscle;	  mainly	  
caused	  by	  a	  build-­‐up	  of	  fatty	  deposits	  on	  the	  inner	  walls	  of	  the	  
blood	  vessels	  that	  reduce	  or	  prevent	  blood	  flow	  to	  the	  heart,	  
which	  can	  result	  in	  angina	  (chest	  pain)	  or	  myocardial	  infarction	  
(heart	  attack).	  
	   	  Stroke	  or	  cerebrovascular	  
disease	  	  
Disease	  of	  the	  blood	  vessels	  supplying	  the	  brain;	  the	  main	  causes	  
of	  stroke	  include	  restriction	  of	  blood	  flow	  to	  the	  brain	  either	  due	  
to	  fatty-­‐acid	  build	  up	  or	  formation	  of	  blood	  clots	  due	  to	  bleeding	  
from	  a	  blood	  vessel	  in	  the	  brain.	  	  	  
	   	  
Peripheral	  arterial	  disease	  	   Disease	  of	  blood	  vessels	  supplying	  the	  arms	  and	  legs.	  
	   	  Cardiomyopathy	   Disease	  of	  the	  heart	  muscle	  where	  the	  muscle	  becomes	  
enlarged,	  thick,	  or	  rigid,	  preventing	  efficient	  pumping	  of	  blood	  
through	  the	  body.	  
	   	  Cardiac	  dysrhythmia	   Disorders	  of	  the	  heart	  rhythm	  due	  to	  abnormal	  electrical	  activity	  
in	  the	  heart.	  
	   	  
Rheumatic	  heart	  disease	  	   Damage	  to	  the	  heart	  muscle	  and	  heart	  valves	  from	  rheumatic	  
fever,	  caused	  by	  streptococcal	  bacteria.	  
	   	  Congenital	  heart	  disease	  	   Malformations	  of	  heart	  structure	  existing	  at	  birth.	  
	   	  
Deep	  vein	  thrombosis	  and	  
Pulmonary	  embolism	  	  
Blood	  clots	  in	  the	  leg	  veins	  which	  can	  dislodge	  and	  move	  to	  the	  
heart	  and	  lungs.	  
Modified	   from	   WHO	   Cardiovascular	   diseases	   Fact	   sheet	   N°317	   (September	   2012)	   (World	   Health	  
Organisation	  2012).	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Family	  and	  twin	  studies	  of	  common	  CVDs	  provide	  evidence	  for	  considerable	  genetic	  
contribution	  (Marenberg	  et	  al.	  1994;	  Wienke	  et	  al.	  2005).	  Hence,	  genetic	  research	  
has	  long	  been	  pursued	  to	  enhance	  our	  understanding	  of	  the	  contributing	  molecular	  
mechanisms,	   with	   the	   potential	   of	   identifying	   new	   therapeutic	   targets	   and	  
improving	  current	  disease	  risk	  prediction	  models.	  	  
	  
There	   are	   two	   main	   approaches	   to	   the	   discovery	   of	   genes	   for	   CVD	   and	   its	   risk	  
factors	   in	   humans	   –	   linkage	   analysis	   and	   genetic	   association.	   For	   Mendelian	  
disorders,	  where	  a	  simple	  pattern	  of	  inheritance	  suggests	  a	  single	  casual	  gene	  with	  
large	   effect	   on	   phenotype	   (Kathiresan	   &	   Srivastava	   2012),	   linkage	   analysis	   has	  
largely	   been	   successful	   in	   identifying	   the	   causal	   mutation.	   For	   example,	   in	   1989	  
Jarcho	   et	   al.	   localised	   the	   chromosomal	   position	   of	   a	   causal	   gene	   for	   familial	  
hypertrophic	  cardiomyopathy	  (Jarcho	  et	  al.	  1989),	  and	  a	  year	  later	  causal	  mutations	  
in	   the	   beta	   cardiac	   myosin	   heavy	   chain	   were	   identified	   within	   this	   region	  
(Geisterfer-­‐Lowrance	   et	   al.	   1990).	   On	   the	   other	   hand,	   complex	   disorders	   follow	  
complex	   inheritance	  patterns	   that	   are	   suggestive	  of	   interaction	  between	  multiple	  
loci	   and	   non-­‐genetic	   factors.	   Early	   genetic	   research	   into	   common	   CVD	   using	   a	  
candidate-­‐gene	   approach	   revealed	   few	   replicated	   positive	   findings.	   For	   example,	  
candidate-­‐gene	  sequencing	   identified	  mutations	   in	  the	  MEF2A	  gene,	  a	  member	  of	  
the	  myocyte	  enhancer	  family	  of	  transcription	  factors.	  This	  was	  the	  first	  locus	  to	  be	  
implicated	   in	   the	   autosomal	   dominant	   form	   of	   CAD	   	   (Wang	   et	   al.	   2003),	   but	   the	  
casual	   role	  of	   this	  gene	  was	  soon	  disputed	  due	   to	   lack	  of	   replication	   (Weng	  et	  al.	  
2005).	  	  
	  
The	  sequencing	  of	  the	  human	  genome	  (Lander	  et	  al.	  2001;	  Venter	  et	  al.	  2001)	  and	  
the	  subsequent	  development	  of	  affordable	  high-­‐throughput	  genotyping	  technology	  
have	   made	   it	   possible	   to	   identify	   associations	   of	   common	   genetic	   variants	   with	  
disease	   events	   or	   with	   risk	   factors	   at	   the	   genome-­‐wide	   level	   –	   genome-­‐wide	  
association	   studies	   (GWAS)	   (described	   later	   in	   section	   1.3.3).	   As	   a	   result,	   the	   last	  
five	  years	  have	  seen	  the	  identification	  of	  numerous	  replicated	  novel	  loci	  for	  some	  of	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the	  most	  important	  CVD	  traits,	  including	  CAD	  (McPherson	  et	  al.	  2007;	  Samani	  et	  al.	  
2007;	   Schunkert	   et	   al.	   2011;	   Davies	   et	   al.	   2012)	   and	   myocardial	   infarction	   (MI)	  
(Helgadottir	  et	  al.	  2007;	  Kathiresan	  et	  al.	  2009).	  	  
	  
Efforts	  have	  also	  been	  focused	  on	  large-­‐scale	  identification	  of	  genetic	  determinants	  
of	   well-­‐known	   modifiable	   CVD	   risk	   factors,	   including	   serum	   lipids	   (e.g.	   low-­‐	   and	  
high-­‐density	   lipoprotein-­‐cholesterol	   (LDL-­‐C	   and	  HDL-­‐C),	   and	   triglycerides)	   (Talmud	  
et	   al.	   2009;	   Teslovich	   et	   al.	   2010;	  Asselbergs	   et	   al.	   2012),	   body	  mass	   index	   (BMI)	  
(Speliotes	   et	   al.	   2010),	   electrocardiogram	   (ECG)	  measures	   (Chambers	   et	   al.	   2010;	  
Pfeufer	  et	  al.	  2010;	  Sotoodehnia	  et	  al.	  2010),	   left	  ventricular	  (LV)	  mass	  (Mayosi	  et	  
al.	  2008;	  Arnett	  et	  al.	  2009),	  carotid-­‐intima	  media	  thickness	  (CIMT)	  (Baldassarre	  et	  
al.	  2010;	  Bis	  et	  al.	  2011)	  and	  blood	  pressure	  (Levy	  et	  al.	  2009;	  Ganesh	  et	  al.	  2013).	  
Some	  of	  these	  risk	  factors	  are	  discussed	  in	  more	  detail	  in	  section	  1.5.	  
	  
The	   proportion	   of	   the	   total	   phenotypic	   variance	   explained	   by	   all	   genetic	  
contributions	  is	  known	  as	  broad-­‐sense	  heritability,	  while	  that	  attributed	  only	  to	  the	  
additive	  genetic	  contribution	  is	  referred	  to	  as	  narrow-­‐sense	  heritability.	  For	  all	  the	  
mentioned	  CVD	  and	  risk	  factor	  traits,	  despite	  the	  discovery	  of	  numerous	  associated	  
loci,	   their	   combined	   effects	   explain	   only	   a	   modest	   fraction	   of	   the	   estimated	  
(narrow-­‐sense)	  heritability	  of	   the	   trait	   (Manolio	  et	  al.	   2009),	   indicating	   that	   there	  
may	  be	  other	  genetic	  factors	  that	  are	  yet	  to	  be	  identified.	  This	  may	  explain	  why	  in	  
most	   analyses	   the	   current	   known	   genetic	   risk	   factors	   have	   failed	   to	   provide	  
substantial	   improvement	   over	   traditional	   non-­‐genetic	   risk	   factors	   in	   disease	   risk	  
prediction	  (Kathiresan	  et	  al.	  2008;	  Talmud	  et	  al.	  2010),	   leaving	  their	  utility	  for	  this	  
purpose	  unclear.	  Another	  application	  of	  genetic	  variants	  has	  been	  in	  addressing	  the	  
question	  of	  whether	  an	  epidemiologically	  observed	  relationship	  between	  risk	  factor	  
and	   outcome	   is	   due	   to	   the	   causal	   effect	   of	   the	   former	   on	   the	   latter,	   termed	  
Mendelian	   randomisation	   (MR)	   (Smith	   &	   Ebrahim	   2003).	   Such	   studies	   have	  
confirmed	  a	  causal	  relationship	  between	  LDL-­‐C	  and	  coronary	  disease	  (Ference	  et	  al.	  
2012;	  Linsel-­‐Nitschke	  et	  al.	  2008).	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In	  the	  rest	  of	  this	  chapter,	  I	  describe	  the	  biology	  and	  genetics	  behind	  CVD	  and	  some	  
of	  the	  above	  mentioned	  risk	  factors,	  as	  well	  as	  introduce	  methodological	  concepts,	  
both	  of	  which	  aim	  to	  provide	  the	  background	  to	  the	  work	  presented	  in	  this	  thesis.	  
	  
1.2 Genetic	  Variation	  and	  Disease	  
Disease	   causing	   variants	   range	   from	   exceedingly	   rare	  mutations	   to	   very	   common	  
genetic	   variations,	   and	   their	   effects	   from	   large	   to	   negligible	   (Marian	   &	   Belmont	  
2011).	   	   Single	   nucleotide	   polymorphisms	   (SNPs),	   which	   consist	   of	   differences	  
between	  individuals	  at	  a	  single	  nucleotide	  position,	  are	  the	  most	  common	  type	  of	  
variation,	  with	   approximately	   15	  million	   SNPs	   identified	   in	   European,	   African	   and	  
Asian	   populations	   (The	   1000	   Genomes	   Project	   Consortium	   2010).	   Other	   types	   of	  
variation	   include	  deletions,	   duplications,	   and	   copy	  number	   variations	   (CNVs).	   The	  
vast	   majority	   of	   known	   SNPs	   are	   thought	   to	   be	   neutral	   as	   they	   are	   located	   in	  
apparently	   non-­‐functional	   regions	   of	   the	   genome	   (Frazer	   et	   al.	   2009).	   However,	  
when	   they	   occur	   within	   coding	   or	   regulatory	   regions	   they	   may	   affect	   protein	  
sequence	  or	  expression,	  potentially	  resulting	  in	  an	  altered	  phenotype.	  	  
	  
Mendelian	   disorders	   are	   usually	   caused	   by	  mutations	   in	   a	   single	   gene	   that	   often	  
have	   large,	   deleterious	   effects.	   Though	   there	   are	   exceptions	   (e.g.	   cystic	   fibrosis	  
transmembrane	  conductance	   regulator	   (CTFR)	  mutations	   that	  cause	  cystic	   fibrosis	  
(Mateu	  et	  al.	  2002)),	  such	  mutations	  tend	  to	  have	  more	  recent	  origins	  and	  are	  rare	  
due	   to	   negative	   selection.	   Though	   important	   for	   conferring	   disease	   risk	   in	   the	  
individual	   carrying	   the	  mutation	   and	   in	   relatives,	   the	   impact	  of	   rare	  mutations	   at	  
the	   population	   level	   is	   usually	   low.	   Complex	   diseases,	   on	   the	   other	   hand,	   are	  
polygenic	  in	  nature	  with	  significant	  genetic	  and	  environmental	  contribution	  (Schork	  	  
1997).	   The	   underlying	   architecture	   of	   common	   complex	   diseases	   has	   been	  
attributed	  to	  four	  possible	  models:	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1. Common	   disease	   –	   common	   variant	   (CD-­‐CV)	   model:	   This	   assumes	   an	  
additive	   contribution	   of	   multiple	   common	   polymorphisms	   (defined	   as	  
having	   a	   minor	   allele	   frequency	   (MAF)	   >5%)	   in	   multiple	   loci	   (Bodmer	   &	  
Bonilla	  2008).	  However,	   almost	  without	  exception,	   the	   combined	  effect	  of	  
common	  genetic	  variants	   	  accounts	   for	  only	  a	  small	  proportion	  of	  the	  trait	  
variance	   –	   referred	   to	   as	   the	   ‘missing	  heritability’	   problem	   (Manolio	   et	   al.	  
2009).	  Despite	  this,	   the	  attributable	  risk	  of	  common	  alleles	   in	  a	  population	  
may	   be	   considerable	   due	   to	   their	   frequency	   in	   the	   population	   (Marian	   &	  
Belmont	  2011).	  
2. Infinitesimal	  model:	   Every	   gene	   contributes	   to	   every	   trait,	   but	  with	   effect	  
sizes	  that	  are	  so	  small	  that	  samples	  greater	  than	  the	  population	  size	  of	  the	  
species	   would	   be	   needed	   to	   detect	   them	   (Gibson	   2012).	   The	   GWAS	   on	  
height	   in	   over	   >180,000	   individuals,	   identified	   hundreds	   of	   variants	   in	   at	  
least	  180	   loci	  that	  passed	  the	  pre-­‐defined	  significance	  threshold,	  but	  these	  
only	  explained	  10%	  of	  the	  phenotypic	  variation	  in	  height	  (Lango	  et	  al.	  2010).	  
Rather	  than	  selecting	  variants	  passing	  a	  pre-­‐defined	  association	  significance	  
threshold,	   a	   recently	   developed	   method	   considering	   all	   SNPs	  
simultaneously,	   estimated	   that	   45%	   of	   the	   phenotypic	   variance	   in	   height	  
was	   explained	   by	   all	   SNPs	   on	   the	   genotyping	   platform	   used	   in	   the	   height	  
GWAS	   (Yang	  et	  al.	  2010).	  This	   	   suggests	   the	   idea	   that	  heritability	   is	  not	   so	  
much	  missing	  as	  it	  is	  hidden	  below	  the	  stringent	  significance	  thresholds	  used	  
in	  GWAS	  (Gibson	  2010).	  
3. Rare	  allele	  model:	  This	  model	  is	  the	  opposite	  of	  the	  CD-­‐CV	  model,	  assuming	  
many	   rare	   alleles	   with	   large	   effects	   are	   the	   main	   genetic	   contributors.	  
(Bodmer	  &	  Bonilla	  2008).	  
	  
4. Broad	   sense	   heritability	   model:	   Where	   a	   combination	   of	   genotypic,	  
environmental	   and	   epigenetic	   interactions	   contribute	   to	   the	   phenotype	  
(Gibson	  2012).	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Currently	  there	  is	   insufficient	  empirical	  evidence	  to	  support	  any	  single	  model,	  and	  
no	  single	  technological	  platform	  to	  assess	  all	  models	  simultaneously.	  However,	  it	  is	  
reasonable	   to	   assume	   that	   allelic	   architecture	   (number,	   type,	   effect	   size	   and	  
frequency	   of	   genetic	   variants)	  may	   differ	   across	   traits	   (Manolio	   et	   al.	   2009),	   and	  
that	  all	  models	  may	  contribute,	  at	  varying	  levels,	  to	  different	  diseases	  or	  traits.	  For	  
example,	  GWAS	  analysis	   identified	  common	  variants	   in	   seven	   loci	  associated	  with	  
triglyceride	   levels,	   while	   re-­‐sequencing	   of	   selected	   genes	   identified	   an	   excess	   of	  
rare,	   non-­‐synonymous	   variants	   across	   four	   genes	   when	   comparing	   individuals	   in	  
extremes	  of	  the	  plasma	  triglyceride	  distribution	  (Johansen	  et	  al.	  2010).	  In	  addition,	  
the	   large	   overlap	   between	   genes	   identified	   by	  GWAS	   and	   those	   identified	   earlier	  
through	  Mendelian	   families	  also	  provides	   support	   for	   	   genetic	   variants	  across	   the	  
spectrum	   of	   allele	   frequencies	   contributing	   to	   complex	   common	   diseases	  
(Kathiresan	  &	  Srivastava	  2012).	  
	  
1.3 Investigating	  the	  Genetic	  Basis	  of	  Disease	  	  
1.3.1 Linkage	  Disequilibrium	  
The	   International	   HapMap	   project	   (HapMap	   Consortium	   2003)	   was	   launched	   in	  
2002	  with	   the	  aim	  of	  providing	  a	  public	   resource	   to	  aid	  medical	  genetic	   research.	  	  
The	  goal	  was	   to	  characterise	  common	  genetic	  variants	   (MAF	  >5%)	   in	  humans	  and	  
determine	  their	  frequency	  and	  correlation	  within	  different	  ethnic	  populations.	  Two	  
hundred	   and	   seventy	   individuals	  with	  African,	   European	   and	  Asian	   ancestry	  were	  
sequenced,	  characterising	  over	  3	  million	  SNPs.	  The	  co-­‐inheritance	  of	  SNP	  alleles	  on	  
a	   chromosome	   leads	   to	   associations	   between	   these	   alleles	   in	   the	   population	  
(known	  as	  linkage	  disequilibrium	  (LD)).	  Recombination	  is	  more	  likely	  to	  occur	  as	  the	  
distance	   between	   two	   SNPs	   increases,	   and	   the	   correlation	   between	   two	   SNPs	   is	  
therefore	  likely	  to	  decline	  with	  physical	  distance	  on	  the	  chromosome.	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The	  presence	  of	   LD	  between	  SNPs	   in	  a	   region	  means	   that	  genotyping	  only	  a	   few,	  
carefully	  chosen	  ‘tag’	  SNPs	  in	  the	  region	  will	  provide	  enough	  information	  to	  predict	  
much	  of	  the	  information	  about	  the	  remainder	  of	  the	  common	  SNPs	  in	  that	  region	  
(HapMap	  Consortium	  2003).	  The	  genomic	  distance	  at	  which	  LD	  decays	  determines	  
how	  many	  genetic	  markers	  are	  needed	  to	  tag	  a	  haplotype	  (Visscher	  et	  al.	  2012).	  On	  
the	   basis	   of	   empirical	   studies,	   it	   has	   been	   estimated	   that	   genotyping	   around	  
500,000	  common	  SNPs,	  combined	  with	  the	  knowledge	  of	  LD	  structure,	  is	  sufficient	  
to	   allow	   the	   vast	  majority	   of	   common	   variants	   to	   be	   tested	   for	   association	   with	  
phenotypes	   in	   non-­‐African	   populations	   (The	   International	   HapMap	   Consortium	  
2005).	   This	   serves	   the	  basis	   for	   commercial	   genome-­‐wide	   association	   SNP	   arrays,	  
which	  due	  to	  the	  limitation	  of	  the	  physical	  size	  of	  the	  array,	  use	  a	  tag	  SNP	  approach	  
to	  capture	  a	   large	  proportion	  of	   the	  variation	   in	   the	  genome	  using	  a	  substantially	  
smaller	  number	  of	  SNPs	  on	  the	  array	  (de	  Bakker	  et	  al.	  2005).	  
	  
With	   recent	   advances	   in	   DNA	   sequencing	   technologies	   (next-­‐generation	  
sequencing),	   the	   1000	   Genomes	   Project	   (The	   1000	   Genomes	   Project	   Consortium	  
2010)	   was	   launched	   in	   2008.	   The	   aim	   was	   to	   discover	   and	   provide	   accurate	  
haplotype	   information	   for	  most	   genetic	   variants	   that	  have	   frequencies	  of	   at	   least	  
1%	   in	   about	   2500	   individuals	   from	   27	   different	   populations	   with	   ancestry	   from	  
Europe,	   East	  Asia,	   South	  Asia,	  West	  Africa	   and	   the	  Americas	   (The	  1000	  Genomes	  
Project	   Consortium	   2010).	   The	   data	   released	   thus	   far	   provides	   a	   much	   deeper,	  
more	   uniform	   picture	   of	   human	   genetic	   variation	   than	   was	   previously	   available	  
through	  HapMap	  (The	  1000	  Genomes	  Project	  Consortium	  2010).	  The	  development	  
of	   computational	   and	   statistical	   methods	   make	   it	   possible	   to	   use	   the	   haplotypic	  
information	   from	   HapMap	   and	   1000	   Genomes	   to	   computationally	   impute	   the	  
genotypes	   in	   samples	   for	   millions	   of	   additional	   variants	   beyond	   those	   that	   are	  
genotyped	  using	   commercial	   SNP	   arrays,	  with	   the	   added	  benefit	   of	   no	   additional	  
genotyping	  cost.	   In	  all	  approaches	  to	  gene	  mapping,	   the	  underlying	  assumption	   is	  
that	  a	  disease-­‐predisposing	  allele	  will	  pass	  from	  generation	  to	  generation	  together	  
with	  other	  variants	  in	  high	  LD	  (Balding	  2006).	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1.3.2 Linkage	  Analysis	  
Linkage	  analysis	  tests	  whether	  a	  genetic	  marker	  tagging	  a	  region	  along	  the	  genome	  
is	   co-­‐transmitted	   with	   disease	  more	   often	   than	   expected	   by	   chance	   within	   large	  
pedigrees,	   followed	   by	   fine-­‐mapping	   of	   these	   regions	   to	   identify	   the	   casual	   gene	  
and	   variant.	   The	   success	   of	   linkage	   studies	   depends	   on	   the	   availability	   of	  
phenotypically	  well-­‐characterised	   families	   that	   include	  a	   sufficiently	   large	  number	  
of	   informative	   affected	   individuals	   (Cambien	  &	   Tiret	   2007)	   and	  where	   the	   causal	  
variants	  have	  strong	  heritability.	  An	  important	  advantage	  of	  linkage	  methods	  is	  that	  
the	   combined	   information	   from	   several	   affected	   families	   has	   the	   potential	   to	  
identify	  a	  causal	  locus	  even	  when	  different	  rare	  variants	  within	  the	  same	  locus	  are	  
responsible	  for	  the	  disease	  in	  different	  families,	  making	  it	  appropriate	  when	  many	  
rare	   variants	   at	   a	   locus	   each	   contribute	   to	   disease	   risk	   (Balding	   2006).	   However,	  
even	   in	   monogenic	   disorders	   the	   relationship	   between	   genotype	   and	   phenotype	  
can	  be	  complex	  due	  to	  three	  genetic	  phenomena:	  
1. Penetrance	   –	   not	   all	   individuals	   with	   a	   given	   genotype	   will	   exhibit	   the	  
phenotype	   associated	   with	   the	   genotype,	   referred	   to	   as	   incomplete	  
penetrance.	  This	  may	  be	  due	  to	  modifier	  gene	  or	  environmental	  interactions	  
(Kathiresan	  &	  Srivastava	  2012).	  
2. Expressitivity	   –	   individuals	   with	   the	   same	   genotype	   can	   show	   varying	  
degrees	  of	  the	  same	  phenotype.	  
3. Pleiotropy	   –	  mutations	   in	   a	   single	   gene	   can	   influence	  multiple	   phenotypic	  
traits.	  
Some	   non-­‐hereditary	   phenotypes,	   induced	   by	   certain	   environmental	   conditions,	  
can	  also	  resemble	  a	  phenotype	  with	  a	  known	  genetic	  cause	  (phenocopy).	  Together	  
these	   make	   gene	   discovery	   more	   difficult,	   since	   genotype	   may	   not	   segregate	  
perfectly	  with	  phenotype	  (Kathiresan	  &	  Srivastava	  2012).	  Linkage	  analysis	  generally	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lacks	  statistical	  power	  for	  identifying	  causal	  variants	  with	  low	  penetrance	  and	  small	  
effect,	  which	  are	  more	  characteristic	  of	  complex	  disease	  traits	  (Balding	  2006).	  	  
	  
1.3.3 Genetic	  Association	  Analysis	  
Genetic	   association	   studies	   compare	   the	   frequency	   of	   genetic	   variants	   in	   control	  
and	   disease	   groups	   of	   unrelated	   individuals,	   or	   test	   for	   association	   with	   a	  
continuous	   trait.	   If	   the	   proportion	   of	   cases	   to	   controls,	   or	   the	   mean	   of	   the	  
continuous	   trait	   significantly	  differs	  between	  the	  genotype	  groups	   for	  a	  particular	  
genetic	   variant,	   then	   this	   provides	   evidence	   for	   association	   (Balding	   2006).	  
Association	   studies	   in	   unrelated	   individuals	   using	   genome-­‐wide	   SNP	   arrays	   have	  
been	   widely	   used	   to	   identify	   genetic	   variants	   associated	   with	   complex	   diseases	  
without	  a	  priori	  knowledge	  of	  candidate	  genes	  and	  pathways,	  with	  the	  assumption	  
that	   the	   associated	   variant	   is	   either	   casual	   or	   is	   tagging	   the	   causal	   variant.	   The	  
power	   to	   detect	   associations	   using	   genome-­‐wide	   platforms	   depends	   directly	   on	  
sample	  size,	  MAF,	  strength	  of	  LD	  between	  the	  genotyped	  variant	  and	  causal	  variant,	  
and	   the	   effect	   size	   (Spencer	   et	   al.	   2009).	   Since	   2005,	   the	   number	   of	   published	  
GWAS	  has	  dramatically	   increased.	  A	  catalogue	  of	  published	  GWAS	   (Hindorff	  et	  al.	  
2009)	  is	  maintained	  by	  the	  National	  Human	  Genome	  Research	  Institute	  (NHGRI)	  at	  
the	  National	  Institutes	  of	  Health	  (NIH).	  By	  mid-­‐2012	  it	  contained	  results	  from	  over	  
1300	  published	  GWAS	  on	  over	  200	  traits.	  	  
	  
Despite	   the	   value	   of	   the	   genome-­‐wide	   approach,	   the	   technology	   still	   has	  
considerable	   cost	   and	   relatively	   low	   power	   to	   detect	   subtle,	   but	   potentially	  
important	   effects,	   in	   studies	   of	   typical	   sample	   sizes	   (a	   few	   thousand	   individuals)	  
(Keating	   et	   al.	   2008).	   In	   addition,	   given	   the	   large	   number	   of	   statistical	   tests	  
performed	   when	   using	   such	   platforms,	   very	   stringent	   statistical	   significance	  
thresholds	  have	  been	  adopted	  to	  reduce	  false	  discoveries,	  at	  the	  cost	  of	  discarding	  
true	  associations.	  This	  is	  evident	  in	  the	  fact	  that	  significant	  associations	  reported	  in	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publications	  explain	  a	  relatively	  small	  proportion	  of	  the	  total	  phenotypic	  variation,	  
despite	  studies	  showing	  a	  much	  higher	  heritability	  estimate	  when	  all	  SNPs	  on	  the	  
genotyping	   platform	   are	   considered	   (Yang	   et	   al.	   2010).	   Due	   to	   the	   tag-­‐SNP	  
approach	  in	  the	  design	  of	  genome-­‐wide	  arrays,	  and	  depending	  on	  the	  size	  of	  the	  LD	  
block	  tagged	  by	  the	  genotyped	  SNPs,	  fine-­‐mapping	  of	  the	  identified	  regions	  is	  often	  
needed	  in	  order	  to	  identify	  the	  causal	  variant.	  In	  addition,	  rare	  genetic	  variants	  are	  
difficult	   to	   tag	   with	   common	   markers	   and	   are	   therefore	   under-­‐represented	   on	  
genome-­‐wide	  platforms.	  	  
	  
Array-­‐based	   genotyping	   technologies	   that	   have	   enabled	   GWAS	   also	   permit	  
flexibility	  in	  choosing	  the	  scope	  and	  density	  of	  SNPs	  for	  candidate	  gene	  studies.	  This	  
has	   led	   to	   the	   development	   of	   several	   custom	   gene-­‐centric	   chips	   such	   as	   the	  
Cardiochip	   (Keating	   et	   al.	   2008)	   designed	   for	   studying	   cardiovascular	   disease,	   the	  
Metabochip	   for	   cardiovascular	   and	  metabolic	   traits	   (Voight	   et	   al.	   2012),	   and	   the	  
Immunochip	   (Cortes	   &	   Brown	   2011)	   for	   auto-­‐immune	   and	   inflammatory	   traits.	  
Compared	   to	   genome-­‐wide	   arrays,	   though	   these	   have	   fewer	   SNPs,	   they	   provide	  
much	   denser	   coverage	   of	   candidate	   genetic	   loci	   enabling	   cost-­‐effective	   fine-­‐
mapping	  of	  loci	  for	  both	  rare	  and	  common	  variants,	  and	  reduce	  the	  multiple-­‐testing	  
problem	  that	  is	  a	  major	  issue	  in	  genome-­‐wide	  studies.	  	  
	  
1.3.4 Association	  with	  Disease	  Outcome	  versus	  Continuous	  Risk	  Factors	  
Association	   studies	   with	   disease	   outcomes	   have	   the	   potential	   to	   uncover	   novel	  
disease	  pathways.	  However,	  there	  are	  two	  major	  limitations	  of	  such	  an	  approach	  to	  
genetic	   discovery.	   Firstly,	   CVD	   encompasses	   a	   range	   of	   conditions,	   and	   for	   the	  
purpose	  of	  GWAS,	  phenotypes	  are	  often	  classified	  on	  the	  basis	  of	  observed	  disease	  
outcomes	  such	  as	  CAD,	  MI	  or	  stroke.	  However,	  even	  within	  these	  broad	  categories	  
individuals	  may	  have	  different	  disease	  aetiologies	  as	  well	  as	  different	  genetic	  and	  
biological	   risk	   factors	   (Arking	   &	   Chakravarti	   2009).	  Secondly,	   the	   success	   of	   such	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studies	   for	   identifying	   common	   variants	  with	   small	   effect	   relies	   heavily	   on	  power	  
and	   sample	   size.	   This	   realisation	   has	   led	   to	   the	   formation	   of	   large,	   collaborative	  
consortia	   which	   enable	   combining	   of	   results	   from	   multiple	   independent	   studies	  
(meta-­‐analysis)	   in	   order	   to	   obtain	   sufficient	   numbers	   of	   case	   samples.	   One	   such	  
effort	   is	  the	  Coronary	  Artery	  Disease	  Genome-­‐wide	  Replication	  And	  Meta-­‐Analysis	  
(CARDIoGRAM)	   consortium	   which	   combines	   14	   CAD	   GWAS,	   accruing	   data	   for	  
22,233	  CAD	  cases	  and	  64,742	  controls	  (Schunkert	  et	  al.	  2011).	  	  
	  
Given	  these	  limitations,	  many	  groups	  have	  diverted	  efforts	  to	  studying	  intermediate	  
CVD	   risk	   factors	   as	   they	   tend	   to	   be	   more	   homogenous	   and	   easily	   obtainable	   in	  
existing	   population	   cohorts.	   Genetic	   determinants	   of	   intermediate	   phenotypes	  
could	  potentially	  be	  linked	  to	  disease	  risk	  using	  a	  step-­‐wise	  process	  of	  association	  in	  
circumstances	  where	  the	  overall	  association	  between	  genotype	  and	  disease	  would	  
be	  too	  small	  for	  direct	  detection	  in	  a	  case-­‐control	  GWAS	  design	  (Carvajal-­‐Carmona	  
2010).	   More	   recently,	   interest	   in	   the	   discovery	   of	   genetic	   determinants	   of	   risk	  
factors	   has	   also	   been	   growing	   given	   their	   potential	   application	   in	  MR	   analysis	   to	  
determine	  the	  causal	  relationship	  between	  risk	  factor	  and	  disease	  (section	  1.6.2).	  
	  
1.4 Genetics	  of	  Cardiovascular	  Disease	  
1.4.1 	  Mendelian	  Disorders	  
1.4.1.1 Cardiomyopathy	  
Cardiomyopathy	   is	   the	   functional	   deterioration	   of	   the	   cardiac	   muscle.	   There	   are	  
several	   types	  of	   cardiomyopathies,	   including	  hypertrophic,	   dilated	  and	   restrictive.	  
The	  most	  common	  type	  is	  hypertrophic	  cardiomyopathy	  (HCM)	  which	  affects	  up	  to	  
1	   in	   500	   individuals	   (Ramaraj	   2008),	   and	   is	   the	   most	   common	   cause	   of	   sudden	  
cardiac	  death	   (SCD)	   in	  young	  people.	  HCM	   is	   characterised	  by	   the	  presence	  of	   LV	  
hypertrophy	   (increase	   in	   cell	   size),	   disorganised	   cardiac	   myocyte	   (muscle	   cell)	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architecture	  and	  widespread	  myocardial	  fibrosis	  (formation	  of	  excess	  fibrous	  tissue)	  
(Maron	   et	   al.	   1995).	   Several	   hundred	   mutations	   in	   over	   20	   different	   HCM	  
susceptibility	   genes	   have	   been	   identified,	  most	   commonly	   in	   sarcomeric	   protein-­‐
coding	  genes	  (Fokstuen	  et	  al.	  2011).	  Other	  HCM	  genes,	  such	  as	  Titin	  (TTN)	  (Satoh	  et	  
al.	   1999)	   and	   Myozenin	   2	   (MYOZ2)	   (Osio	   et	   al.	   2007),	   code	   for	   sarcomere-­‐
interacting	  Z-­‐disc	  proteins,	  which	  provide	  mechanic	  stability	  and	  act	  as	  nodal	  points	  
for	  signalling	  (Knöll	  et	  al.	  2011).	  Though	  there	  are	  several	  known	  genetic	  causes	  for	  
cardiomyopathy,	   in	   around	   25-­‐35%	   of	   HCM	   patients	   the	   mutation	   remains	  
unknown	  (Seidman	  et	  al.	  2011).	  There	  is	  also	  marked	  variation	  in	  expressitivity	  and	  
penetrance,	  with	  some	  patients	  remaining	  asymptomatic	  throughout	  their	  lifetime	  
(Charitakis	  &	  Basson	  2010),	  making	  genotype-­‐phenotype	  correlation	  complex.	  	  	  
	  
1.4.1.2 Arrhythmogenic	  Disease	  
Cardiac	   arrhythmia	   is	   characterised	   by	   an	   abnormal	   heart	   rhythm,	   whereby	   the	  
heart	  beats	  too	  fast	  (tachycardia),	  too	  slow	  (bradycardia)	  or	  irregularly	  (fibrillation).	  
Arrhythmogenic	   diseases	   can	   be	   caused	   by	   mutations	   in	   ion	   channels	   and	   ion	  
channel-­‐controlling	  genes	  (e.g.	  SCN5A,	  sodium	  channel,	  voltage-­‐gated,	  type	  V,	  alpha	  
subunit;	   KCNA5,	   potassium	   voltage-­‐gated	   channel,	   shaker-­‐related	   subfamily,	  
member	  5),	  as	  well	  as	  calcium	  regulatory	  proteins,	  all	  of	  which	  play	  an	   important	  
role	   in	   the	   propagation	   of	   the	   electrical	   signal	   in	   the	   heart,	   resulting	   in	   the	  
synchronised	   contraction	   and	   relaxation	   of	   the	   atrial	   and	   ventricular	   chambers.	  
Arrhythmogenic	  diseases	   include	   long-­‐QT	   syndrome,	   short-­‐QT	   syndrome,	  Brugada	  
syndrome	   and	   catecholaminergic	   polymorphic	   ventricular	   tachycardia.	   The	   vast	  
proportion	  of	  SCD	  cases	  are	  due	  to	  cardiomyopathies	  and	  arrhythmogenic	  disease	  
(Pazoki	  et	  al.	  2010).	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1.4.1.3 Lipid	  Disorders	  
Familial	   hypercholesterolaemia	   (FH)	   is	   an	   autosomal	   dominant	   disorder	   with	   an	  
estimated	  prevalence	  of	  1	  in	  500	  in	  the	  UK	  (Marks	  et	  al.	  2003).	  It	  is	  characterised	  by	  
exceptionally	  high	  total	  cholesterol	  and	  LDL-­‐C	  levels	  and	  is	  associated	  with	  a	  greatly	  
elevated	  risk	  of	  CHD	  and	  death	  (Simon	  Broome	  Register	  Group	  1991).	  Mutations	  in	  
three	  genes	  are	  known	  to	  cause	  FH:	  LDL	  receptor	  (LDLR),	  apolipoprotein	  B	  (APOB),	  
and	   proprotein	   convertase	   subtilisin/kexin	   type	   9	   (PCSK9)	   (the	   functions	   of	   the	  
encoded	   proteins	   are	   discussed	   in	   section	   1.5.2.1).	   However,	   in	   about	   60%	   of	  
clinically	   diagnosed	   FH	   patients	   no	   mutations	   are	   detected	   in	   these	   three	   genes	  
(Taylor	  et	  al.	  2010;	  Talmud	  et	  al.	  2013).	  
	  
1.4.2 Complex	  Disorders	  –	  Atherosclerosis-­‐Related	  Disorders	  
The	   underlying	   disease	   process	   in	   coronary	   heart	   and	   cerebrovascular	   disease	   is	  
atherosclerosis.	   Atherosclerosis	   is	   a	   multi-­‐factorial	   process	   resulting	   in	   the	  
thickening	  and	  hardening	  of	  arteries	  due	  to	  the	  build	  up	  of	  plaque	  (a	  combination	  
of	  white	   blood	   cells,	   fatty	   acids,	   fibrous	   tissue,	   cholesterol	   and	   calcium	   deposits)	  
within	   the	   artery	  walls.	   This	   results	   in	   the	   narrowing	   of	   the	   artery	   and	   restricted	  
blood	  flow.	  The	  plaque	  can	  rupture	  leading	  to	  the	  formation	  of	  a	  blood	  clot	  which	  
may	  completely	  block	  the	  artery.	  If	  this	  process	  occurs	  within	  the	  coronary	  artery,	  
which	   supplies	   the	  heart,	   it	   results	   in	  MI,	  while	   complete	  blockage	  of	   the	   carotid	  
artery	  supplying	  the	  brain	  results	  in	  stroke.	  	  
	  
As	  mentioned	  previously,	  early	  candidate	  gene	  studies	  failed	  to	  identify	  replicated	  
associations	  with	  CAD.	  However,	  in	  the	  last	  5	  years	  the	  widespread	  use	  of	  genome-­‐
wide	  association	  analysis	  has	   led	  to	  a	  huge	   increase	   in	  the	  discovery	  of	  replicated	  
genetic	   variants	   associated	   with	   cardiovascular	   phenotypes	   including	   CAD,	   MI,	  
heart	  failure,	  and	  stroke.	  In	  2007,	  three	  studies	  (Helgadottir	  et	  al.	  2007;	  McPherson	  
et	  al.	  2007;	  Samani	  et	  al.	  2007)	  simultaneously	   reported	  genetic	  variants	  within	  a	  
Chapter	  1:	  Cardiovascular	  Risk	  Factors	  
	   	  
	  
29	  
	   	   	  
region	  on	  chromosome	  9p21.3	  associated	  with	  CAD	  and	  MI,	  and	  since	  then	  many	  
other	   studies	   have	   confirmed	   this	   association.	   The	   region	   does	   not	   contain	   any	  
annotated	   genes	   and	   research	   into	   the	   functional	   relevance	   of	   this	   region	   is	  
ongoing.	   At	   the	   end	   of	   2011,	   26	   CAD-­‐risk	   loci	   had	   been	   identified	   through	   large	  
GWASs	   (Zeller	   et	   al.	   2011),	   with	   all	   loci	   exhibiting	   small	   to	   modest	   effect	   sizes.	  
Several	   loci	   included	  well-­‐known	   lipid	  genes,	   such	  as	  LDLR	   and	  PCSK9,	   supporting	  
the	  importance	  of	  LDL-­‐C	  in	  disease	  development	  (Lusis	  2012).	  A	  few	  others	  showed	  
evidence	   of	   association	   with	   hypertension,	   however,	   for	   most	   there	   was	   no	  
established	  functional	  link	  to	  CVD	  pathways.	  
	  
Despite	   the	   identification	  of	  multiple	   loci	  associated	  with	  disease,	   their	   combined	  
effect	   explains	   a	   relatively	   small	   proportion	   of	   the	   total	   phenotypic	   variance.	  
Heritability	  of	  CAD	  has	  been	  estimated	  at	  around	  40%	  (Marenberg	  et	  al.	  1994),	  and	  
the	  SNPs	  identified	  by	  the	  CARDIoGRAM	  study	  together	  with	  previously	  known	  loci	  
explain	  approximately	  10%	  of	  the	  additive	  genetic	  variance	  of	  CAD	  	  (Schunkert	  et	  al.	  
2011).	  	  
	  
1.5 Cardiovascular	  Risk	  Factors	  
1.5.1 Left	  Ventricular	  Mass	  
1.5.1.1 Background	  
An	   increase	   in	   LV	   mass	   is	   associated	   with	   a	   higher	   incidence	   of	   cardiovascular	  
events	  (Levy	  et	  al.	  1990).	  Gender	  (independent	  of	  body	  size),	  age,	  blood	  pressure,	  
ethnicity	  and	  BMI	  are	  all	  important	  determinants	  of	  this	  trait.	  LV	  mass	  measures	  are	  
used	   in	   the	   diagnosis	   of	   left	   ventricular	   hypertrophy	   (LVH),	   the	   abnormal	  
enlargement	  of	  the	  LV	  muscle	  tissue,	  which	  is	  a	  major	  risk	  factor	  for	  CVD	  (Kannel	  et	  
al.	   1987).	   LVH	   is	   a	   major	   cause	   of	   morbidity	   and	   mortality	   in	   hypertensive	  
individuals,	   and	   historically	   it	   was	   considered	   to	   be	   an	   adaptive	   response	   to	  
increased	  dynamic	  load	  caused	  by	  high	  blood	  pressure.	  However,	  the	  presence	  and	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magnitude	   of	   LVH	   varies	   substantially	   among	   individuals	   with	   similar	   blood	  
pressure,	  and	  the	  relation	  between	  LV	  mass	  and	  cardiovascular	   risk	  has	  shown	  to	  
be	   continuous	   in	   hypertensive	   individuals	   (Schillaci	   et	   al.	   2000).	   Furthermore,	  
studies	  on	  pathways	   resulting	   in	   LVH	  have	   shown	   that	   LVH	  may	  also	  occur	   in	   the	  
absence	  of	  clear-­‐cut	  recognisable	  changes	  in	  cardiac	  loading	  conditions	  (De	  Simone	  
et	   al.	   2001).	   Therefore,	   the	   discovery	   of	   genetic	   factors	   that	   contribute	   to	   even	  
small	  increases	  in	  LV	  mass	  will	  likely	  have	  clinical	  importance.	  
	  
1.5.1.2 Measurement	  of	  LV	  Mass	  
LV	   mass	   can	   be	   measured	   by	   echocardiography,	   cardiac	   magnetic	   resonance	  
imaging	   (MRI)	   or	   ECG.	   Echocardiography	   uses	   ultrasound	   techniques	   to	   obtain	  
ventricular	  dimensions.	  Mathematical	   formulas	   are	   then	  used	   to	  estimate	   cardiac	  
volume	   by	   fitting	   ventricular	   shape	   to	   geometric	   figures	   such	   as	   ellipse,	   cylinder,	  
cone,	  and	  truncated	  polyhedrons	  (Foppa	  et	  al.	  2005).	  MRI	  calculates	  volume	  from	  a	  
three-­‐dimensional	   set	  of	   images,	  without	   requirement	   for	  any	  assumptions	  about	  
ventricular	  geometry.	  ECG	  is	  a	  graphical	  representation	  of	  the	  electrical	  activity	  of	  
the	  heart	  over	  time	  (Figure	  1.1)	  as	  measured	  by	  electrodes	  placed	  on	  the	  surface	  of	  
the	   skin	   (Figure	   1.2).	   The	   different	   ECG	   components	   are	   used	   to	   calculate	   ECG	  
indices	  of	  LV	  mass	  (Figure	  1.2).	  Increased	  LV	  mass	  is	  known	  to	  increase	  the	  height	  
and	   depth	   of	   the	   QRS	   complex	   (Figure	   1.1)	   and	   the	   length	   of	   the	   QRS	   duration	  
(Figure	  1.1).	  
	  
Many	  different	   criteria	   for	   electrocardiographic	   LV	  mass	   (ECG-­‐LV	  mass)	  measures	  
have	   been	   proposed	   over	   the	   years,	   the	   most	   commonly	   used	   including	   Cornell	  
Product,	   Sokolow-­‐Lyon	   Index,	  QRS	  Voltage	   Product	   and	  QRS	  Voltage	   Sum	   (Figure	  
1.2).	   These	   four	   indices	   incorporate	   different	   components	   of	   the	   ECG,	   show	  
differential	   pairwise	   correlation	   (shown	   in	   Section	   2.3.2)	   and	   have	   a	   range	   of	  
reported	  heritability	  estimates	  (mentioned	  below).	   	  Each	  measure,	  therefore,	  may	  
provide	  independent	  information.	  Though	  cardiac	  	  MRI	  	  is	  currently	  	  considered	  	  the	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P	  wave:	  Represents	  atrial	  depolarisation	   that	   results	   in	   the	  contraction	  of	   the	  atria	  and	  the	  expulsion	  of	  
blood	  into	  the	  ventricles.	  
	  
QRS	   complex:	   Corresponds	   to	   ventricular	   depolarisation.	   The	   first	   downward	   deflection	   in	   the	   QRS	  
complex	  is	  the	  Q	  wave,	  which	  represents	  septal	  depolarisation.	  The	  first	  upward	  deflection	  of	  the	  QRS	  is	  
called	  the	  R	  wave.	  Most	  of	  the	  ventricle	  is	  activated	  during	  the	  R	  wave.	  The	  R	  wave	  may	  be	  unusually	  tall	  in	  
the	  presence	  of	  left	  ventricular	  hypertrophy.	  The	  rim	  of	  the	  ventricular	  muscle	  is	  the	  last	  to	  contract	  and	  
this	  late	  depolarisation	  is	  represented	  by	  the	  S	  wave,	  shown	  as	  the	  downward	  deflection	  following	  the	  R	  
wave.	   An	   abnormally	   large	   S	   wave	   may	   also	   indicate	   hypertrophy.	   If	   a	   second	   upward	   deflection	   is	  
recorded,	  this	  is	  indicative	  of	  a	  problem	  in	  the	  ventricular	  conduction	  system,	  including	  conduction	  blocks	  
in	  the	  branches	  of	  the	  bundle	  of	  His.	  These	  are	  referred	  to	  as	  the	  R-­‐prime	  and	  S-­‐prime	  waves	  (R’	  and	  S’).	  	  
	  
QRS	  Duration:	  	  Duration	  of	  the	  QRS	  complex.	  
	  
ST	  segment:	  The	  isoelectric	  period	  when	  the	  entire	  ventricle	  is	  depolarized	  and	  roughly	  corresponds	  to	  the	  
plateau	  phase	  of	  the	  ventricular	  action	  potential.	  
	  
T	  wave:	  Represents	  repolarisation	  and	  relaxation	  of	  the	  ventricles.	  
	  
QT	  interval:	  Measured	  from	  the	  beginning	  of	  the	  QRS	  complex	  to	  the	  end	  of	  the	  T	  wave,	  the	  QT	  interval	  
represents	  the	  time	  for	  both	  ventricular	  depolarisation	  and	  repolarisation	  to	  occur.	  It	  is	  dependent	  on	  the	  
heart	   rate	   (the	   faster	   the	  heart	   rate,	   the	  shorter	   the	  QT	   interval)	  and	   is	   therefore	  usually	   reported	  after	  
correcting	  for	  heart	  rate.	  
	  
(Images	  modified	  from	  www.cvphysiology.com	  and	  www.cardionetics.com)	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Figure	  1.2	  Left	  ventricular	  mass	  indices	  from	  12-­‐lead	  ECG.	  
	  
The	  figure	  shows	  the	  placement	  of	  10	  electrodes	  (6	  chest	  and	  4	  limb)	  for	  the	  measurement	  
of	  12-­‐lead	  ECG.	  ECG-­‐LV	  mass	  indices	  are	  calculated	  as	  follows:	  
	  
• Sokolow-­‐Lyon	  Index	  (µV)	  =	  SV1	  +	  max	  (RV5,	  RV6)	  i.e.	  	  (Sokolow	  &	  Lyon	  1949)	  
• Cornell	   Product	   (µV.s)	  =	  Cornell	   voltage	   x	  QRS	  Duration	   (where	   Cornell	   voltage	   =	  
RaVL	  +	  SV3	  	  (600µV	  added	  for	  females)	  (Casale	  et	  al.	  1987)	  
• QRS	  Voltage	  Sum	   (µV)	  =	  the	  sum	  of	  |Q|	  +	  R	  +	  |S|	  +	  R’	  +	  |S’|	  amplitudes	   in	  all	  12	  
leads	  	  (Molloy	  et	  al.	  1992;	  Okin	  et	  al.	  1995)	  
• QRS	  Voltage	  Product	  (µV.s)	  =	  QRS	  Voltage	  Sum	  x	  QRS	  duration	  (Molloy	  et	  al.	  1992;	  
Okin	  et	  al.	  1995)	  
where,	  
SV1	  and	  SV3	  –	  amplitude	  of	  the	  S	  wave	  as	  measured	  by	  lead	  V1	  and	  lead	  V3	  
RV5	  and	  RV6	  –	  amplitude	  of	  the	  R	  wave	  as	  measured	  by	  leads	  V5	  and	  V6	  
RaVL	  –	  amplitude	  of	  the	  R	  wave	  as	  measured	  by	  the	  aVL	  lead	  
|Q|	  and	  |S|	  –	  absolute	  amplitude	  of	  Q	  wave	  and	  S	  wave	  
|R’|	  and	  |S’|	  –	  absolute	  amplitude	  of	  R’	  and	  S’	  wave	  
R	  –	  amplitude	  of	  the	  R	  wave	  	  
	  
(Images	  from	  www.thinkingmedicine.com/elearning/electro/electro2.html	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gold	   standard	   for	  estimating	   LV	  mass,	   its	  utility	   is	   restricted	  due	   to	  high	   cost	   and	  
limited	   availability.	   There	   is	   evidence	   that	   echocardiographically-­‐derived	   LV	  mass	  
(echo-­‐LV	   mass)	   has	   greater	   sensitivity	   than	   ECG-­‐LV	   mass	   for	   LVH	   diagnosis.	  
However,	   a	   study	   in	   475	  elderly	  men	   comparing	  echo-­‐LV	  mass	  with	   ECG-­‐LV	  mass	  
(based	  on	  Cornell	  Product)	  	  	  for	  	  	  the	  	  	  diagnosis	  	  	  of	  	  	  LVH	  concluded	  	  	  that	  	  the	  	  two	  	  
predict	   	  mortality	   independently	   	   of	   	   each	   	   other	   	   and	   other	   	   CVD	   	   risk	   	   factors,	  	  
suggesting	   that	   they	   capture	   somewhat	   different	   information	   on	   cardiac	   status	  
(Sundström	  et	  al.	  2001).	  The	  cost	  and	  operational	  considerations	  tend	  to	   limit	  the	  
use	  	  of	  	  echocardiography	  	  in	  	  large-­‐scale	  	  population	  	  studies	  and	  	  clinical	  trials.	  The	  
ECG,	   on	   the	   other	   hand,	   is	   inexpensive	   and	   data	   easily	   obtainable	   or	   already	  
available	  for	  participants	  of	  existing	  epidemiological	  studies.	  
	  
1.5.1.3 Genetics	  of	  Left	  Ventricular	  Mass	  and	  Hypertrophy	  	  
Echo-­‐LV	  mass	  has	  significant	  heritability,	  with	  reported	  estimates	  between	  24-­‐50%	  
(Swan	  et	  al.	  2003;	  Post	  &	  Levy	  1994).	  ECG-­‐LV	  mass	  indices	  have	  also	  been	  shown	  to	  
have	   significant	   heritability	   (Sokolow-­‐Lyon	   Index	   ~40%,	   Cornell	   Product	   ~23%)	  
(Mayosi	   2002).	   Until	   recently,	   discovery	   of	   genes	   associated	  with	   LVH	   in	   humans	  
has	  mostly	  been	   restricted	   to	   severe	   familial	   forms	  of	  hypertrophy,	   such	  as	  HCM,	  
with	  causal	  mutations	  being	  identified	  in	  several	  sarcomeric	  protein-­‐coding	  genes.	  
However,	   it	   is	   unclear	   whether	   genetic	   variation	   in	   these	   genes	   influences	   less	  
severe	  forms	  of	  LVH.	  Genes	   involved	   in	  haemodynamic	   load,	  calcium	  homeostasis	  
and	  cell	  growth	  have	  also	  been	  suggested	  to	  play	  a	  role	  in	  LVH	  development	  (Arnett	  
et	   al.	   2004).	   For	   example,	   polymorphisms	   in	   the	   angiotensin	   converting	   enzyme	  
(ACE),	   which	   plays	   an	   important	   role	   in	   arterial	   vasoconstriction,	   have	   been	  
associated	  with	  LVH	  in	  some	  studies	  (Gharavi	  et	  al.	  1996;	  Perticone	  et	  al.	  1997),	  but	  
have	  failed	  to	  replicate	  in	  others	  (Kauma	  et	  al.	  1998;	  Gomez-­‐Angelats	  et	  al.	  2000).	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A	  previous	  genome-­‐wide	  linkage	  analysis	  of	  ECG-­‐	  and	  echo-­‐LV	  mass	  in	  hypertensive	  
families	  found	  suggestive	  evidence	  for	  loci	  on	  chromosomes	  10q23.1	  for	  Sokolow-­‐
Lyon	  Index,	  on	  17p13.3	  for	  Cornell	  Product	  and	  on	  5p14.1	  for	  echo-­‐LVH	  (Mayosi	  et	  
al.	   2008).	   The	   identified	   regions,	  however,	  were	   large	  and	   spanned	   several	   genes	  
and	  a	  causal	  mutation	  has	  yet	  to	  be	  identified	  in	  these	  regions.	  However,	  a	  recent	  
study	  did	  show	  that	  one	  of	  the	  SNPs	  in	  the	  17p13.3	  region	  lies	  within	  the	  3’UTR	  of	  a	  
gene	  with	   unknown	   function,	  TLCD2,	  which	   is	   also	   immediately	   downstream	  of	   a	  
microRNA	  (miR-­‐22)	  (Harper	  et	  al.	  2013).	  MicroRNAs	  are	  a	  group	  of	  small	  non-­‐coding	  
RNA	  molecules	   involved	  in	  posttranscriptional	  gene	  regulation,	  and	  there	  are	  now	  
several	   studies	   supporting	   the	   role	   of	  miR-­‐22	   as	   a	   pro-­‐hypertrophic	   modulating	  
miRNA	  (Jentzsch	  et	  al.	  2012;	  Gurha	  et	  al.	  2012;	  Xu	  et	  al.	  2012).	  Therefore,	  miR-­‐22	  
and	  TLCD2	  may	  be	  strong	  candidates	  to	  account	  for	  this	  observation	  (Harper	  et	  al.	  
2013).	   The	   few	   GWAS	   studies	   that	   have	   been	   published	   have	   not	   been	   very	  
successful	   in	   identifying	   many	   common	   variants.	   Two	   studies	   on	   echo-­‐LV	   mass	  
(including	   the	   largest	   GWAS	   to	   date	   for	   this	   trait,	   with	   discovery	   in	   12,612	  
individuals	   and	   replication	   in	   4,094	   individuals)	   reported	   no	   definite	   associations	  
with	   LV	   mass	   (Vasan	   et	   al.	   2009;	   Arnett	   et	   al.	   2011).	   Therefore,	   the	  
pathophysiological	   mechanisms	   that	   underlie	   LVH	   remain	   incompletely	  
characterised	   and	   genetic	   studies	   may	   help	   expose	   mechanisms	   not	   previously	  




Lipids	   have	  been	   known	  CVD	   risk	   factors	   for	   over	   half	   a	   century.	   Cholesterol	   and	  
triglycerides	  are	   two	   types	  of	   lipids	   that	   circulate	  within	   the	  blood.	  Triglyceride	   is	  
the	  form	  in	  which	  dietary	  intake	  of	  fat	  or	  excess	  carbohydrate	  is	  stored.	  Cholesterol	  
is	   an	   essential	   steroid	   found	   in	   the	   plasma	   membrane	   of	   all	   cells	   and	   is	   the	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precursor	   to	  all	   steroid	  hormones.	  Cholesterol	   is	  present	   in	   tissues	  and	   in	  plasma	  
either	   as	   free	   cholesterol	   or	   as	   a	   storage	   form,	   combined	  with	   a	   long-­‐chain	   fatty	  
acid	   (cholesteryl	   ester)	   (Mayes	   &	   Botham	   2012).	   The	   cholesterol	   in	   the	   body	   is	  
synthesised	  and	  also	  provided	  by	  the	  average	  diet.	  When	  cholesterol	   levels	   in	  the	  
blood	   are	   excessive,	   the	   liver	   secretes	   it	   into	   bile	   for	   excretion	   from	   the	   body.	  
Lipids,	   being	   insoluble	   in	   aqueous	   solution,	   are	   transported	   in	   plasma	   by	  
apolipoproteins,	   forming	   lipid-­‐protein	   complexes	   known	   as	   lipoproteins	   (Feher	   &	  
Richmond	   2006).	   LDL	   (apolipoprotein	   B	   being	   the	   main	   protein	   component)	   and	  
HDL	   (apolipoprotein	   A1	   being	   the	   main	   protein	   component)	   are	   two	   classes	   of	  
lipoproteins.	  Plasma	  lipoproteins	  are	  characterised	  by	  the	  proportion	  of	  protein	  in	  
the	   lipoprotein	   complex,	   which	   determines	   their	   density.	   There	   are	   five	   major	  
density	   classes:	   chylomicrons,	   very	   low-­‐density	   lipoprotein	   (VLDL),	   intermediate-­‐
density	  lipoprotein	  (IDL),	  LDL	  and	  HDL	  (Feher	  &	  Richmond	  2006).	  Plasma	  LDL	  is	  the	  
vehicle	   of	   uptake	   of	   cholesterol	   and	   cholesteryl	   ester	   by	  many	   tissues	  while	  HDL	  
transports	  excess	  cholesterol	   to	  the	   liver	   for	  elimination	   (Mayes	  &	  Botham	  2012).	  
There	   are	   three	  main	   pathways	   involved	   in	   the	   synthesis	   and	   transport	   of	   lipids	  
within	  the	  body:	  
1. Exogenous	  (Dietary)	  Lipid	  Pathway:	  After	  digestion	  and	  absorption	  of	  dietary	  
fat,	   triglycerides	   and	   cholesterol	   are	   packaged	   into	   chylomicrons	   in	   the	  
intestine.	   Chylomicrons	   consist	  mainly	   of	   triglycerides.	   These	   are	   secreted	  
into	   the	   lymphatic	   system	  and	  eventually	   join	   the	  blood	  circulation.	  When	  
the	   chylomicrons	   reach	   muscle	   and	   adipose	   tissue,	   the	   triglycerides	   are	  
hydrolysed	  by	  lipoprotein	  lipase	  (LPL)	  to	  release	  fatty	  acids	  that	  are	  taken	  up	  
by	  the	  cells	  for	  energy	  or	  storage.	  The	  remaining	  components	  are	  known	  as	  
chylomicron	  remnants.	  Cholesterol	   that	   is	  not	  used	  by	   the	  cells	   remains	   in	  
the	   chylomicron	   remnants	   and	   these	   are	   eventually	   taken	   up	   by	   the	   liver	  
(Figure	  1.3).	  Apolipoprotein	  	  	  E	  	  (ApoE),	  	  the	  	  	  main	  	  protein	  	  	  component	  	  	  of	  
chylomicron	  remnants,	  acts	  as	  a	  binding	  ligand	  for	  receptors	  located	  on	  the	  
liver.	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2. Endogenous	   Pathway:	   This	   involves	   the	   synthesis	   of	   cholesterol	   and	  
triglycerides	   by	   the	   liver.	   These	   are	   transported	   in	   the	   blood	   stream	   to	  
muscle	   and	   adipose	   tissue	   by	  VLDLs,	  where	   triglycerides	   are	   processed	  by	  
LPL.	   Some	  of	   the	  VLDL	   remnant	  particles	   are	   removed	   from	  circulation	  by	  
the	   liver	   via	   LDL	   receptors,	   while	   others	   are	   hydrolysed	   to	   form	   smaller,	  
denser	  LDL	  particles,	  which	  are	  cholesterol-­‐rich	  particles	   (Figure	  1.3).	  Most	  
of	   the	   LDL	   particles	   are	   also	   taken	   up	   by	   LDL	   receptors	   on	   hepatic	   cells,	  
releasing	   free	   cholesterol	   which	   accumulates	   within	   the	   liver	   cells.	   The	  
number	  of	  LDL	  receptors	  on	  the	  surface	  of	  the	  liver	  determines	  how	  quickly	  
LDL	  particles	  are	  cleared	  from	  the	  bloodstream.	  When	  cells	  have	  abundant	  
cholesterol,	  LDL	  receptor	  synthesis	  at	  the	  level	  of	  transcription,	  is	  blocked	  to	  
prevent	   further	   cholesterol	   uptake.	   Conversely,	   more	   LDL	   receptors	   are	  
made	   when	   the	   cell	   is	   deficient	   in	   cholesterol.	   Proprotein	   convertase	  
subtilisin/kexin	   type	   9	   (encoded	   by	   the	  PCSK9	   gene)	   is	   believed	   to	   induce	  
degradation	  of	  LDL	  receptors	   in	  the	   liver,	   resulting	   in	  reduced	  clearance	  of	  
LDL	  particles	  from	  the	  blood.	  
3. Reverse	   Cholesterol	   Transport:	   This	   is	   the	   process	   by	   which	   excess	  
cholesterol	   is	   removed	   from	   the	   tissues	   and	   returned	   to	   the	   liver	   by	  HDL,	  
where	  it	   is	  metabolised	  to	  bile	  acids	  and	  salts	  that	  are	  eliminated	  from	  the	  
body.	  	  
	  
Excess	  circulating	  LDL-­‐C	  can	  penetrate	  endothelial	  walls	  where	  it	  is	  oxidised	  by	  free	  
radicals	   and	   becomes	   toxic	   to	   cells.	   The	   damage	   caused	   to	   the	   artery	   wall	   by	  
oxidised	   LDL	   triggers	   an	   immune	   response,	   resulting	   in	   the	   recruitment	   of	  
macrophages	   to	   the	   site	   of	   damage.	   The	  oxidised	   LDL	  molecules	   are	   taken	  up	  by	  
macrophages	   which	   become	   engorged	   and	   form	   foam	   cells	   (cholesterol-­‐loaded	  
cells)	  (Libby	  et	  al.	  2011).	  These	  foam	  cells	  may	  rupture,	  depositing	  a	  greater	  amount	  
of	   oxidised	   cholesterol	   into	   the	   artery	   wall.	   This	   deposition	   of	   necrotic	   debris	  
provokes	  	  further	  	  inflammation,	  continuing	  	  the	  cycle	  (Lusis	  2012).	  The	  surrounding	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Figure	  1.3	  Synthesis	  of	   lipoprotein	  complexes	   in	  the	  small	   intestine,	   liver,	  and	  blood	  plasma	  and	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muscle	  cells	   secrete	  a	  collagen-­‐rich	  extracellular	  matrix	   to	  cover	   the	   lesion	  with	  a	  
fibrous	  cap	  that	  separates	  the	  plaque	  from	  the	  blood	  (Figure	  1.4).	  The	  formation	  of	  
plaque	  causes	  the	  artery	  to	  narrow	  and	  restricts	  blood	  flow.	  Rupture	  of	  the	  plaque	  
leads	  to	  the	  formation	  of	  a	  blood	  clot	  which	  may	  completely	  block	  the	  artery.	  	  High	  
levels	   of	   circulating	   LDL-­‐C	   are	   known	   to	   contribute	   to	   the	   development	   of	  
atherosclerosis,	   while	   high	   levels	   of	   circulating	   HDL-­‐C	   are	   thought	   to	   have	   a	  
protective	  effect	  from	  atherosclerosis,	  as	  it	  removes	  excess	  cholesterol	  deposited	  in	  
the	  blood	  vessels	  and	  transports	  it	  back	  to	  the	  liver.	  
	  








1.5.2.2 Measurement	  of	  Lipid	  Levels	  
Serum	   total	   cholesterol	   and	   triglycerides	   can	   be	   measured	   using	   a	   centrifugal	  
analyser.	  HDL-­‐C	  can	  be	  measured	  by	  first	  precipitating	  apoB-­‐containing	  lipoproteins	  
(non-­‐HDL-­‐C	   components)	  with	   dextran	   sulphate-­‐magnesium	   chloride,	   followed	  by	  
centrifugation.	   The	   HDL-­‐C	   in	   the	   supernatant	   can	   then	   be	   measured	   by	   an	  
enzymatic	  procedure.	  Direct	  measurement	  of	  LDL-­‐C	  is	  time-­‐consuming	  and	  requires	  
expensive	   instrumentation	   that	   is	  not	  available	   in	   routine	   laboratories	   (Branchi	  et	  
al.	   1998).	   Therefore,	   LDL-­‐C	   is	   commonly	   calculated	   from	   HDL-­‐C	   and	   triglyceride	  
measurements	  using	  an	  empirical	  equation	  -­‐	  the	  Friedewald	  formula	  (Friedewald	  et	  
blood	  clot	  
Image	  taken	  from	  http://users-­‐phys.au.dk/jvn/Research-­‐CABRA.htm	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al.	   1972).	   	   However,	   the	   accuracy	   of	   LDL-­‐C	   estimation	   can	   be	   affected	   by	   serum	  
triglyceride	   levels	   and	   errors	   inherent	   to	   the	  methods	   used	   to	   obtain	   HDL-­‐C	   and	  
triglyceride	  measures.	  
	  
1.5.2.3 Lipid	  Genetics	  
Plasma-­‐lipid	   levels	   are	   highly	   heritable	   traits	   with	   estimates	   ranging	   from	   40%	   –	  
70%	   (Krauss	   2008;	   Weiss	   et	   al.	   2006).	   A	   major	   contributor	   to	   LDL-­‐C	   and	   total	  
cholesterol	   levels	   is	  the	  APOE	  gene	  which	  codes	  for	  apolipoprotein	  E.	  SNPs	  at	  two	  
sites	   (rs7412	   and	   rs429358)	   result	   in	   three	  major	   protein	   isoforms	   with	   either	   a	  
cysteine	   (cys)	   or	   arginine	   (arg)	   residue	   at	   positions	   112	   and	   158:	   ApoE2	   (cys112,	  
cys158),	   ApoE3	   (cys112,	   arg158;	   the	   most	   common	   form),	   and	   ApoE4	   (arg112,	  
arg158)	  (Utermann	  et	  al.	  1980;	  Weisgraber	  et	  al.	  1981)	  (Table	  1.2)	  	  
	  
Table	  1.2	  Combinations	  of	  rs429358	  and	  rs7412	  responsible	  for	  the	  observed	  APOE	  alleles.	  	  
APOE	  alleles	   rs429358	   rs7412	  
ε2	   T	   T	  
ε3	   T	   C	  
ε4	   C	   C	  
Not	  observed	   C	   T	  
	  
	  
These	   differences	   in	   the	   amino	   acid	   composition	   affect	   its	   binding	   to	   hepatic	  
lipoprotein	  receptors.	  The	  three	  common	  alleles:	  ε2,	  ε3	  and	  ε4,	  result	  in	  six	  possible	  
genotypes:	  ε2ε2,	  ε2ε3,	  ε2ε4,	  ε3ε3,	  ε3ε4	  and	  ε4ε4.	  A	  large	  meta-­‐analysis	  in	  61,463	  
healthy	   participants	   showed	   an	   approximately	   linear	   relationship	   of	   APOE	  
genotypes	   with	   LDL-­‐C	   levels,	   and	   with	   coronary	   risk	   in	   21,331	   cases	   and	   47,467	  
controls	   (Figure	   1.5).	   However,	   the	   presence	   of	   the	   Apoe	   E2/E2	   genotype	   is	   also	  
known	  to	  cause	  hyperlipoproteinemia	  type	  III,	  characterised	  by	  the	  accumulation	  of	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remnant	  lipoproteins	  in	  the	  plasma	  and	  development	  of	  premature	  atherosclerosis,	  
which	  complicates	  the	  relationship	  with	  CVD.	  
	  
Figure	  1.5	  Association	  of	  APOE	  genotypes	  with	  lipid	  levels	  and	  coronary	  risk.	  (a)	  Differences	  in	  LDL-­‐
C	  levels	  and	  (b)	  odds	  ratios	  for	  coronary	  disease	  by	  APOE	  genotypes	  using	  individuals	  with	  the	  ε3ε3	  
genotype	  as	  reference	  group.	  Size	  of	  data	  markers	  is	  proportional	  to	  the	  inverse	  of	  the	  variance	  of	  
the	  weighted	  mean	  difference	  or	  odds	  ratios	  (ε3ε3	  is	  represented	  by	  a	  square	  with	  arbitrarily	  fixed	  
size)	  and	  vertical	  lines	  represent	  95%	  confidence	  intervals	  (CIs).	  	  
(a)	   	   	   	   	   	   	   (b)	  
	  
Images	  taken	  from	  Bennet	  et	  al	  (2007).	  
	  
Several	   large-­‐scale	   association	   analyses	   have	   identified	   large	   numbers	   of	   genetic	  
variants	   associated	   with	   lipid	   traits	   (Talmud	   et	   al.	   2009;	   Teslovich	   et	   al.	   2010;	  
Asselbergs	  et	  al.	  2012),	  some	  of	  which	  have	  also	  been	  shown	  to	  be	  associated	  with	  
CAD	   (Teslovich	   et	   al.	   2010).	   These	   loci	   explain	   around	   10-­‐15%	   of	   the	   total	  
phenotypic	   variance	   of	   the	   lipid	   traits	   (Teslovich	   et	   al.	   2010).	  Many	   of	   these	   loci	  
show	   strong	   overlap	   with	   those	   responsible	   for	  Mendelian	   disorders	   -­‐	   of	   the	   19	  
genes	  identified	  as	  monogenic	  causes	  of	  extremely	  low	  or	  high	  levels	  of	  LDL-­‐C,	  HDL-­‐
C	   and	   triglycerides,	   common	   variants	   in	   or	   near	   16	   of	   these	   genes	   have	   been	  
identified	  through	  GWAS	  (Kathiresan	  &	  Srivastava	  2012)	  (Figure	  1.6).	  Around	  one-­‐
third	  of	  the	  identified	  genes	  are	  known	  to	  play	  a	  role	  in	  lipid	  metabolism,	  including	  
those	   that	   are	   already	   targets	   of	   lipid-­‐modifying	   therapies.	   The	   rest	   offer	   novel	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insight	  into	  lipid	  biology,	  and	  for	  a	  few	  of	  these,	  mouse	  models	  have	  subsequently	  
confirmed	   their	   role	   in	   lipoprotein	   regulation	   (Musunuru	  et	   al.	   2010;	  Varbo	  et	   al.	  
2011).	  Therefore,	  despite	  each	  independent	  SNP	  explaining	  a	  very	  small	  proportion	  
of	   the	   phenotypic	   variance,	   the	   biological	   and	   therapeutic	   value	   of	   the	   gene	  
mapped	  by	  the	  variant	  may	  be	  very	  high.	  
	  
Figure	  1.6	  Lipid	  Genetic	  Loci.	  Of	  19	  genes	  previously	  implicated	  in	  Mendelian	  lipid	  disorders,	  16	  lie	  
within	   100	   kilobases	   of	   one	   of	   the	   lead	   SNPs	  mapped	   by	  GWAS,	   including	   nine	   that	   lie	  within	   10	  
kilobases	  of	  the	  nearest	  lead	  SNP.	  
	  
Image	  taken	  from	  Kathiresan	  &	  Srivastava	  (2012).	  
	  
1.5.3 Carotid	  Intima-­‐Media	  Thickness	  
1.5.3.1 Background	  
CIMT	  is	  a	  measure	  of	  the	  thickness	  of	  the	  two	  inner-­‐most	  layers,	  the	  tunica	  intima	  
and	   tunica	  media,	   of	   the	   carotid	   artery	   wall.	   The	   right	   and	   left	   common	   carotid	  
arteries	   extend	  up	   the	   right	   and	   left	   side	   of	   the	   neck,	   respectively,	   to	   supply	   the	  
head,	  neck	  and	  brain	  with	  oxygenated	  blood.	  The	  common	  carotid	  arteries	  branch	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at	   the	   bifurcation	   point	   into	   the	   internal	   (supplying	   the	   brain)	   and	   external	  
(supplying	  the	  face	  and	  neck)	  carotid	  arteries	  (Figure	  1.7).	  
	  
Figure	  1.7	  Carotid	  arteries.	  	  
	  
Image	  taken	  from	  http://www.umm.edu/graphics/images/en/13939.jpg	  
	  
	  
Increased	   CIMT	   is	   strongly	   associated	   with	   atherosclerosis	   and	   cardiovascular	  
events	   (Bots	   et	   al.	   1997;	   Chambless	   et	   al.	   1997,	   2000;	   O’Leary	   et	   al.	   1999).	   As	   a	  
result,	   it	   is	   commonly	   used	   as	   a	   surrogate	   endpoint	   for	   cardiovascular	   events	   in	  
intervention	  trials.	  The	  use	  of	  a	  surrogate	  marker	  in	  clinical	  drug	  trials	  is	  much	  more	  
cost-­‐effective,	  as	  the	  sample	  size	  requirements	  are	  not	  as	  large,	  and	  the	  follow-­‐up	  
time	  not	  as	  long	  compared	  to	  trials	  with	  disease	  morbidity	  or	  mortality	  end-­‐points.	  
Trials	  using	  CIMT	  as	  a	  surrogate	  end-­‐point	  determine	  drug	  efficacy	  by	  its	  ability	  to	  
regress	  or	  slow	  progression	  of	  CIMT,	  with	  the	  assumption	  that	  this	  translates	  into	  a	  
reduction	  in	  cardiovascular	  risk.	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1.5.3.2 Measurement	  of	  CIMT	  
CIMT	  can	  be	  measured	  using	  non-­‐invasive	  ultrasound	   imaging	  as	   shown	   in	   Figure	  
1.8.	   Measurements	   can	   be	   made	   from	   different	   combinations	   of	   segments	  
(common	  carotid,	  carotid	  bifurcation	  and/or	  internal	  carotid	  artery),	  walls	  (far	  wall	  
and/or	  near	  wall),	  and	  angles	  (single	  angle	  or	  a	  combination	  of	  angles)	  (Dogan	  et	  al.	  
2010),	   all	   of	   which	   are	   associated	  with	   differences	   in	   reproducibility,	  magnitude,	  
and	   precision	   of	   CIMT	   measurement	   (Dogan	   et	   al.	   2010).	   	   Lack	   of	   standardised	  
protocol	  for	  CIMT	  measurement	  usually	  means	  that	  there	  is	  significant	  diversity	  in	  
the	  protocols	  used	  to	  measure	  CIMT	  in	  different	  studies.	  
	  
Figure	  1.8	  Ultrasound	  scan	  of	  the	  carotid	  artery.	  The	  arrows	  mark	  the	  inside	  border	  of	  the	  carotid	  
tunica	  intima	  (innermost)	  layer,	  which	  is	  in	  direct	  contact	  with	  the	  blood,	  and	  the	  outside	  border	  of	  
the	  tunica	  media,	  which	  consists	  of	  smooth	  muscle	  and	  elastic	  tissue.	  	  
	  
Image	  taken	  from	  http://londoncardiovascularclinic.co.uk	  
	  
1.5.3.3 Genetics	  of	  CIMT	  
CIMT	  constitutes	  an	  attractive	  quantitative	  intermediate	  disease	  phenotype	  for	  the	  
study	  of	  atherosclerosis-­‐related	  CVD	  (Gertow	  et	  al.	  2012).	  Although	  family	  studies	  
have	   shown	   consistent	   evidence	   for	   moderate	   heritability	   for	   CIMT	   (Zhao	   et	   al.	  
2008;	  Sacco	  et	  al.	  2009),	  candidate	  gene	  studies	  have	  not	  found	  consistent	  genetic	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associations	  with	   CIMT	   (Bis	   et	   al.	   2011).	   Two	   large-­‐scale	   association	   studies	   have	  
reported	   significant,	   but	   different,	   associations	  with	   common	  CIMT.	   The	   first	   is	   a	  
GWAS	  meta-­‐analysis	   identifying	  three	  independent	   loci,	   including	  the	  APOC1	  gene	  
(codes	  for	  apolipoprotein	  C1)	  on	  19q13,	  a	  region	  that	  also	   includes	  APOE,	  APOC2,	  
and	   APOC4	   genes	   (Bis	   et	   al.	   2011),	   and	   the	   second	   a	   gene-­‐centric	   analysis	  
identifying	  the	  BCAR1-­‐CFDP1-­‐TMEM170A	  locus	  on	  chromosome	  16,	  which	  was	  also	  
shown	  to	  be	  associated	  with	  CAD	  (Gertow	  et	  al.	  2012).	  
	  
1.6 Applications	  of	  Genetic	  Variants	  
1.6.1 Disease	  Risk	  Prediction	  
In	  clinical	  practice,	  risk	  prediction	  algorithms	  have	  been	  used	  to	  identify	  individuals	  
at	  high	   risk	  of	  developing	  CVD	   in	   the	   short	   term.	  These	   individuals	   could	   then	  be	  
selected	   to	   receive	   therapeutic	   or	   lifestyle	   interventions	   that	   would	   reduce	   their	  
risk	  and	  prevent	  or	  postpone	  the	  occurrence	  of	  disease.	  With	  the	  development	  of	  
LDL-­‐C-­‐lowering	   drugs,	   as	   well	   as	   several	   randomised-­‐controlled	   treatment	   trials	  
confirming	   their	   casual	   role	   in	   the	   development	   of	   CHD	   (LaRosa	   et	   al.	   2000;	   The	  
Lipid	   Research	   Clinics	   Coronary	   Primary	   Prevention	   Trial	   1984),	   a	   more	   targeted	  
approach	  has	  been	  adopted	  world-­‐wide	  in	  order	  to	  balance	  the	  inconvenience,	  risks	  
and	  costs	  of	  intervention	  with	  the	  potential	  benefits	  of	  risk	  reduction	  (Dent	  2009).	  
Prescription	   of	   LDL-­‐C-­‐lowering	   statin	   drugs	   for	   primary	   prevention	   of	   CHD	   in	   the	  
general	   population	   was	   initially	   informed	   by	   lipid	   level	   thresholds.	   However,	  
cholesterol	  levels	  identify	  patients	  at	  risk	  of	  future	  coronary	  events	  only	  moderately	  
well	   (Law	   &	   Wald	   2002).	   Many	   individuals	   have	   a	   cholesterol	   concentration	  
sufficient	  to	  raise	  the	  risk	  of	  coronary	  events,	  but	  the	  strength	  of	  the	  association	  of	  
LDL-­‐C	   with	   coronary	   events	   is	   only	   modest,	   with	   about	   a	   three-­‐fold	   relative	  
difference	   in	   the	   risk	   of	   coronary	   events	   among	   those	   at	   the	   extremes	   of	   the	  
population	   LDL-­‐C	   distribution	   (Di	   Angelantonio	   et	   al.	   2009).	   There	   is	   a	   lot	   of	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supporting	  evidence	  that	  major	  CVD	  risk	   factors	   like	  blood	  pressure	  or	  blood	   lipid	  
levels	  are	  individually	  poor	  predictors	  of	  a	  patient’s	  CVD	  risk	  when	  compared	  with	  
multifactor	   CVD	   risk	   prediction	   estimates	   (Jackson	  2008).	   As	   a	   result,	   current	  UK,	  
European,	   and	   Australasian	   guidelines	   recommend	   prescription	   of	   statins	   on	   the	  
basis	  of	  absolute	  CVD	  risk	  rather	  than	  solely	  on	  LDL-­‐C	  thresholds.	  	  	  
	  
Guidelines	  from	  the	  National	  Institute	  for	  Health	  and	  Clinical	  Excellence	  (NICE)	  and	  
other	  associations	  recommend	  commencing	  statin	  therapy	  in	  individuals	  estimated	  
to	   have	   a	   10	   year	   absolute	   risk	   of	   CVD	   greater	   than	   20%	   (NICE,	   2010).	   The	  
recommended	   methods	   for	   evaluating	   absolute	   CVD	   risk	   incorporate	   multiple,	  
established	   risk	   factors.	   The	  most	  widely-­‐used	  model	   is	   the	   Framingham	   10	   year	  
CVD	  risk	  score	  (Anderson	  et	  al.	  1991).	  This	  method	  uses	  a	  multivariable	  regression	  
equation	  derived	  from	  a	  population	  sample	  of	  the	  Framingham	  Heart	  Study	  and	  the	  
Framingham	  Offspring	  Study	  (Anderson	  et	  al.	  1991).	  The	  Framingham	  Heart	  Study	  
has	  been	  operational	   for	  more	   than	  40	  years	   and	  has	   identified	  a	  number	  of	   risk	  
factors	   that	   have	   a	   cumulative	   impact	   on	   CVD	   (Anderson	   et	   al.	   1991).	   The	   initial	  
study	   in	   around	   5,500	   residents	   of	   Framingham,	   a	   town	   in	   Massachusetts,	   USA,	  
included	  parents	  and	  offspring	  between	  the	  age	  of	  30	  and	  74	  who	  were	  initially	  free	  
of	   cardiovascular	   disease	   and	   presented	   prediction	   equations	   for	   several	   CVD	  
endpoints	  based	  on	  measurements	  of	   several	   known	   risk	   factors,	   including	   lipids,	  
age,	  sex,	  blood	  pressure,	  smoking	  habit,	  and	  diabetes	  status	  	  (Anderson	  et	  al.	  1991).	  
Other	   risk	   scores	   used	   in	   Europe	   include	   QRISK	   (Hippisley-­‐Cox	   et	   al.	   2007),	  
EuroSCORE	  (Nashef	  et	  al.	  1999)and	  PROCAM	  (Assmann	  et	  al.	  2002),	  with	  the	  latter	  
incorporating	  information	  on	  family	  history,	  a	  surrogate	  for	  genetic	  effects.	  	  
	  
Unfortunately,	  all	   the	  available	   risk	  models	  are	   far	   from	  perfect.	  This	   rests	  on	  the	  
fact	   that	  our	  knowledge	  of	   the	  disease’s	  aetiology	   is	   incomplete,	  both	   in	  terms	  of	  
which	   risk	   factors	   are	   independently	   important	   and	   how	   they	   should	   each	   be	  
weighted.	  Many	   of	   the	   important	   risk	   factors,	   such	   as	   blood	   pressure	   and	   serum	  
cholesterol	   level,	   also	   show	   considerable	   intra-­‐individual	   variation	   and	   cannot	   be	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measured	   with	   sufficient	   accuracy	   to	   support	   risk	   assessment	   with	   the	   required	  
degree	  of	   certainty	   (Dent	  2009).	  Given	   the	  number	  of	   genetic	   variants	  associated	  
with	   CVD	   risk	   factors	   there	   is	   great	   interest	   in	   their	   utility	   for	   improving	   risk	  
prediction,	   since	  genotype	   is	   fixed	   from	  conception	  and	   should	   therefore	   capture	  
long-­‐term	   differences	   in	   risk	   factor	   values	   without	   the	   biological	   variation	   that	  
affects	  measurement.	  	  
	  
1.6.2 Mendelian	  Randomisation	  Analysis	  
1.6.2.1 Background	  
Many	   known	   risk	   factors	   for	   CVD	   have	   been	   identified	   through	   epidemiological	  
studies	  that	  have	  examined	  the	  direct	  association	  of	  the	  observed	  risk	  factor	  with	  
disease	   outcome.	   Identification	   of	   modifiable	   risk	   factors	   can	   inform	   lifestyle	   or	  
therapeutic	  interventions	  to	  reduce	  disease	  risk.	  However,	   inferring	  causality	  from	  
observational	   data	   is	   problematic	   as	   it	   is	   not	   always	   clear	   which	   of	   the	   two	  
associated	   variables	   is	   the	   cause	   and	   which	   the	   effect,	   or	   whether	   both	   are	  
common	   effects	   of	   a	   third	   unobserved	   variable,	   or	   confounder	   (Sheehan	   et	   al.	  
2008).	  Confounding	  factors	  such	  as	  social,	  behavioural	  and	  environmental	   factors,	  
are	  often	  more	  difficult	  to	  measure	  and	  control	  for,	  and	  it	  may	  not	  be	  possible	  to	  
identify	  and	  account	  for	  all	  the	  relevant	  confounders.	  	  
	  
Randomised	   controlled	   trials	   provide	   the	   most	   robust	   estimate	   of	   causal	   effect,	  
however,	   they	   are	   not	   always	   feasible	   and	   have	   cost	   and	   ethical	   implications	  
(Lawlor	   et	   al.	   2004).	   One	   approach	   which	   circumvents	   the	   issues	   faced	   in	  
observational	   studies,	   and	   that	   is	   increasingly	   being	   used	   to	   determine	   causal	  
relationships,	   is	   MR	   analysis.	   MR	   is	   a	   relatively	   recent	   development	   in	   genetic	  
epidemiology	  where	  genetic	  variants	  are	  used	  as	  a	  proxy	  for	  modifiable	  risk	  factors	  
that	  are	  associated	  with	  disease	   (Thomas	  &	  Conti	  2004).	  Since	  heritable	  units	  are	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randomly	   assigned	   at	   conception,	   genotypes	   should	   not	   be	   associated	   with	  
confounding	   factors,	   such	   as	   smoking	   and	   socioeconomic	   circumstances,	   nor	   will	  
the	  genotype	  be	  affected	  by	  disease	  processes	  that	  influence	  the	  intermediate	  risk	  
factor	  (reverse-­‐causation)	  (Smith	  &	  Ebrahim	  2003).	  	  
	  
Observational	   studies,	   for	   example,	   have	   shown	   C-­‐reactive	   protein	   (CRP),	   a	  
nonspecific	  marker	  of	   acute	  phase	   inflammatory	   response,	   to	  be	  a	   strong	  marker	  
for	   CHD	   risk	   (Chambless	   et	   al.	   1997).	   	   Inflammation	   plays	   a	   key	   role	   in	   the	  
underlying	  disease	  process	   for	   the	  development	  of	  CHD,	  and	  CRP	   is	   currently	   the	  
most	   widely	   used	   biomarker	   of	   inflammation	   (Ridker	   et	   al.	   2000).	   However,	   it	   is	  
unclear	   whether	   CRP	   is	   a	   causal	   factor.	   If	   a	   casual	   relationship	   is	   established,	   it	  
would	   warrant	   the	   development	   of	   drugs	   specifically	   targeted	   at	   reducing	   CRP	  
activity.	  However,	  if	  CRP	  levels	  are	  simply	  a	  marker	  of	  inflammation,	  targeting	  CRP	  
is	   unlikely	   to	   be	   an	   effective	   means	   of	   reducing	   cardiovascular	   disease	   burden.	  
Epidemiological	   studies	   may	   identify	   spurious	   associations	   due	   to	   confounding	  
factors	   related	   to	  both	  exposure	  and	  disease	  outcome.	   In	   the	  case	  of	  CRP,	  higher	  
levels	   are	   associated	   with	   smoking,	   which	   is	   also	   a	   risk	   factor	   for	   CHD,	   and	   this	  
three-­‐way	   relationship	   (Figure	   1.9)	   might	   confound	   the	   purported	   causal	   link	  
between	  CRP	  and	  CHD	  (Lawlor	  et	  al.	  2008).	  	  
	  
Figure	  1.9	  The	  Mendelian	  randomisation	  paradigm	  using	  CRP	  and	  CHD	  as	  an	  example.	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A	  recent	  meta-­‐analysis	  used	  MR	  analysis	  to	   look	  at	  the	  association	  of	  known	  CRP-­‐
associated	  genetic	  variants	  with	  CHD	  in	  47	  studies	  (total	  N	  =	  194,418,	  with	  46,557	  
CHD	   cases)	   (Wensley	   et	   al.	   2011).	   Their	   findings	   indicate	   that	   CRP	   concentration	  
itself	  is	  unlikely	  to	  be	  even	  a	  modest	  causal	  factor	  in	  CHD.	  	  
	  
1.6.2.2 Principles	  of	  Instrumental	  Variable	  Analysis	  
The	   method	   of	   instrumental	   variables	   (IVs)	   is	   an	   established	   method	   in	  
econometrics	  used	  to	  estimate	  causal	  relations	  using	  observational	  data	  (Angrist	  et	  
al.	  1996).	  Standard	   regression	  estimates	  of	   the	   relation	  of	   interest	  may	  be	  biased	  
because	   of	   the	   presence	   of	   unmeasured	   confounding	   factors,	   reverse	   causality,	  
selection	   bias,	   or	   measurement	   error	   (Stock	   2001).	   In	   such	   cases	   a	   third,	  
`instrumental'	   variable	   can	  be	  used	   to	  extract	   variation	   in	   the	  variable	  of	   interest	  
that	  is	  unrelated	  to	  these	  problems.	  This	  variation	  can	  then	  be	  used	  to	  estimate	  its	  
causal	  eﬀect	  on	  an	  outcome	  measure	   (Stock	  2001).	   IV	  analysis	  where	  genotype	   is	  
used	  as	  an	  instrument	  is	  known	  as	  MR.	  	  A	  valid	  instrument	  is	  defined	  as	  a	  variable	  
that	  satisfies	  the	  following	  three	  assumptions:	  
1. The	  instrument	  (G),	  which	  in	  MR	  analysis	  is	  genotype,	  is	  strongly	  associated	  
with	  the	  modifiable	  risk	  factor	  of	  interest	  (X)	  (Figure	  1.10).	  
2. The	  instrument	  (G)	  is	  independent	  of	  any	  unmeasured	  confounding	  factors,	  
(U)	  (Figure	  1.10).	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Figure	  1.10	  The	  Mendelian	  randomisation	  model.	  G,	  a	  genetic	  instrument	  with	  a	  specific	  effect	  on	  





1.6.2.3 Estimating	  Causal	  Effects	  using	  IV	  Methods	  
In	  the	  case	  of	  linear	  associations	  and	  a	  continuous	  outcome,	  the	  IV	  estimate	  of	  the	  








ˆˆ = 	  
where	   GYβˆ 	   is	   the	   coefficient	   for	   the	   regression	   of	   outcome	   Y	   on	   the	   genetic	  
instrument	  G,	  and	   GXβˆ 	  is	  the	  coefficient	  for	  the	  regression	  of	  the	  exposure	  X	  on	  the	  
genetic	   instrument	   G	   (Thomas	   &	   Conti	   2004;	   Lawlor	   et	   al.	   2008).	   The	   above	  
estimator	   IVβˆ 	   only	  applies	  when	   there	   is	   a	   single	   IV	   (Lawlor	  et	  al.	   2008)	  and	   this	  
approach	   is	  known	  as	  the	  ratio	  of	  coefficients	  method.	  Where	  there	   is	  more	  than	  
one	   IV,	   the	   simplest	   and	   most	   commonly	   used	   technique	   is	   the	   two-­‐stage	   least	  
squares	   (2SLS)	  method	   (Basmann	   1957).	   The	   IV	   estimate	   is	   derived,	   as	   the	   name	  
suggests,	  by	  two	  regression	  steps:	  	  
1. Performing	  a	   least-­‐squares	   regression	  of	   the	   intermediate	  phenotype	  X	  on	  
the	  instrumental	  variable	  G.	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2. A	  second	  least-­‐squares	  regression	  of	  the	  outcome	  Y	  on	  the	  predicted	  values	  
of	   X	   obtained	   from	   the	   ﬁrst	   regression.	   2SLS	   assumes	   linear	   relationship	  
between	   G,	   X	   and	   Y.	   The	   causal	   estimate	   is	   derived	   from	   this	   second	  
regression.	  
Both	  2SLS	  and	   the	   ratio	  method	  are	  applicable	  with	  a	   single	   instrument,	   in	  which	  
case	   the	   causal	   estimates	   are	   identical,	   but	   2SLS	   can	   also	   be	   used	   with	  multiple	  
instruments.	  
	  
1.6.2.4 Instrument	  Strength	  and	  Weak	  Instrument	  Bias	  
The	   power	   to	   detect	   a	   casual	   relationship	   depends	   on	   the	   sample	   size	   and	   the	  
strength	   of	   the	   instrument,	   which	   in	   MR	   studies	   depends	   on	   the	   proportion	   of	  
variance	  explained	  by	  the	  known	  genetic	  factors	  (R2)	  (Pierce	  et	  al.	  2010).	  Although	  
genetic	  variants	  are	  independent	  of	  confounders,	  confounders	  will	  not	  be	  perfectly	  
balanced	   between	   genotypic	   sub-­‐groups	   in	   finite	   samples	   (Burgess	   &	   Thompson	  
2011).	   If	   the	   instrument	   is	  weak	   and	   does	   not	   explain	  much	   of	   the	   intermediate	  
phenotypic	  variance,	  the	  chance	  difference	  in	  confounders	  may	  explain	  more	  of	  the	  
phenotypic	   difference	   between	   sub-­‐groups	   than	   the	   instrument	   (Burgess	   &	  
Thompson	  2011).	  In	  finite	  samples,	  IV	  estimates	  are	  biased	  in	  the	  same	  direction	  as	  
ordinary	  least	  squares	  (OLS)	  (a	  method	  for	  estimating	  the	  unknown	  parameters	  in	  a	  
linear	  regression	  model)	  estimates	  between	  the	  observed	  intermediate	  phenotype	  
and	  outcome.	   The	  magnitude	  of	   the	   bias	   of	   IV	   estimates	   approaches	   that	   of	  OLS	  
estimates	   as	  R2	   approaches	   zero	   (Bound	  et	   al.	   1995).	  However,	   it	   is	   important	   to	  
note	   that	   the	   sample	   sizes	   typical	   of	   genetic	   studies	   nowadays	   are	   usually	   large	  
enough	  to	  avoid	  weak	  instrument	  bias.	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1.6.2.5 Population	  Stratification	  
Since	   independent	  heritable	  units	  are	  randomly	  assigned	  from	  parent	  to	  offspring	  
during	  gamete	  formation,	  they	  are	  not	  expected	  to	  be	  affected	  by	  any	  confounding	  
factors	   other	   than	   ancestry	   (Pierce	   et	   al.	   2010).	   Presence	   of	   population	  
stratification	  may	  therefore	  violate	  the	  second	  assumption	  of	  IV	  analysis.	  However,	  
restricting	   analysis	   within	   ethnically	   homogenous	   populations	   or	   incorporating	  
population	  structure	  into	  the	  analysis	  should	  overcome	  this	  problem.	  
	  
1.6.2.6 Pleiotropy	  
SNPs	   identified	   from	   association	   studies	   may	   be	   within	   pleiotropic	   genes	   (genes	  
that	  affect	  multiple	  phenotypic	  traits)	  that	  influence	  outcome	  directly	  or	  indirectly	  
through	   risk	   factors	   other	   than	   the	   intermediate	   trait	   of	   interest	   (Palmer	   et	   al.	  
2011).	   Unless	   it	   is	   known	   that	   these	   other	   risk	   factors	   are	   in	   the	   same	   pathway	  
downstream	   of	   the	   intermediate	   trait	   of	   interest,	   these	   may	   not	   be	   valid	  
instruments.	   In	   the	   case	   of	   protein	   traits,	   such	   as	   CRP	   levels	   where	   a	   cis-­‐acting	  
genetic	   variant	   is	   used	   as	   an	   instrument,	   it	   is	   known	   that	   any	   association	   of	   this	  
variant	  with	  other	  risk	  factors	  is	  via	  the	  downstream	  effect	  on	  CRP	  and	  assumptions	  
for	  MR	  are	  not	  violated.	  However,	   in	  the	  case	  of	  non-­‐protein	  traits,	  such	  as	   lipids,	  
several	   SNPs	   in	   different	   genes	   have	   been	   reported	   to	   be	   associated	   with	   more	  
than	  one	  of	  the	  three	  lipid	  fractions	  and	  also	  with	  other	  CVD	  risk	  factors.	  Such	  SNPs	  
may	  violate	  the	  assumptions	  of	  IV	  and	  would	  need	  to	  be	  carefully	  considered	  when	  
used	  in	  MR	  analysis.	  	  
	  
1.6.2.7 Linkage	  Disequilibrium	  
Genetic	   association	   studies	   rely	   on	   the	   LD	   between	   tag	   SNPs	   and	   functional	  
variants.	  IV	  assumptions	  are	  not	  violated	  when	  tag	  SNPs	  are	  used	  as	  IVs,	  unless	  they	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are	  also	  in	  LD	  with	  a	  functional	  variant	  that	  affects	  the	  outcome	  through	  a	  pathway	  
that	  does	  not	  include	  the	  risk	  factor	  of	  interest	  (Palmer	  et	  al.	  2011).	  
	  
1.6.2.8 Single	  SNP,	  Genetic	  Risk	  Score	  and	  Multiple	  SNP	  IVs	  
When	  multiple	  SNPs	  are	  associated	  with	  an	  exposure	  of	  interest,	  either	  a	  single	  SNP	  
may	  be	  chosen	  as	  the	  IV,	  the	  SNPs	  can	  be	  used	  as	  multiple	  IVs	  ,	  or	  multiple	  SNPs	  can	  
be	  combined	  into	  a	  single	  genetic	  risk	  score	  IV	  (Figure	  1.11).	  	  
Figure	   1.11	   Causal	   diagram	   for	   a	  Mendelian	   randomisation	   study.	   (a)	   a	   single	   SNP	   instrumental	  
variable,	  (b)	  multiple,	  independent	  instrumental	  variables	  and	  (c)	  combining	  SNPs	  into	  a	  composite	  
genetic	  score	  instrumental	  variable.	  The	  effect	  size	  for	  each	  relationship	  is	  denoted	  by	  β.	  
	  
Image	  taken	  from	  Pierce	  et	  al	  (Pierce	  et	  al.	  2010)	  
Previous	  lipid	  MR	  analyses	  have	  either	  used	  the	  single	  most	  significantly	  associated	  
SNP	  as	  an	  instrument	  (Sarwar	  et	  al.	  2010)	  or	  a	  combined	  genetic	  risk	  score	  where	  
the	  lead	  SNP	  from	  each	  locus	  has	  been	  selected	  (Kathiresan	  et	  al.	  2008;	  Levy	  et	  al.	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2009).	   Methodological	   studies	   have	   shown	   that	   a	   combined	   genetic	   score	   or	  
multiple	   instruments	   approach	   are	   more	   appropriate	   when	   multiple	   SNPs	   are	  
associated	  with	  the	  exposure	  (Pierce	  et	  al.	  2010;	  Burgess	  &	  Thompson	  2011).	  
	  
1.7 Thesis	  Outline	  
As	  the	  title	  of	  my	  thesis	  suggests,	  the	  focus	  of	  my	  PhD	  has	  been	  two-­‐fold:	  Firstly,	  to	  
improve	   the	   understanding	   of	   the	   biology	   behind	   well-­‐known	   cardiovascular	   risk	  
factors,	   and	   secondly	   to	   explore	   the	   application	   of	   known	   genetic	   variants	  
associated	   with	   CVD	   risk	   factors	   in	   disease	   risk	   prediction,	   and	   in	   determining	  
causality	  between	  CVD	  risk	  factors	  and	  clinically	  relevant	  outcomes.	  	  
	  
In	  Chapter	  2	  I	  report	  the	  large-­‐scale	  discovery	  of	  genetic	  variants	  associated	  with	  LV	  
mass.	   As	   mentioned	   in	   section	   1.5.1,	   the	   pathophysiological	   mechanisms	   of	   LVH	  
remain	   incompletely	   characterised,	   and	   novel	   loci	   associated	   with	   LV	   mass	   may	  
provide	   insight	   into	   the	   pathways	   involved	   in	   the	   development	   of	   LVH.	   Initially,	  
digital	  ECG	  measures	  were	  available	   for	  around	  5000	   individuals	   from	  20	  London-­‐
based	  Civil	  service	  departments	  (Whitehall	  II	  (WHII)	  Cohort).	  These	  individuals	  had	  
also	  been	  genotyped	  using	  the	  Cardiochip	  SNP	  array.	  To	   increase	  the	  sample	  size,	  
and	   hence	   power	   for	   detection	   of	   genetic	   associations,	   collaboration	   with	   two	  
additional	  UK	   studies:	   the	  British	  Women’s	  Health	   and	  Heart	   Study	   (BWHHS)	   and	  
the	  Genetic	  Regulation	  of	  Arterial	  Pressure	  of	  Humans	  in	  the	  Community	  (GRAPHIC)	  
study	   doubled	   the	   sample	   size	   for	   discovery	   through	  meta-­‐analysis	   of	   summary-­‐
level	  data.	  Both	  additional	  studies	  had	  digital	  ECG	  data,	  and	  study	  participants	  had	  
already	   been	   genotyped	   using	   the	   Cardiochip.	   Significant	   associations	   were	  
validated	  in	  three	  additional	  replication	  cohorts.	  
In	  Chapter	  3,	   I	   explore	   the	  potential	   of	   known	   lipid-­‐associated	  genetic	   variants	   in	  
risk	  prediction	  for	  clinically	  relevant	  outcomes,	  including	  high	  CVD	  risk	  status,	  need	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for	  lipid	  therapeutic	  intervention,	  and	  CHD	  outcome.	  The	  ability	  of	  genetic	  data	  to	  
discriminate	   individuals	   in	   each	   outcome	   category	   was	   compared	   with	   the	  
commonly	  used	  non-­‐genetic	  CVD	  risk	  score	  –	  the	  Framingham	  10	  yr	  CVD	  risk	  score.	  
This	  work	  was	  based	  on	  lipid	  genetic	  variants	  identified	  by	  a	  large-­‐scale	  association	  
analysis	   in	   the	  WHII	   study	   published	   in	   2009	   (Talmud	   et	   al.	   2009).	   Analysis	   was	  
carried	  out	  in	  two	  British	  cohorts	  –	  WHII	  and	  BWHHS.	  	  
	  
Finally,	  I	  use	  known	  genetic	  variants	  associated	  with	  lipids	  to	  determine	  their	  causal	  
relationship	   with	   common	   CIMT.	   Clinical	   trials	   of	   drugs	   targeting	   HDL-­‐C	   and	  
triglycerides	   that	   use	   progression	   of	   CIMT	   as	   a	   marker	   for	   drug	   efficacy	   have	  
provided	  contradictory	  results,	  leaving	  their	  causal	  role	  in	  atherosclerosis	  and	  CHD	  
uncertain.	  Since	  many	  lipid-­‐associated	  variants	  have	  been	  identified,	  I	  assessed	  the	  
suitability	   of	   different	   approaches	   for	   instrument	   development	   for	   LDL-­‐C,	   HDL-­‐C	  
and	  triglycerides	  in	  Chapter	  3.	  The	  final	  instruments,	  together	  with	  a	  second	  set	  of	  
independently	   derived	   instruments	   based	   on	   SNPs	   reported	   by	   the	   GLGC,	   were	  
applied	   in	   an	   MR	   analysis	   in	   WHII,	   in	   around	   3000	   individuals,	   and	   in	   the	   IMT	  
Progression	   as	   Predictors	   of	   Vascular	   Events	   in	   a	   High	   Risk	   European	   Population	  
(IMPROVE)	  study,	  in	  around	  3400	  individuals,	  to	  determine	  the	  casual	  relationship	  
between	  the	  three	  lipid	  fractions	  and	  common	  CIMT.	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2 Discovery	  of	  Genetic	  Determinants	  of	  Left	  Ventricular	  
Mass	  
2.1 Introduction	   	  
Measures	  of	  LV	  mass	  are	  used	  in	  the	  diagnosis	  of	  LVH,	  the	  abnormal	  enlargement	  
of	   the	   LV	  muscle	   tissue,	   which	   is	   a	  major	   cause	   of	  morbidity	   and	  mortality.	   The	  
relation	  between	  LV	  mass	  and	  cardiovascular	  risk	  has	  shown	  to	  be	  continuous	  (Levy	  
et	   al.	   1989;	   Schillaci	   et	   al.	   2000),	   therefore	   the	   discovery	   of	   genetic	   factors	   that	  
contribute	   to	  even	   small	   increases	   in	   LV	  mass	  will	   likely	  have	   clinical	   importance.	  
Though	   echocardiography	   is	  more	   sensitive	   than	   ECG	   for	   detecting	   LVH,	   the	   cost	  
and	  operational	   considerations	   limit	   its	  use	   in	   large-­‐scale	  population	   studies.	   ECG	  
data	   is	   more	   widely	   available	   in	   existing	   cohorts	   and	   several	   methods	   exist	   to	  
calculate	  indices	  of	  LV	  mass	  from	  this	  data	  (refer	  to	  section	  1.5.1.2).	  
	  
Though	   both	   echocardiographic	   and	   ECG	   LV	  mass	  measures	   have	   shown	   to	   have	  
significant	   heritability	   (Mayosi	   2002),	   to	   date	   very	   few	   loci	   have	   been	   robustly	  
associated	   with	   these	   traits.	   Two	   studies	   on	   echo-­‐LV	  mass	   (including	   the	   largest	  
GWAS	  to	  date	  for	  this	  trait,	  with	  discovery	  in	  12,612	  individuals	  	  and	  replication	  in	  
4,094	  individuals	  –	  the	  EchoGen	  consortium)	  reported	  no	  definite	  associations	  with	  
LV	  mass	  (Vasan	  et	  al.	  2009;	  Arnett	  et	  al.	  2011).	  A	  study	  in	  a	  total	  of	  202	  individuals	  
from	  the	  extreme	  tails	  of	  the	  LV	  mass	  distribution	  and	  replication	  in	  704	  Caucasian	  
individuals	  reported	  associations	  in	  two	  regions	  (5p13.2	  and	  12q14.3)	  (Arnett	  et	  al.	  
2009),	   and	   a	   genome-­‐wide	   linkage	   analysis	   found	   suggestive	   evidence	   for	   loci	   on	  
chromosomes	  10q23.1	  for	  the	  Sokolow-­‐Lyon	  index,	  and	  on	  17p13.3	  for	  the	  Cornell	  
product	  (Mayosi	  et	  al.	  2008).	  It	  is	  unclear	  whether	  genetic	  variation	  in	  genes	  causal	  
of	  Mendelian	  forms	  (e.g.	  sarcomeric	  genes)	  influences	  less	  severe	  forms	  of	  LVH	  as	  
these	  have	  not	  been	  identified	  in	  previous	  studies.	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Given	   the	   lack	  of	   loci	   reported	   for	   LV	  mass,	   and	   the	   increasing	   interest	  of	   linking	  
genetic	   variants	   affecting	   genes	   involved	   in	   cardiovascular	   disease	   pathways	   and	  
the	  more	  common	  forms	  of	  LVH,	  a	  large-­‐scale	  cardiovascular	  gene-­‐centric	  analysis	  
of	   four	  ECG-­‐derived	   indices	  of	   LV	  mass	   (Sokolow-­‐Lyon	   Index,	  Cornell	  Product,	  12-­‐
lead	  QRS	  Voltage	  Sum	  and	  12-­‐lead	  QRS	  Voltage	  Product)	  was	  carried	  out	   in	   three	  
population-­‐based	   cohorts:	   British	   Women’s	   Health	   and	   Heart	   Study	   (BWHHS),	  
Genetic	   Regulation	   of	   Arterial	   Pressure	   of	   Humans	   in	   the	   Community	   (GRAPHIC)	  
study	  and	  Whitehall	   II	   (WHII),	  with	  a	   total	  sample	  size	  over	  10,000	   individuals.	  All	  
studies	   had	   previously	   collected	   digital	   ECG	   and	   biometric	   data,	   and	   genotyped	  
individuals	   using	   the	   Illumina	   cardiovascular	   gene-­‐centric	   50K	   SNP	   array	  
(Cardiochip)	  (Keating	  et	  al.	  2008).	  Promising	  signals	  were	  replicated	  in	  three	  further	  
cohorts,	  with	  a	  total	  sample	  size	  of	  11,777	  individuals.	  	  
	  
2.2 Materials	  &	  Methods	   	  
2.2.1 Discovery	  Study	  Cohorts	  
2.2.1.1 British	  Women’s	  Heart	  and	  Health	  Study	  (BWHHS)	  
The	   BWHHS	   is	   a	   prospective	   cohort	   study	   of	   4286	   British	   women	   who	   were	  
between	   the	   ages	   of	   60	   and	   79	   at	   baseline	   (1999	   -­‐	   2001)	   (Ebrahim	   et	   al.	   2008).	  
Participants	   were	   randomly	   selected	   from	   general	   practice	   registers	   in	   23	   British	  
towns	  (Lawlor	  et	  al.	  2003).	  Baseline	  demographic,	  anthropometric,	  12-­‐lead	  ECG	  and	  
biological	   data	  were	   collected	   between	   1999	   and	   2001	   and	   used	   in	   this	   analysis.	  
During	  this	  time	  face-­‐to-­‐face	  interviews	  were	  also	  conducted	  for	  the	  completion	  of	  
medical	   questionnaires,	   and	   a	   DNA	   repository	   was	   made.	   Ethical	   committee	  
approval	  was	  obtained	  for	  the	  study.	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2.2.1.2 	  Genetic	  Regulation	  of	  Arterial	  Pressure	  of	  Humans	  in	  the	  Community	  
(GRAPHIC)	  Study	  	  
The	  GRAPHIC	   study	   selected	   2024	   individuals	   from	  520	  nuclear	   families	   recruited	  
from	   the	   general	   population	   in	   Leicestershire,	   UK,	   between	   2003	   -­‐	   2005	   for	   the	  
purpose	   of	   investigating	   the	   genetic	   determinants	   of	   blood	   pressure	   and	   related	  
cardiovascular	  traits	  (Tobin	  et	  al.	  2008).	  Families	  were	  included	  if	  both	  parents	  were	  
aged	   between	   40	   and	   60	   years,	   and	   two	   offspring	   were	   18	   years	   or	   older	   and	  
wished	  to	  participate.	  A	  detailed	  medical	  history	  was	  obtained	  from	  study	  subjects	  
by	   standardised	   questionnaires,	   and	   clinical	   examinations	   were	   performed	   by	  
research	   nurses	   following	   standard	   procedures.	   Blood	   samples	   and	   other	  
measurements	  such	  as	  height,	  weight,	  waist-­‐hip	  ratio,	  clinic	  and	  ambulatory	  blood	  
pressure,	   and	   12-­‐lead	   ECG	   were	   obtained	   from	   participants.	   Ethical	   committee	  
approval	  was	  obtained	  for	  the	  study.	  
	  
2.2.1.3 Whitehall	  II	  (WHII)	  
The	  WHII	   study	   recruited	  10,308	  participants	   (70%	  men)	  between	  1985	  and	  1989	  
from	   20	   London-­‐based	   Civil	   service	   departments	   (Marmot	   &	   Brunner	   2005).	   The	  
study	  was	   initially	   set	   up	   as	   a	   longitudinal	   study	   of	   cardiorespiratory	   disease	   and	  
diabetes.	  Clinical	  measurements	  are	  taken	  every	  5	  years	  and	  postal	  questionnaires	  
are	   conducted	   in	   between	   clinical	   phases.	   Clinical	   data	   were	   available	   from	   four	  
phases:	   1985	   -­‐	   1988,	   1991	   -­‐	   1993,	   1995	   -­‐	   1999	   and	   2003	   -­‐	   2004.	   Clinical	   and	  
questionnaire	   data	   collected	   between	   1991	   and	   1993	   provided	   the	   first	  
comprehensive	  phenotypic	  dataset	  for	  WHII	  and	  is	  considered	  the	  baseline	  phase.	  
By	   2003,	   only	   6914	   of	   the	   original	   10,308	   participants	   attended	   the	   clinic.	   Blood	  
samples	   for	  DNA	  were	  collected	  between	  2002	  and	  2004.	  For	   the	  purpose	  of	   this	  
study,	   data	   collection	   from	   2003	   -­‐	   2004	   provided	   the	   most	   comprehensive	   ECG	  
data,	   and	   these	   were	   used	   in	   the	   calculation	   of	   the	   ECG-­‐LV	   mass	   indices	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investigated	  in	  this	  analysis.	  Participant	  age	  during	  this	  period	  ranged	  between	  50	  
and	  75.	  Ethical	  committee	  approval	  was	  obtained	  for	  the	  study.	  
	  
2.2.2 Replication	  Study	  Cohorts	  
2.2.2.1 British	  Regional	  Heart	  Study	  (BRHS)	  
The initial focus of the BRHS was on the prevalence and incidence of CVD and their 
relations to established behavioural and biological risk factors (Walker	  et	  al.	  2004).	  
The	  study	  comprises	  of	  7735	  men	  aged	  between	  40	  and	  59	  years	  recruited	  from	  24	  
medium	  sized	  British	  towns	  between	  1978	  and	  1980.	  Clinical	  measurements	  were	  
made	  at	  baseline.	  	  Twenty	  years	  later	  (1998	  -­‐	  2000)	  participants	  were	  re-­‐measured,	  
including	  the	  application	  of	  12-­‐lead	  ECG,	  and	  whole	  blood	  samples	  taken	  for	  DNA	  
analysis.	  Phenotypic	  measures	  from	  the	  follow-­‐up	  phase	  (1998	  -­‐	  2000)	  were	  used	  in	  
this	  analysis.	  Ethical	  committee	  approval	  was	  obtained	  for	  the	  study.	  
	  
2.2.2.2 British	  Genetics	  of	  Hypertension	  (BRIGHT)	  Study	  
	  The	  BRIGHT	  study	  comprises	  of	  hypertensive	  families	  recruited	  between	  1996	  and	  
2002.	   Cases	  were	   defined	   as	   having	   blood	   pressure	   readings	   ≥150/100	  mmHg	   (if	  
based	  on	  one	  reading),	  or	  ≥145/95	  mmHg	  (if	  based	  on	  the	  mean	  of	  three	  readings).	  
Each	  family	  contained	  at	  least	  two	  affected	  siblings,	  in	  whom	  onset	  of	  hypertension	  
was	   diagnosed	   before	   the	   age	   of	   60	   years.	   Hypertensive	   individuals	   who	   self-­‐
reportedly	   consumed	  more	   than	  21	  units	   of	   alcohol	   per	  week;	   had	  diabetes;	   had	  
intrinsic	   renal	  disease;	  had	  a	   self-­‐reported	  history	  of	   secondary	  hypertension	   that	  
was	   confirmed	   by	   the	   family	   physician;	   or	   had	   coexisting	   illness,	   were	   excluded.	  
Recruitment	  was	  aimed	   for	  hypertensive	   individuals	  with	  BMI	   less	   than	  30	  kg/m2.	  
ECGs	  were	  obtained	  at	   the	   time	  of	   recruitment.	  Only	  single	   individuals	   from	  each	  
Chapter	  2:	  Materials	  &	  Methods	  
	   	  
	  
59	  
	   	   	  
family	   were	   genotyped	   (Caulfield	   et	   al.	   2003).	   Ethical	   committee	   approval	   was	  
obtained	  for	  the	  study.	  
	  
2.2.2.3 Prevention	  of	  Renal	  and	  Vascular	  End	  Stage	  Disease	  (PREVEND)	  Study	  
The	   PREVEND	   study	   is	   a	   prospective	   investigation	   of	   the	   natural	   course	   of	  
albuminuria	   (elevated	   levels	  of	  albumin	   in	   the	  urine),	  and	   its	   relationship	   to	   renal	  
and	  cardiovascular	  disease.	  The	  patients	  of	   the	  PREVEND	  cohort	  were	   selected	   in	  
1997	   from	   40,856	   individuals	   from	   the	   general	   population	   in	   the	   Netherlands	  
(Smilde	  et	  al.	  2005).	  In	  total,	  8592	  subjects	  were	  included	  in	  the	  PREVEND	  baseline	  
cohort.	  At	  baseline	  (1997-­‐1998)	  biometric	  measurements	  were	  taken;	  participants	  
completed	   a	   questionnaire	   on	   demographics,	   CVD	   history,	   renal	   disease	   history,	  
and	  use	  of	  hypertensive	  medication;	  blood	  pressure	  was	  measured;	  a	  fasting	  blood	  
sample	  was	  drawn	  and	  standard	  12-­‐lead	  ECGs	  were	   recorded.	   	  Ethical	   committee	  
approval	  was	  obtained	  for	  the	  study.	  
	  
2.2.3 Calculation	  of	  ECG-­‐LV	  Mass	  Indices	  
For	   all	   studies	   the	   standard	   12-­‐lead	   ECG	   digital	   data	   was	   transferred	   to	   the	  
University	  of	  Glasgow	  ECG	  Core	  Lab	  based	  at	   the	  Glasgow	  Royal	   Infirmary,	  where	  
they	   were	   reviewed	   manually	   and	   checked	   for	   technical	   problems	   which	   would	  
have	   interfered	  with	  analysis.	   	  Technically	  unsatisfactory	  ECGs	  (which	  may	   include	  
ECGs	  of	  individuals	  with	  existing	  CHD)	  were	  excluded.	  The	  reviewed	  ECGs	  were	  then	  
analysed	   by	   the	   University	   of	   Glasgow	   ECG	   analysis	   program	   (Macfarlane	   et	   al.	  
2005)	  and	  four	  LV	  mass	  indices	  (Sokolow-­‐Lyon	  Index,	  Cornell	  Product,	  12-­‐lead	  QRS	  
Voltage	  Sum	  and	  12-­‐lead	  QRS	  Voltage	  Product)	   generated	   (refer	   to	  Figure	  1.2	   for	  
calculation	   of	   these	   measures).	   This	   software	   meets	   all	   of	   the	   required	  
specifications	   in	   terms	   of	   measurement	   accuracy	   and	   is	   used	   widely	   in	   various	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commercial	  products	  and	  clinical	  trials.	  For	  each	  ECG-­‐LV	  mass	  index,	  outliers	  more	  
than	   3	   standard	   deviations	   (SD)	   away	   from	   the	   mean	   were	   excluded	   from	   the	  
analysis.	  Based	  on	  the	  observed	  distribution	  of	   the	  phenotypic	  measures,	  analysis	  
was	  done	  on	  untransformed	  data.	  
	  
2.2.4 Genotyping	  	  
The	  discovery	  cohorts	  were	  all	  genotyped	  using	  the	  ITMAT	  Broad-­‐CARe	  (Cardiochip)	  
(Keating	  et	  al.	  2008).	  The	  Cardiochip	  is	  a	  gene-­‐centric	  SNP	  array	  containing	  ~50,000	  
SNPs	  covering	  ~2000	  loci	  that	  are	  known	  to	  be	  involved	  in	  cardiovascular	  pathways,	  
as	   determined	   from	   GWAS	   of	   vascular	   and	   inflammatory	   disease	   and	  
comprehensive	  literature	  searching.	  During	  array	  design,	  gene	  loci	  were	  prioritised	  
into	  3	  density	  groups:	  
• Group	  1	  (n	  =	  435	  loci):	  Genes	  and	  regions	  with	  a	  high	  likelihood	  of	  functional	  
significance,	  including	  established	  mediators	  of	  vascular	  disease,	  loci	  derived	  
from	   GWAS	   and	   those	   shown	   to	   be	   associated	   with	   cardiovascular	  
phenotypes	   of	   interest.	   SNPs	   were	   inclusive	   of	   the	   intronic,	   exonic,	  
untranslated	   regions	   (UTRs)	   and	   5	   kilobases	   of	   the	   proximal	   promoter	  
regions.	  The	  average	  number	  of	  SNPs	  in	  the	  Group	  1	  loci	  is	  ~35.6	  (Keating	  et	  
al.	  2008)	  
• Group	   2	  (n	   =	   1,349	   loci):	   Candidate	   loci	   that	   are	   potentially	   involved	   in	  
phenotypes	  of	  interest.	  SNPs	  were	  inclusive	  of	  intronic,	  exonic	  and	  flanking	  
UTRs.	  The	  average	  number	  of	  SNPs	  in	  the	  Group	  2	  loci	  is	  ~16.3	  (Keating	  et	  al.	  
2008)	  
• Group	   3	  (n	   =	   232	   loci):	   Comprised	   mainly	   of	   the	   larger	   genes	   (>100	   kb)	  
which	  were	  of	   lower	  interest	  a	  priori.	  Only	  non-­‐synonymous	  SNPs	  (nsSNPs)	  
and	   known	   functional	   variants	   of	   MAF>0.01	   were	   captured	   for	   these	   loci	  
(Keating	  et	  al.	  2008)	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Genotyping	   in	  each	  study	  was	  done	  at	  different	  genotyping	  centres.	  However,	   for	  
all	   studies	   that	   used	   the	   Cardiochip,	   genotypes	   were	   called	   using	   the	   Illumina	  
BeadStudio	   (version	   3)	   Genotyping	   Module	   using	   the	   default	   GenCall	   software	  
application	   (Illumina	   2005)	   to	   automatically	   cluster	   and	   call	   genotypes	   from	   the	  
intensity	   data.	   The	   same	   quality	   control	   (QC)	   criteria	   were	   applied,	   in	   the	   order	  
specified	  below,	  to	  each	  discovery	  study	  to	  ensure	  data	  integrity.	  	  
1. Exclusion	  of	  low-­‐performing	  SNPs,	  where	  the	  percentage	  of	  missing	  calls	  per	  
SNP	  was	  >	  10%.	  
2. Exclusion	  of	  low-­‐quality	  samples	  with	  percentage	  missing	  calls	  >	  5%.	  
3. Identity-­‐by-­‐descent	   (IBD)	  was	  used	   to	  estimate	   relatedness	  between	  every	  
pair	  of	   individuals	   in	   the	  dataset.	   IBD	   is	  a	  measure	  of	  how	  many	  alleles	  at	  
any	   marker	   in	   each	   of	   the	   two	   samples	   came	   from	   the	   same	   ancestral	  
chromosomes.	  IBD	  was	  calculated	  using	  PLINK	  software	  (Purcell	  et	  al.	  2007)	  
which	   uses	   a	   Hidden	   Markov	   Model	   in	   which	   the	   hidden	   IBD	   state	   is	  
estimated	   given	   the	   observed	   identity-­‐by-­‐state	   (IBS	   -­‐	   a	   measure	   of	   how	  
many	   alleles	   at	   any	  marker	   in	   each	   of	   the	   two	   samples	   happen	   to	   be	   the	  
same).	   IBD	   should	   identify	  known	   duplicates	   that	   have	   been	   genotyped	  
multiple	  times	  for	  quality	  control	  purposes.	  IBD	  will	  also	  identify	  individuals	  
in	   the	   study	   sample	   that	   have	   unknown	   residual,	   non-­‐trivial	   degrees	   of	  
relatedness,	  which	   can	   violate	   the	   independence	   assumptions	   of	   standard	  
statistical	   techniques	   (McCarthy	   et	   al.	   2008).	   Unexpected	   duplicate	   pairs	  
may	   indicate	   sample	   mix-­‐up	   or	   sample	   contamination.	   Given	   the	   gene-­‐
centric	   design	   of	   the	   array	   with	   dense	   coverage	   of	   loci,	   there	   are	   many	  
clusters	  of	  highly	  correlated	  SNPs.	  To	  avoid	  biases	  from	  groups	  of	  correlated	  
markers,	  pairwise	  IBD	  was	  performed	  on	  a	  pruned	  set	  of	  ‘independent’	  SNPs	  
selected	  based	  on	  a	  SNP	  pairwise	  correlation	  threshold	  (R2<0.5).	  One	  sample	  
from	   each	   known	   duplicate	   or	   related	   pair	   was	   removed	   from	   further	  
analysis.	  Unknown	  duplicate	  samples	  are	  likely	  to	  arise	  from	  contamination	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or	  mix-­‐up,	  and	   these	  were	  also	  excluded.	  Since	  GRAPHIC	   is	  a	   family-­‐based	  
study,	  related	  individuals	  were	  included	  in	  the	  data	  and	  family	  structure	  was	  
taken	  into	  account	  in	  downstream	  analysis.	  
4. Multidimensional	  scaling	  (MDS)	  was	  used	  to	  investigate	  any	  structure	  in	  the	  
data	  which	  may	   be	   due	   to	   population	   structure,	   family	   relatedness,	   long-­‐
range	  LD	  or	  genotyping	  assay	  artefacts.	   	  MDS	   is	  a	  method	   that	   represents	  
measurements	   of	   similarity	   (or	   dissimilarity)	   among	   pairs	   of	   objects	   as	  
distances	   between	   points	   in	   a	   low-­‐dimensional	   space	   (Borg	   &	   Groenen	  
2005).	   MDS	   can	   be	   applied	   to	   either	   IBD	   or	   IBS	   to	   identify	   population	  
structure	   and	   outliers.	   In	   this	   case,	   MDS	   was	   applied	   to	   the	   pairwise	   IBS	  
distances	  (calculated	  using	  the	  same	  set	  of	  independent	  SNPs	  as	  for	  the	  IBD	  
calculation)	   to	   cluster	   groups	   of	   individuals	   with	   similar	   genotypes.	   MDS	  
allows	   the	   representation	   of	   the	   genotype	   data	   in	   a	   lower-­‐dimensional	  
space,	   in	   this	   case	   only	   3	   dimensions	   were	   used,	   which	   enables	   the	  
visualisation	  of	  any	  significant	  structure	  present	   in	  the	  data.	  Together	  with	  
self-­‐reported	   ethnicity,	   arbitrary	   cut-­‐offs	   were	   used	   to	   exclude	   non-­‐
Caucasian	  samples	  and	  any	  additional	  outliers	  based	  on	  the	  plot	  of	  the	  first	  
3	  dimensions	  from	  the	  MDS	  analysis.	  This	  is	  shown	  for	  WHII	  data	  in	  	  Figure	  
2.1.	  
5. Samples	  where	   the	   genotype-­‐inferred	   sex	   did	   not	  match	   the	   reported	   sex	  
were	   excluded.	   This	   was	   determined	   by	   looking	   at	   the	   call	   rates	   of	   the	   Y	  
chromosome	   SNPs	   and	   also	   by	   calculating	   the	   homozygosity	   rate	   of	   X	  
chromosome	   SNPs.	   Discordance	   between	   reported	   and	   genetically-­‐
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Figure	   2.1	   Population	   structure	   in	   WHII	   based	   on	   multidimensional	   scaling.	   The	   first	   3	  
dimensions	   are	  plotted	  below.	   Individuals	   in	   black	  have	   self-­‐reported	  Caucasian	   ethnicity	   and	  
those	   in	   red	   have	   self-­‐reported	   non-­‐Caucasian	   ethnicity.	   The	   three	   clusters	   correspond	   to	  
Caucasian,	   Asian	   and	   African	   ancestry.	   Individuals	   that	   clustered	   away	   from	   the	   Caucasian	  









6. The	   Hardy-­‐Weinberg	   equilibrium	   (HWE)	   test	   determines	   whether	   the	  
observed	   genotype	   frequencies	   for	   a	   SNP	   significantly	   differ	   from	   the	  
expected	   frequencies,	   and	   is	   used	   to	   flag	   poorly	   performing	   assays	   and	  
anomalous	  genotype	  clustering.	  The	  HWE	  test	  was	  performed	  after	  removal	  
of	   outliers	   and	   in	   founders	   only.	   SNPs	   with	   HWE	   p-­‐value	   <	   1	   x	   10-­‐04	   are	  
considered	  to	  be	  of	  poor	  quality	  (Laurie	  et	  al.	  2010)	  and	  were	  excluded	  from	  
further	  analysis.	  	  
7. Rare	   SNPs	   are	  more	   prone	   to	   error,	   as	   fewer	   samples	   would	   be	   within	   a	  
genotype	   cluster	   and	   most	   clustering-­‐based	   calling	   algorithms	   do	   not	  
perform	   well	   with	   rare	   alleles	   (Neale	   and	   Purcell	   2008;	   Teo	   2008).	   The	  
power	   to	   detect	   association	   is	   also	  much	   lower	   for	   rare	   SNPs.	   Therefore,	  
SNPs	  with	  minor	  allele	  frequency	  (MAF)	  <	  1%	  were	  excluded	  from	  analysis.	  
SNPs	   and	   samples	   that	   passed	   the	   above	   QC	   filters	   were	   used	   in	   the	   discovery	  
association	  analysis.	  For	   replication	  of	   the	  SNPs	  taken	  forward	   from	  the	  discovery	  
phase,	  genotypes	  were	  generated	  de	  novo	  for	  the	  PREVEND	  Study	  and	  BRHS	  using	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KASPAR	  assays	  (KBioSciences)	  and	  extracted	  in	  silico	  from	  Cardiochip	  array	  data	  for	  
the	  BRIGHT	  Study.	  Replication	  studies	  with	  existing	  Cardiochip	  data	  used	  their	  own	  
QC	  steps	  and	  thresholds,	  which	  were	  similar	  to	  those	  used	  for	  the	  discovery	  studies.	  
For	  all	  studies	  analysis	  was	  restricted	  to	  Caucasian	  samples.	  
	  
2.2.5 Statistical	  Analysis	  
2.2.5.1 Within-­‐Study	  Association	  Analysis	  
In	   each	   of	   the	   discovery	   cohorts,	   linear	   regression	   analyses	   were	   performed	   for	  
each	   SNP	   with	   each	   ECG-­‐LV	   mass	   index	   assuming	   a	   per-­‐allele	   additive	   genetic	  
model.	  Age,	  sex,	  BMI,	  and	  systolic	  blood	  pressure	  (SBP)	  were	  added	  as	  covariates	  in	  
the	   model.	   For	   individuals	   on	   blood	   pressure	   lowering	   medication,	   SBP	   was	  
adjusted	  by	  adding	  a	  constant	  of	  15mmHg	  based	  on	  a	  study	  comparing	  methods	  for	  
adjusting	  blood	  pressure	  for	  treatment	  effects	  (Tobin	  et	  al.	  2005).	  Covariates	  were	  
selected	  based	  on	  prior	  knowledge	  of	  non-­‐genetic	  risk	  factors	  of	  LVH.	  In	  GRAPHIC,	  
additional	   adjustments	   for	   age2	   (due	   to	   the	   older	   age	   of	   parents	   compared	   to	  
children	   in	   the	   cohort)	   and	   familial	   correlation	   were	   taken	   into	   account	   using	  
generalised	  estimating	  equations	  with	  an	  exchangeable	  correlation	  structure	  (Liang	  
&	  Zeger	  1986).	  	  
	  
2.2.5.2 Between-­‐Study	  Meta-­‐Analysis	  
Meta-­‐analysis	   is	   a	   statistical	   method	   for	   combining	   results	   (in	   this	   case	   the	   per-­‐
allele	   beta-­‐coefficients)	   from	   multiple	   independent	   studies	   to	   estimate	   the	  
combined	  effect.	  This	  has	  more	  power	  to	  detect	  an	  effect	  than	  any	  of	  the	  studies	  
individually.	   	   Since	   some	   studies	   may	   have	   more	   precise	   estimates	   than	   others,	  
rather	   than	   calculating	   a	   simple	   mean	   of	   the	   effect	   sizes,	   a	   weighted	   mean	   is	  
calculated	  where	  the	  study-­‐specific	  effects	  are	  weighted	  by	  the	  inverse	  of	  the	  study	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variance	  i.e.	  studies	  with	  large	  variance	  will	  be	  down-­‐weighted	  and	  contribute	  less	  
to	   the	   overall	   effect	   estimate.	   Meta-­‐analysis	   can	   be	   performed	   using	   a	   fixed	   or	  
random	  effects	  model.	  Under	  the	  fixed	  effect	  model	  it	  is	  assumed	  that	  there	  is	  one	  
true	  effect	  size	  which	  is	  shared	  by	  all	  the	  included	  studies.	  By	  contrast,	  the	  random	  
effects	  model	  allows	  the	  true	  effect	  to	  vary	  from	  study	  to	  study.	  This	  between	  study	  
heterogeneity	  is	  incorporated	  into	  the	  meta-­‐analysis.	  	  
The	   relative	   strengths	   of	   fixed	   and	   random	   effects	   analyses	   remain	   controversial	  
(Thompson	   et	   al.	   2011)	   and	   both	   have	   been	   applied	   in	   published	  meta-­‐analyses.	  
Heterogeneity	   was	   measured	   using	   I²	   (Higgins	   et	   al.	   2003),	   which	   describes	   the	  
percentage	   of	   variation	   across	   studies	   attributed	   to	   heterogeneity	   rather	   than	  
chance.	  An	   I2	   value	  of	   0%	   indicates	  no	  observed	  heterogeneity,	   and	   larger	   values	  
show	   increasing	   heterogeneity.	   Because	   ~30%	   of	   SNPs	   passing	   the	   discovery	  
threshold	  (specified	  below)	  showed	  moderate	  to	  high	  heterogeneity	  (I2	  between	  40	  
and	   70),	   a	   random-­‐effects	   model	   was	   applied	   using	   the	   commonly	   used	  
DerSimonian	  and	  Laird	  procedure	  for	  a	  random	  effects	  meta-­‐analysis	  (DerSimonian	  
&	   Laird	   1986),	   whereby	   the	   between-­‐study	   heterogeneity	   estimates	   are	   used	   to	  
adjust	   the	   standard	  errors	  of	   each	   study-­‐specific	   estimate.	   The	   fixed	  effect	  meta-­‐
analysis	  did	  not	   identify	  SNPs	   in	  any	  additional	  genes	  to	  the	  ones	  reported	  by	  the	  
random	  effects	  model.	  Therefore	  only	   results	   from	  the	   random	  effects	  model	  are	  
reported	  here.	  
	  
If	  a	  Bonferroni	  correction	  for	  multiple	  testing	  of	  33,950	  SNPs	  that	  passed	  QC	  in	  all	  
three	   discovery	   cohorts	   was	   applied,	   the	   p-­‐value	   threshold	   would	   have	   been	  
1.47x10-­‐6.	  However,	  given	  the	  lower	  number	  of	  independent	  SNPs,	  the	  higher	  prior	  
odds	  of	  association	  due	  to	  the	  informed	  selection	  of	  loci	  covered	  by	  the	  array	  and	  
the	  opportunity	   to	  eliminate	   false	  positives	  at	   the	   replication	  stage,	   the	  discovery	  
threshold	  to	  take	  SNPs	  forward	  for	  replication	  was	  relaxed	  to	  1x10-­‐4.	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2.2.5.3 Conditional	  Analysis	  
Typically	   many	   SNPs	   in	   a	   region	   harbouring	   one	   or	   more	   causal	   variant(s)	  	  
demonstrate	  univariate	  associations	  with	   the	   traits	  of	   interest	  but	   the	  majority	  of	  
these	   associations	   are	   indirect	   and	   operate	   through	   LD	   with	   the	   causal	   site(s).	  
When	   multiple	   SNPs	   within	   the	   same	   locus	   reached	   significance,	   conditional	  
association	  analyses	  were	  performed,	  whereby	  the	  lead	  (most	  significant)	  SNP	  was	  
added	   to	   the	   linear	   regression	   model	   as	   a	   covariate.	   Any	   SNPs	   that	   remained	  
significant	  at	  the	  discovery	  threshold	  in	  conditional	  analysis	  were	  considered	  to	  be	  
independent	   association	   signals	   from	   the	   lead	   SNP.	   If	   the	  most	   significant	   SNP	   in	  
the	  conditional	  analysis	  passed	  the	  discovery	  p-­‐value	  threshold	  it	  was	  also	  added	  as	  
a	   covariate	   to	   the	   regression	   model	   in	   addition	   to	   the	   original	   lead	   SNP.	   This	  
process	  was	   repeated	  until	  no	  more	  SNPs	   showed	  an	  association	  p-­‐value	   less	   the	  
discovery	  threshold.	  All	  independent	  signals	  were	  taken	  forward	  for	  replication.	  
	  
2.2.5.4 Genomic	  Inflation	  
When	  association	  analysis	  is	  carried	  out	  on	  a	  large	  number	  of	  SNPs	  it	   is	   important	  
to	   test	   the	   distribution	   of	   the	   test	   statistic	   in	   comparison	  with	   the	   expected	   null	  
distribution.	  Any	  deviation	  of	   the	  observed	  test	  statistic	  distribution	   from	  the	  null	  
distribution	  may	  suggest	  systematic	  bias	  (from	  unrecognized	  population	  structure,	  
analytical	   approach,	   genotyping	   artefacts,	   array	   design	   etc).	   This	   deviation	   is	  
quantified	   by	   calculating	   the	   genomic	   inflation	   factor	   and	   can	   be	   visualised	   by	  
quantile–quantile	   (QQ)	   plots.	   The	   genomic	   inflation	   factor,	   lambda,	   is	   defined	   as	  
the	   ratio	   of	   the	   median	   of	   the	   observed	   distribution	   of	   the	   test	   statistic	   to	   the	  
expected	  median,	  thus	  quantifying	  the	  extent	  of	  the	  bulk	  inflation	  (Devlin	  &	  Roeder	  
1999).	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2.2.5.5 Replication	  
Linear	   regression	  analysis	  was	  carried	  out	   in	  each	  of	   the	  three	  replication	  cohorts	  
for	  the	  selected	  SNPs	  with	  the	  ECG-­‐LV	  mass	  trait	  with	  which	  they	  were	  significantly	  
associated	  in	  the	  discovery	  stage.	  As	  before,	  age,	  sex,	  BMI	  and	  corrected	  SBP	  were	  
added	  as	  covariates	  in	  the	  regression	  model.	  A	  meta-­‐analysis	  of	  the	  results	  from	  the	  
replication	  studies	  was	  done	  using	   the	  same	  method	  as	   in	   the	  discovery	  phase.	  A	  
Bonferroni	   correction	   for	   the	   number	   of	   independent	   signals	   taken	   forward	   for	  	  
replication	  (12	  SNPs)	  was	  applied	  to	  the	  standard	  0.05	  significance	  threshold,	  giving	  
a	  replication	  threshold	  of	  p=4.17x10-­‐3.	  	  
	  
2.2.5.6 Calculation	  of	  Variance	  Explained	  
A	   univariate	   linear	   regression	   was	   used	   to	   determine	   the	   proportion	   of	   trait	  
variation	   (R2)	   explained	  by	  each	  of	   the	   four	   replicated	  SNPs	  within	  each	   study.	   In	  
GRAPHIC	  only	  the	  parental	  generation	  was	  used	  to	  calculate	  the	  R2	  value.	  	  
	  
2.2.5.7 Top	  Decile	  Analysis	  
To	  examine	  the	  effect	  of	  each	  of	  the	  four	  replicated	  SNPs	  on	  the	  odds	  of	  being	   in	  
the	  top	  decile	  of	  their	  associated	  trait	  distribution	  i.e.	  QRS	  Voltage	  Sum	  (rs2290893,	  
rs2292462,	   rs4966014)	   and	   Cornell	   Product	   (rs6797133),	   logistic	   regression	   was	  
performed	  in	  each	  discovery	  study	  (adjusting	  for	  the	  same	  covariates	  as	  previously),	  
and	   the	   results	   meta-­‐analysed	   using	   random	   effects.	   In	   addition,	   to	   look	   at	   the	  
combined	  effect	  of	  the	  three	  QRS	  Voltage	  Sum-­‐associated	  SNPs,	  a	  genetic	  risk	  score	  
was	  generated	  for	  each	  individual	  which	  was	  the	  sum	  of	  the	  number	  of	  risk	  alleles	  
(trait-­‐raising	  alleles)	  across	  the	  three	  SNPs	  (for	  a	  single	  SNP,	  an	  individual	  can	  have	  
0,	  1	  or	  2	  risk	  alleles),	  assuming	  a	  per-­‐allele	  additive	  effect.	   Individuals	  carrying	  0-­‐2	  
risk	   alleles	   were	   used	   as	   the	   reference	   group,	   and	   the	   odds	   of	   being	   in	   the	   top	  
Chapter	  2:	  Materials	  &	  Methods	  
	   	  
	  
68	  
	   	   	  
decile	   of	  QRS	   Voltage	   Sum	  were	   calculated	   for	   subjects	   carrying	   3,	   4,	   5	   or	   6	   risk	  
alleles.	  
	  
2.2.6 Functional	  Analysis	  
Bioinformatics	   resources	   were	   used	   to	   assess	   if	   the	   replicated	   SNPs,	   or	   SNPs	   in	  
strong	   LD	  with	   them,	   could	   have	   a	   functional	   impact	   on	   nearby	   genes.	   For	   SNPs	  
found	  in	  coding	  regions,	  their	  likelihood	  of	  affecting	  protein	  structure	  and	  function	  
was	   assessed	   using	   Polyphen	   (http://genetics.bwh.harvard.edu/pph/),	   which	   uses	  
structural	  knowledge,	  evolutionary	  conservation	  and	  knowledge	  of	  functional	  sites	  
to	   assess	   how	   likely	   an	   amino	   acid	   substitution	   will	   alter	   protein	   structure	   and	  
function	   (Adzhubei	   et	   al.	   2010).	   For	   SNPs	   found	   outside	   of	   coding	   regions	   the	  
RegulomeDB	   bioinformatics	   server	   (http://regulome.stanford.edu/)	   was	   used	   to	  
assess	   whether	   the	   SNPs	   were	   found	   within	   any	   regulatory	   regions,	   which	   may	  
suggest	  a	  regulatory	  role	  on	  gene	  expression.	  The	  RegulomeDB	  server	  uses	  publicly	  
available	  data	  to	  annotate	  SNPs	  within	  known	  and	  predicted	  regulatory	  elements.	  
One	   such	   available	   resource	   is	   the	   Encyclopaedia	   of	   DNA	   Elements	   (ENCODE)	  
(Birney	   et	   al.	   2007).	   The	   ENCODE	   project	   used	   genome-­‐wide	   experimental	  
techniques	  to	  identify	  the	  following	  regulatory	  regions	  in	  multiple	  cell	  types:	  
1. Transcription	   factor	   (TF)	   binding	   sites	   identified	   by	   chromatin	   immuno-­‐
precipitation	  with	  sequencing	  (ChIP-­‐Seq)	  (Landt	  et	  al.	  2012).	  TF-­‐bound	  DNA	  
from	   nuclear	   extract	   can	   be	   isolated	   using	   a	   TF-­‐specific	   antibody	   (by	  
chromatin	   immuno-­‐precipitation)	   and	   then	   sequenced.	   Mapping	   the	  
sequenced	  DNA	  fragments	  to	  the	  genome	  locates	  the	  regions	  where	  the	  TF	  
was	  bound.	  
2. Open	   chromatin	   regions	   –	   Active	   regulatory	   regions	   (including	   enhancers,	  
silencers	  and	  promoters)	   tend	   to	  have	  an	  open	  chromatin	   structure	  which	  
allows	   access	   to	  DNA-­‐binding	   regulatory	   proteins.	   The	   open	   nature	   of	   the	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chromatin	   structure	  also	   increases	   sensitivity	  of	   these	   regions	   to	  digestion	  
by	   nucleases	   such	   as	   DNase	   I.	   DNase	   I	   hypersensitive	   sites	   sequencing	  
(DNase-­‐Seq)	   (Song	   &	   Crawford	   2010)	   was	   used	   to	   map	   DNase	   I	  
hypersensitivity	  sites	  across	   the	  genome.	  Open	  chromatin	   regions	  can	  also	  
be	   identified	   by	   Formaldehyde-­‐Assisted	   Isolation	   of	   Regulatory	   Elements	  
with	   sequencing	   (FAIRE-­‐Seq)	   which	   separates	   nucleosomes	   from	   open	  
chromatin.	   Sequencing	   of	   these	   open	   chromatin	   regions	   followed	   by	  
mapping	  onto	  the	  genome	  provides	  the	  location	  of	  these	  regions.	  
3. Histone-­‐methylation	   -­‐	   chemical	   modifications	   (e.g.	   methylation	   and	  
acylation)	   to	   the	   histone	   proteins	   present	   in	   chromatin	   influence	   gene	  
expression	   by	   changing	   how	   accessible	   the	   chromatin	   is	   to	   transcription.	  
Specific	   histone	   modifications	   can	   differentiate	   between	   promoter	   and	  
enhancer-­‐sites	   e.g.	   H3K4Me3	   is	   Histone	  H3	  with	   the	   addition	   of	   3	  methyl	  
groups	   to	   Lysine	   reside	   4,	   which	   is	   associated	  with	   active	   promoters.	   The	  
same	   ChIP-­‐Seq	  method	   using	   antibodies	   specific	   for	   each	   type	   of	   histone	  
modification	   can	   be	   applied	   to	   identify	   regions	   where	   specific	   histone	  
modification	  has	  occurred.	  	  
In	  addition,	  the	  RegulomeDB	  server	  queries	  TF	  binding	  site	  databases	  which	  contain	  
information	   on	   both	   predicted	   and	   experimentally	   validated	   TF	   binding	   sites.	  
Another	  source	  of	  functional	  information	  is	  expression	  quantitative	  trait	  loci	  (eQTL)	  
data.	   These	   are	   genomic	   loci	   that	   regulate	   expression	   levels	   of	   mRNAs.	  
RegulomeDB	   queries	   eQTL	   data	   from	   lymphoblastoid	   cells	   (Montgomery	   et	   al.	  
2010).	  The	  Genevar	  v3.2.0	  software	  (Yang	  et	  al.	  2010)	  was	  also	  used	  to	  query	  eQTL	  
datasets	  from	  lymphoblastoid	  cells,	  skin	  cells,	  adipose	  tissue,	  T-­‐cells	  and	  fibroblasts	  
(Grundberg	  et	  al.	  2012;	  Stranger	  et	  al.	  2012;	  Nica	  et	  al.	  2011;	  Dimas	  et	  al.	  2009).	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2.2.7 Comparison	  of	  ECG-­‐	  and	  Echo-­‐LV	  Mass-­‐Associated	  Variants	  
To	  assess	   if	  any	  of	   the	  replicated	  SNPs	  were	  also	  associated	  with	  echo-­‐LV	  mass,	  a	  
look-­‐up	   of	   their	   association	   in	   the	   EchoGen	   Consortium	   (Vasan	   et	   al.	   2009),	  who	  
were	  responsible	  for	  the	  largest	  published	  GWA	  meta-­‐analysis	  on	  echo-­‐LV	  mass	  to	  
date,	  was	  carried	  out.	  Briefly,	  EchoGen	  had	  performed	  meta-­‐analysis	  of	  GWA	  data	  
from	  5	  population-­‐based	  cohort	  studies	  (Cardiovascular	  Health	  Study,	  Framingham	  
Heart	   Study,	   Rotterdam	   Study,	   Multinational	   Monitoring	   of	   Trends	   and	  
Determinants	   in	   Cardiovascular	   Disease	   study	   (MONICA-­‐KORA),	   and	   Gutenberg	  
Heart	   Study)	   with	   a	   total	   sample	   size	   of	   12,612.	   Within	   each	   study	   summary	  
estimates	  for	  each	  SNP	  were	  obtained	  using	  linear	  regression	  assuming	  an	  additive	  
model	  with	  age,	  sex,	  height	  and	  weight	  as	  covariates,	  and	  a	  meta-­‐analysis	  carried	  
out	  using	  an	  inverse	  variance	  fixed	  effect	  model.	  
	  
2.2.8 Association	  with	  Candidate	  Genes	  
Previous	   studies	   have	   suggested	   association	   of	   variants	   in	   genes	   of	   the	   renin-­‐
angiotensin	  system	  cascade	  with	  LVH,	  notably	  the	  A1166C	  variant	  in	  angiotensin	  II	  
receptor,	  type	  1	  (AGTR1),	  the	  M235T	  polymorphism	  in	  angiotensinogen	  (AGT),	  the	  
insertion/deletion	   (I/D)	   polymorphism	   in	   the	   ACE	   gene	   and	   the	   -­‐344	   C/T	  
polymorphism	   in	   cytochrome	   P450,	   family	   11,	   subfamily	   B,	   polypeptide	   2	  
(CYP11B2).	  Genes	   involved	   in	  haemodynamic	   load,	  calcium	  homeostasis	  have	  also	  
been	   suggested	   to	   play	   a	   role	   in	   LVH	   development	   and	   causal	   mutations	   in	  
sarcomeric-­‐protein	  coding	  genes	  are	  known	  to	  be	  responsible	  for	  Mendelian	  forms	  
of	   cardiac	   hypertrophy.	   Association	   of	   such	   genes	   implicated	   in	   LVH	   (identified	  
through	  literature	  search)	  were	  also	  reported.	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2.3 Results	  
2.3.1 Cohort	  Characteristics	  
After	  QC,	  the	  discovery	  sample	  with	  genotype	  data	  comprised	  of	  10,497	  individuals:	  
3414	  from	  BWHHS,	  2024	  from	  GRAPHIC	  and	  5059	  from	  the	  WHII	  Study.	  Replication	  
was	   undertaken	   in	   3	   additional	   cohorts	   (PREVEND,	   BRHS	   and	   BRIGHT)	   totalling	  
11,777	   individuals.	   Discovery	   and	   replication	   cohort	   characteristics	   are	   shown	   in	  
Table	  2.1.	  
	  
2.3.2 Phenotype	  Distribution	  
The	   distributions	   of	   the	   ECG-­‐LV	  mass	  measures	  were	   very	   similar	   in	   each	   cohort	  
(Figure	   2.2).	   There	   was	   strong	   intra-­‐individual	   correlation	   between	   12-­‐lead	   QRS	  
Voltage	   Sum	   and	   12-­‐lead	   QRS	   Voltage	   Product,	   moderate	   correlations	   between	  
either	  Cornell	  Product	  or	  Sokolow-­‐Lyon	   index	  and	  the	  12-­‐lead	  QRS	   indices	  and	  no	  
correlation	  between	  Cornell	  Product	  and	  Sokolow-­‐Lyon	  index	  (Table	  2.2).	  	  
	  
2.3.3 SNP	  Quality	  Control	  Analysis	  
After	  genotyping	  QC,	  over	  34,000	  SNPs	  in	  each	  study	  remained	  for	  analysis.	  A	  large	  
number	  of	   these	  were	  excluded	  due	  to	   low	  MAF	  (<1%),	  since	  rare	  SNPs	  are	  more	  
prone	  to	  genotyping	  error.	  A	  total	  of	  33,950	  SNPs	  were	  present	  in	  all	  three	  studies	  
after	  applying	  QC	  thresholds.	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Table	  2.2	  Pearson	  correlation	  coefficients	  for	  traits	  and	  covariates.	  	  








BWHHS	   -­‐0.0139	  
1.000	  
	  
GRAPHIC	   -­‐0.0588	  
	  
WHII	   -­‐0.0265	  
	  
QRS	  Voltage	  Sum	  	  
BWHHS	   0.3917	   0.614	  
1.000	  
GRAPHIC	   0.1199	   0.7499	  
WHII	   0.330	   0.684	  
QRS	  Voltage	  
Product	  
BWHHS	   0.6138	   0.429	   0.8434	  
GRAPHIC	   0.2121	   0.6425	   0.9269	  
WHII	   0.444	   0.500	   0.880	  
	  
	  
2.3.4 Association	  Analysis	  
A	   total	   of	   47	   SNPs	   in	   12	   loci	   passed	   the	   discovery	  meta-­‐analysis	   p-­‐value	  
threshold	   of	   1x10-­‐4.	   The	   QQ	   plots	   for	   each	   cohort	   show	   that	   the	  
distribution	   of	   the	   observed	   p-­‐values	   did	   not	   deviate	   much	   from	   the	  
expected	   distribution	   (Figure	   2.3),	   with	   genomic	   inflation	   factors	   ranging	  
between	  1.000	  and	  1.09.	  Conditional	  analysis	  of	  the	  lead	  SNPs	  in	  each	  locus	  
did	  not	  identify	  any	  additional	  independent	  effects	  and	  therefore	  only	  the	  
lead	  SNPs	  were	  selected	  for	  replication.	  	  These	  comprised	  six	  SNPs	  selected	  
on	  the	  basis	  of	  an	  association	  with	  12-­‐lead	  QRS	  Voltage	  Sum,	  one	  with	  12-­‐
lead	  QRS	  Voltage	  Product,	  four	  with	  Cornell	  Product	  and	  one	  with	  Sokolow-­‐
Lyon	  Index	  (Table	  2.3).	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2.3.5 Replication	  
Of	   the	  12	  SNPs	   taken	   forward	   for	   replication,	   four	  showed	  evidence	  of	   significant	  
association	   for	   their	   specific	   trait	   in	   the	   replication	   studies	   after	   allowing	   for	  
multiple	  testing	  (p-­‐value	  <	  4.17x10-­‐3)	  (Table	  2.3).	  These	  were	  variants	  in	  the	  PTGES3	  
(12q13.3),	  NMB	  (15q25.2)	  and	  IGF1R	  (15q26.3)	  genes	  for	  12-­‐lead	  QRS	  Voltage	  Sum	  
and	   the	  SCN5A	   (3p22.2)	  gene	   for	  Cornell	  Product.	  Meta-­‐analysis	  of	   the	  combined	  
discovery	  and	  replication	  data	  gave	  p-­‐values	  of	  3.74x10-­‐8,	  3.23x10-­‐9,	  1.26x10-­‐7	  and	  
1.22x10-­‐7	   for	   the	   lead	   SNPs	   in	   the	   PTGES3	   (rs2290893),	  NMB	   (rs2292462),	   IGF1R	  
(rs4966014)	   and	  SCN5A	   (rs6797133)	   loci,	   respectively.	   	   For	  each	  of	   the	   replicated	  
loci	  the	  study-­‐specific	  estimates	  for	  each	  SNP	  and	  the	  pattern	  of	  association	  across	  
the	   four	   ECG-­‐LV	  mass	   traits	   in	   the	   regions	   are	   shown	   in	   Figure	  2.4	   –	   Figure	  2.11.	  
Summary	   findings	   in	   the	   replication	   samples	   for	   the	  8	  SNPs	   that	  did	  not	  pass	   the	  
replication	  p-­‐value	  threshold	  are	  also	  shown	  in	  Figure	  2.12	  A-­‐H.	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Figure	  2.12	  A-­‐H	  Forest	  plots	  of	  unreplicated	  SNPs.	  Associations	  are	  reported	  by	  study	  separately	  for	  
the	   discovery	   and	   replication	   cohorts,	   together	   with	   pooled	   discovery,	   replication	   and	   overall	  
estimates.	  Beta-­‐coefficients	   (with	  95%	  confidence	   intervals)	  describe	  per	  allele	  effect	  of	   the	  minor	  
allele	  of	  the	  SNP	  for	  the	  trait	  shown.	  The	  heterogeneity	  index	  (I2)	  value	  is	  shown	  in	  the	  bottom	  left	  
hand	  corner.	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2.3.6 Variance	  Explained	  	  
The	  percentage	  of	   trait	  variance	  explained	  by	  each	  of	   the	   four	  novel	   loci	  was	   less	  
than	  0.	  5%	  in	  each	  study	  (Table	  2.4).	  	  
	  
Table	  2.4	  Percentage	  variance	  explained.	  	  
	   	   	  
%	  Variance	  Explained	  
SNP	   Gene	  Locus	   Trait	   BWHHS	   GRAPHIC	   WHII	  
rs6797133	   SCN5A	   Cornell	  Product	   0.12	   0.08	   0.25	  
rs2290893	   PTGES3	   QRS	  Voltage	  Sum	   0.26	   0.46	   0.06	  
rs2292462	   NMB	   QRS	  Voltage	  Sum	   0.11	   0.17	   0.34	  
rs4966014	   IGF1R	   QRS	  Voltage	  Sum	   0.28	   0.01	   0.11	  
	  
2.3.7 Risk	  Allele	  Count	  
To	  investigate	  the	  potential	  clinical	  relevance	  of	  these	  findings,	  the	  extent	  to	  which	  
carriage	  of	  a	   trait-­‐raising	  allele	   increased	   the	  chance	  of	  being	   in	   the	   top	  decile	  of	  
the	  trait	  distribution	  was	  determined.	  Carriage	  of	  the	  rs6797133	  (SCN5A)	  risk-­‐allele	  
increased	  the	  chances	  of	  being	  in	  the	  top	  decile	  of	  the	  Cornell	  Product	  distribution	  
by	  8%,	  while	  carriage	  of	  the	  rs2292462	  (NMB)	   risk-­‐allele	   increased	  the	  chances	  of	  
being	  in	  the	  top	  decile	  of	  the	  QRS	  Voltage	  Sum	  distribution	  by	  19%	  (Figure	  2.13).	  To	  
assess	   the	   combined	  effects	  of	   the	   three	   loci	   (PTGES3,	  NMB	   and	   IGF1R)	   affecting	  
QRS	  Voltage	   Sum,	   the	   odds	   ratio	   of	   being	   in	   the	   top	   decile	   of	   the	   trait	   for	   those	  
carrying	   3	   or	   more	   trait-­‐raising	   alleles	   versus	   those	   carrying	   0-­‐2	   alleles	   was	  
calculated.	  Individuals	  carrying	  6	  risk	  alleles	  had	  a	  1.60-­‐fold	  (95%	  CI	  =	  1.20	  –	  2.29)	  
increased	  likelihood	  of	  being	  in	  the	  top	  decile	  of	  the	  QRS	  Voltage	  Sum	  distribution	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Figure	  2.13	  Odds	  Ratios	  for	  being	  in	  the	  top	  decile	  for	  the	  associated	  ECG-­‐LV	  mass	  trait	  per	  trait-­‐
raising	  allele	   for	  each	  of	   the	   four	   replicated	  SNPs.	  Data	   from	  meta-­‐analysis	  of	  all	   three	  discovery	  
cohorts	  are	  shown	  and	  represented	  as	  odds	  ratio	  (95%	  CI)	  and	  association	  p-­‐values.	  For	  rs2290893,	  
rs2292462	   and	   rs4966014	   the	   odds	   ratios	   for	   being	   in	   the	   top	   decile	   of	   the	   QRS	   Voltage	   Sum	  
distribution	  are	  shown,	  while	  for	  rs6797133	  the	  odds	  ratios	  for	  being	  in	  the	  top	  decile	  of	  the	  Cornell	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Figure	  2.14	  Meta	  analysis	  of	  the	  odds	  ratio	  for	  being	  in	  the	  top	  decile	  for	  QRS	  Voltage	  Sum	  decile	  
The	  group	  carrying	  0-­‐2	  alleles	  was	  used	  as	  the	  reference	  group.	  	  	  Data	  shows	  the	  odds	  ratio	  and	  95%	  
CI	   of	   each	   risk-­‐allele	   score	   derived	   from	   the	   three	   SNPs	   associated	   with	   this	   trait	   (rs2290893,	  
rs2292462,	  rs4966014).	  The	  sample	  size	  in	  each	  risk	  allele	  and	  decile	  group	  are	  shown	  at	  the	  bottom	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2.3.8 Functional	  Analysis	  
SNP	  rs2290893	  is	  located	  in	  the	  first	  intron	  of	  the	  PTGES3	  gene.	  Based	  on	  analysis	  
using	  the	  RegulomeDB	  server	  there	  was	  evidence	  that	  this	  SNP	  could	  have	  an	  effect	  
on	   protein	   binding	   and	   expression:	   it	   was	   found	   within	   a	   region	   enriched	   for	  
histone-­‐modifications	   characteristic	   of	   both	   promoters	   and	   enhancers,	   as	  well	   as	  
within	  a	  DNase	  hypersensitive	   region,	   characteristic	  of	  active	  promoters.	  The	  SNP	  
also	   lies	   within	   an	   experimentally-­‐determined	   binding	   site	   for	   the	   transcription	  
factor	   Cdx-­‐2.	   It	   was	   also	   significantly	   associated	   with	   higher	   RBMS2	   (a	   gene	  
upstream	  of	  PTGES3)	   expression	   in	  adipose	  and	   skin	   tissue	   (p-­‐value	  <	  1x10-­‐06).	  At	  
the	  NMB	  locus,	  the	  lead	  SNP	  rs2292462	  was	  associated	  with	  expression	  of	  NMB	  in	  
adipose	  tissue	   (p-­‐value	  <	  1x10-­‐06).	  The	  SNP	  was	  also	   in	  LD	  (r2=0.48,	  D’=1.0)	  with	  a	  
non-­‐synonymous	  SNP	  (rs1051168,	  Proline	  to	  Threonine),	  234	  base	  pairs	  away	  that	  
had	  an	  association	  signal	  (p-­‐value	  =	  4.3x10-­‐5)	  with	  QRS	  Voltage	  Sum	  in	  the	  discovery	  
meta-­‐analysis,	  comparable	  with	  that	  of	  the	  lead	  SNP.	  However,	  based	  on	  Polyphen	  
prediction	  this	  SNP	  is	  unlikely	  to	  affect	  protein	  structure	  or	  function.	  There	  was	  no	  
evidence	  to	  support	  any	  functional	  impact	  of	  the	  other	  two	  SNPs.	  
	  
2.3.9 Variants	  Associated	  with	  Echo-­‐LV	  Mass	  	  	  
There	  was	  no	  evidence	  for	  association	  of	  any	  of	  the	  replicated	  variants	  with	  echo-­‐
LV	  mass	  in	  the	  EchoGen	  data	  (Table	  2.5).	  
Table	  2.5	  Association	  of	  ECG-­‐LV	  mass	  signals	  with	  echo-­‐LV	  mass.	  	  















rs2290893	   PTGES3	   12	   55364887	   A	   G	   -­‐0.08	   0.46	   0.87	   0.36	  
rs2292462	   NMB	   15	   83001758	   G	   T	   -­‐0.33	   0.45	   0.47	   0.46	  
rs4966014	   IGF1R	   15	   97065541	   C	   T	   0.18	   0.54	   0.74	   0.32	  
rs6797133	   SCN5A	   3	   38631037	   A	   G	   0.17	   0.45	   0.71	   0.39	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2.3.10 Association	  with	  Candidate	  Genes	   	  
Renin-­‐angiotensinogen	   system	   polymorphisms,	   previously	   suggested	   to	   be	  
associated	   with	   LVH,	   were	   not	   associated	   with	   ECG-­‐LV	   mass	   indices	   (Table	   2.6).	  	  
Upon	   examination	   of	   variants	   in	   other	   candidate	   genes	   and	   pathways	   linked	   to	  
development	   of	   LVH,	   nominal	   associations	   with	   variants	   in	   several	   genes	   were	  
found	  (Table	  2.7).	  Although	  the	   level	  of	  significance	  achieved	  for	  these	  variants	   in	  
the	  context	  of	   the	   large	  number	  of	   SNPs	  examined	  cannot	  exclude	   the	  possibility	  
that	   many	   of	   these	   associations	   are	   false	   positives,	   their	   location	   within	   genes	  




2.4.1 Summary	  of	  Results	  
Large-­‐scale	   association	   meta-­‐analysis	   identified	   four	   genetic	   variants	   robustly	  
associated	   with	   some	   of	   the	   ECG-­‐derived	   indices	   of	   LV	   mass,	   providing	   novel	  
insights	   into	  the	  genetic	  determinants	  of	   this	  widely	  assessed	  cardiovascular	   trait.	  
The	  SNPs	  demonstrated	  association	  with	  Cornell	   Product	   at	  3p22.2	   in	  SCN5A	   and	  
with	  QRS	  Voltage	  Sum	  at	  12q13.3	  in	  PTGES3,	  15q25.2	  in	  NMB	  and	  15q26.3	  in	  IGF1R.	  
These	  variants	  do	  not	  appear	   to	  be	  associated	  with	  echo-­‐LV	  mass	  suggesting	   that	  
these	  phenotypes	  may	  measure	  somewhat	  distinct	  aspects	  of	  cardiac	  biology.	  	  
	  
2.4.2 Insulin	  Growth	  Factor	  Pathway	  in	  Cardiac	  Biology	  	  
Cardiac	  hypertrophy	  is	  characterised	  by	  an	  increase	  in	  cardiomyocyte	  size,	  disarray	  
of	  myofibrils,	  fibrosis	  in	  the	  extracellular	  matrix,	  re-­‐activation	  of	  fetal	  transcriptional	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programs,	   and	   decreased	   cardiac	   function	   (Sun	   et	   al.	   2009).	   Cardiac	   myocytes	  
undergo	  rapid	  proliferation	  during	  fetal	  life,	  but	  in	  the	  perinatal	  period	  proliferation	  
ceases.	   Adult	   cardiac	   myocytes	   generally	   do	   not	   re-­‐enter	   the	   cell	   cycle	   when	  
exposed	  to	  growth	  signals,	  and	  further	  increases	  in	  cardiac	  mass	  are	  partly	  achieved	  
through	  an	  increase	  in	  cell	  size	  (hypertrophy)	  (Ahuja	  et	  al.	  2007).	  The	  association	  of	  
variants	   in	   the	   insulin	  growth	   factor	  1	   receptor	   (IGF1R)	   gene	  with	  ECG-­‐LV	  mass	   is	  
plausible	  given	  the	  current	  knowledge	  of	  the	  role	  of	  the	  IGF	  pathway	  in	  the	  heart.	  
IGF1	  binds	  to	  IGF1R	  triggering	  a	  signalling	  cascade	  that	  plays	  an	  essential	  regulatory	  
role	   in	   cardiac	   biology.	   During	   the	   post-­‐natal	   period,	   the	   switch	   in	   cardiac	  
metabolism	   and	   	   the	   cardiomyocyte’s	   withdrawal	   from	   the	   cell	   cycle	   is	  
characterized	  by	  a	  marked	  decrease	  in	  the	  expression	  of	  IGF1	  and	  IGF1R	  (Knezevic	  
et	   al.	   2012).	   There	  have	  been	   several	  mouse	   studies	   that	  have	  demonstrated	   the	  
importance	  of	  the	  IGF-­‐1	  signalling	  pathway	  in	  cardiac	  remodelling.	  Transgenic	  mice	  
over-­‐expressing	   IGF1R	   in	   the	   heart	   displayed	   cardiac	   hypertrophy,	  which	  was	   the	  
result	  of	  an	  increase	  in	  myocyte	  size	  (McMullen	  et	  al.	  2004).	  A	  recent	  study	  in	  mice	  
also	  demonstrated	  that	  postnatal	  repression	  of	  cardiac	  IGF1R	  is	  associated	  with	  the	  
up-­‐regulation	   of	   a	   micro-­‐RNA	   (miR-­‐378)	   promoting	   cardiomyocyte	   apoptosis	  
(Knezevic	   et	   al.	   2012).	   IGF-­‐1-­‐injected	   hearts	   of	   infarcted	   mice	   showed	   improved	  
ventricular	   function	  and	  cardiomyocyte	  survival	   (Urbanek	  et	  al.	  2005;	  Welch	  et	  al.	  
2002).	   Interestingly,	   SNPs	   in	   the	   IGF1	  gene	  did	  not	   show	  association	  with	  ECG-­‐LV	  
mass	  traits	  in	  this	  analysis.	  
	  
2.4.3 SCN5A	  
Mutations	   in	   SCN5A,	   which	   encodes	   the	   sodium	   channel,	   voltage-­‐gated,	   type	   V,	  
alpha	   sub-­‐unit,	   cause	   long	   QT	   syndrome,	   a	   Mendelian	   arrhythmogenic	   disease	  
characterised	  by	  a	  prolonged	  QT	  interval	  (represents	  the	  ventricular	  contraction	  on	  
the	  ECG	  (refer	  to	  Figure	  1.1).	  SNPs	  in	  this	  gene	  have	  been	  associated	  with	  two	  other	  
ECG	  parameters,	  PR	   Interval	  and	  QRS	  duration	   (Chambers	  et	  al.	  2010;	  Holm	  et	  al.	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2010).	   Increased	   LV	  mass	   is	   known	   to	   increase	   the	   height	   and	   depth	   of	   the	  QRS	  
complex	  and	   the	   length	  of	   the	  QRS	  duration.	  Association	  of	  SCN5A	  variants	  were	  
only	   observed	   with	   the	   two	   ECG-­‐LV	   mass	   indices	   incorporating	   QRS	   duration	  —	  
Cornell	   Product	   and	  QRS	   Voltage	   Product.	   Given	   the	   high	   correlation	   of	   the	  QRS	  
Voltage	   Product	   with	   the	   QRS	   Voltage	   Sum	   and	   the	   lack	   of	   association	   with	   the	  
latter	  index	  which	  incorporates	  the	  amplitude	  of	  the	  Q,	  R	  and	  S	  waves	  but	  not	  the	  
duration,	   it	   is	   unclear	   whether	   the	   observed	   association	   of	   SCN5A	   variants	   with	  
ECG-­‐LV	  mass	   reflects	   changes	   in	   the	   function	   of	   the	   sodium	   channel	   that	   simply	  
affect	  the	  propagation	  of	  the	  electrical	  signal,	  or	  whether	  variants	  in	  SCN5A	  actually	  
affect	  myocyte	  size.	  
	  	  
2.4.4 PTGES3	  and	  NMB	  
Neither	  PTGES3	  nor	  NMB	  are	  a	  priori	  biological	  candidates	  likely	  to	  influence	  ECG-­‐
LV	  mass.	  PTGES3	  codes	  for	  prostaglandin	  E	  synthase	  3	  (also	  known	  as	  p23	  or	  TERT	  
binding	   protein).	   NMB	   codes	   for	   neuromedin	   B,	   the	   mammalian	   homologue	   of	  
bombesin-­‐like	  peptide.	  Fine-­‐mapping	  of	  these	  regions	  may	  help	  identify	  the	  causal	  
gene	  in	  these	  regions.	  
	  
2.4.5 Sarcomeric	  Protein-­‐Coding	  Genes	  
Though	   SNPs	   in	  MYOZ2	   (Myozenin	   2)	   and	   TTN	   (Titin),	   both	   playing	   an	   important	  
role	   in	   sarcomere	   structure	   and	   function,	   did	   not	   pass	   the	   replication	   threshold,	  
they	   showed	   suggestive	   evidence	   for	   association	   in	   the	   replication	   studies.	  Given	  
that	  both	  genes	  are	  associated	  with	  hypertrophic	  cardiomyopathy	  (Osio	  et	  al.	  2007;	  
Satoh	  et	  al.	  1999),	  they	  may	  be	  plausible	  candidates	  for	  LV	  mass	  variation.	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2.4.6 Comparison	  of	  Echo-­‐LV	  Mass	  and	  ECG-­‐LV	  Mass	  
Interestingly,	  the	  loci	  associated	  with	  ECG	  indices	  of	  LV	  mass	  did	  not	  show	  evidence	  
of	  association	  with	  echo-­‐derived	  LV	  mass	  in	  the	  large	  meta-­‐analysis	  by	  the	  EchoGen	  
Consortium	   (Vasan	   et	   al.	   2009).	   However,	   several	   observations	   indicate	   that	   the	  
two	  may	  reflect	  different	  biological	  processes.	  The	  electrocardiogram	  measures	  the	  
algebraic	   sum	   of	   the	   action	   potentials	   of	   myocardial	   fibres.	   Therefore,	   the	   ECG	  
changes	   in	   cardiac	   hypertrophy	   reflect	   the	   electrical	   remodelling	   of	   the	   action	  
potential	   of	   the	   cardiac	   myofibres,	   which	   is	   measured	   in	   voltage	   and	   time	   (Hill	  
2003).	   By	   contrast,	   the	   echocardiogram	   captures	   anatomical	   remodelling	   of	   the	  
myofibres,	   fibroblasts,	   other	   interstitial	   changes	   (such	   as	   inflammation)	   and	   the	  
cardiac	   chambers	   of	   the	   heart.	   This	   is	   reflected	   in	   the	   poor	   correlation	   between	  
ECG-­‐	   and	   echo-­‐LV	  mass	  measures	   in	   several	   clinical	   contexts	   (Casale	   et	   al.	   1987;	  
Epstein	  et	  al.	  1990;	  Rosenzweig	  et	  al.	  1991).	  More	  direct	  evidence	  that	  they	  may	  be	  
genetically	  different	  comes	  from	  assessment	  of	  ECG-­‐LVH	  indices	  and	  echo-­‐LV	  mass	  
in	  the	  same	  families	  showing	  greater	  heritability	  for	  the	  ECG	  indices	  (Mayosi	  2002).	  
This	  observation	  underscores	   the	   importance	  and	   relevance	  of	   identifying	  genetic	  
determinants	  of	  both	  traits.	  	  
	  
2.4.7 Combined	  Effect	  of	  Four	  Loci	  	  
Consistent	   with	   variants	   identified	   for	   other	   complex	   quantitative	   traits,	   the	  
amount	   of	   trait	   variance	   explained	   by	   each	   SNP	   individually	   was	   low	   (<1%).	  	  
Carriage	  of	   the	   trait-­‐raising	  allele	   at	   each	  of	   the	   locus	  was	  associated	  with	  an	  8	   -­‐	  
19%	  higher	  probability	  of	  lying	  in	  the	  top	  10%	  of	  the	  population	  distribution	  for	  that	  
trait.	   The	   effect	   of	   the	   three	   loci	   affecting	   QRS	   Voltage	   Sum	   was	   additive.	  
Individuals	  carrying	  all	  six	  trait	  raising	  alleles	  for	  these	  loci	  (~	  6%	  of	  the	  population)	  
had	  a	  1.60	  (95%	  CI	  =	  1.23	  -­‐	  2.29)	  fold	  increased	  probability	  of	  lying	  in	  the	  top	  decile	  
for	   QRS	   Voltage	   Sum	   compared	   with	   those	   carrying	   0-­‐2	   alleles.	   Whether	   these	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differences	   impact	  on	  the	  cardiovascular	  risk	  associated	  with	  ECG-­‐LVH	  will	  require	  
further	  evaluation	  in	  large-­‐scale	  population	  samples.	  
	  
2.4.8 Limitations	  
The	  	  Cardiochip	  	  array	  contains	  only	  about	  10%	  of	  all	  genes	  in	  the	  human	  genome	  
with	   a	   known	   or	   suspected	   cardiovascular	   function	   (Keating	   et	   al.	   2008).	   While	  
providing	  a	  cost-­‐effective	  analysis	  of	  variants	  in	  these	  genes,	  a	  significant	  limitation	  
is	   that	   it	   does	  not	  provide	   full	   genome	   coverage	   and	   there	   are	   likely	   to	  be	  many	  
missed	  variants	  with	  similar	  or	  indeed	  greater	  effects	  than	  those	  identified	  that	  lie	  
outside	   of	   known	   cardiovascular	   pathways.	   	   Even	   within	   the	   genes	   studied	  
additional	   variants	   may	   not	   have	   been	   identified,	   given	   the	   threshold	   used	   for	  
taking	  variants	  forward	  for	  replication.	  Larger	  and	  more	  comprehensive	  studies	  will	  
be	  required	  to	  identify	  more	  loci	  associated	  with	  ECG-­‐LV	  mass	  traits	  and	  explain	  a	  
larger	   proportion	   of	   their	   variances.	   	   Analysis	   in	   the	   extremes	   of	   the	   LV	   mass	  
distribution	  may	  be	  an	  additional	  strategy	  for	  genetic	  discovery	  if	  larger	  studies	  are	  
available.	  
	  
As	  with	  any	  study	  of	  this	  type,	  the	  association	  findings	  provide	  a	  first	  step	  towards	  
identifying	   and	   studying	   the	   functionality	   of	   candidate	   genes	   in	   the	   associated	  
region.	   For	   some	   of	   the	   identified	   regions,	   where	   no	   functional	   link	   to	   LV	   mass	  
could	   be	   identified,	   the	   causal	   gene	   is	   unclear.	   In	   such	   cases	   fine-­‐mapping	   via	  
imputation	  of	  additional	  SNPs	  or	  sequencing	   in	   these	   regions	  may	  help	   refine	   the	  
location	  of	  the	  causal	  gene	  and	  variant.	  
	  
Though	   there	   is	   evidence	   for	   some	   of	   these	   SNPs	   being	   associated	   with	   gene	  
expression	  of	  nearby	  genes,	  to	  establish	  a	  more	  confirmatory	  role	  in	  relation	  to	  the	  
trait	  of	  interest,	  eQTL	  analysis	  of	  heart	  tissue	  would	  need	  to	  be	  carried	  out.	  Though	  
the	  data	  is	  not	  yet	  available	  for	  all	  tissues,	  the	  Genotype-­‐Tissue	  Expression	  project	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(https://commonfund.nih.gov/GTEx/),	   an	   initiative	   to	   understand	   how	   genetic	  
variation	   may	   control	   gene	   activity	   and	   its	   relationship	   to	   disease,	   is	   currently	  
underway,	  which	  will	   eventually	   provide	   eQTL	   data	   in	   heart	   tissue.	   SNPs	   that	   fall	  
within	   regulatory	   regions	   may	   alter	   transcription	   factor	   binding,	   histone	  
methylation	  signatures	  and	  chromatin	  accessibility.	  Experimental	  techniques	  can	  be	  
used	   to	   measure	   allele-­‐specific	   differences	   in	   protein	   binding	   (electrophoretic	  
mobility	   shift	   assay),	   gene	   expression	   (luciferase	   reporter	   assay)	   and	   open	  
chromatin	   (FAIRE),	   to	   confirm	   the	   functional	   role	   of	   SNPs.	   However,	   this	  
information	  would	  still	  need	  to	  be	  related	  to	  changes	  in	  phenotype.	  
	  
Though	   these	   findings	   provide	   new	   insights	   into	   the	   genetic	   influences	   on	   a	  
routinely	   recorded	   clinically-­‐relevant	   cardiovascular	   trait,	   the	   biologic	  meaning	   of	  
the	  findings	  requires	  consideration	  of	  the	  specific	  traits,	  variants	  and	  genes	  at	  the	  
loci,	   and	   annotations	   of	   their	   potential	   functions	   before	   their	   possible	   clinical	  
relevance	  will	  be	  understood.	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3 Lipid-­‐Associated	  Genetic	  Variants	  for	  Risk	  Prediction	  
3.1 Introduction	  
Ideally,	  a	  predictive	  model	  would	  be	  able	  to	  categorise	  people	  dichotomously	  into	  
those	   who	   would	   develop	   CHD	   and	   those	   who	   would	   not	   (Dent	   2009).	   Those	  
predicted	   to	   have	   a	   CHD	   event	   could	   then	   be	   targeted	   to	   receive	   therapeutic	   or	  
lifestyle	   interventions	   that	   would	   reduce	   their	   risk	   and	   prevent	   or	   postpone	   the	  
occurrence	   of	   the	   disease.	   Unfortunately,	   all	   available	   risk	   models	   are	   far	   from	  
perfect	   and	   there	   is	   ongoing	   research	   into	   whether	   additional	   risk	   factors	   can	  
improve	  current	  risk	  prediction	  models.	  
	   	  
Blood	   lipid	   levels	   have	   been	   known	   CVD	   risk	   factors	   for	   over	   half	   a	   century,	   and	  
therapeutic	   intervention	   for	  primary	  prevention	  of	  CVD	   in	   the	  general	  population	  
was	   initially	   informed	   by	   lipid	   level	   thresholds.	   However,	   lipid	   levels	   identify	  
patients	   at	   risk	   of	   future	   coronary	   events	   only	   moderately	   well.	   NICE	   and	   other	  
organisations	   recommend	   commencing	   LDL-­‐C-­‐lowering	   statin	   therapy	   for	   primary	  
prevention	   in	   individuals	  estimated	   to	  have	  a	  10	  year	  absolute	   risk	  of	  CVD	  >20%,	  
where	   the	   recommended	  methods	   for	  evaluating	  absolute	  CVD	   risk	   are	  based	  on	  
multiple,	  established	  risk	   factors.	  The	  most	  widely-­‐used	  model	   is	   the	  Framingham	  
10	  year	  CVD	  risk	  score	  (Anderson	  et	  al.	  1991),	  based	  on	  analysis	  carried	  out	  in	  the	  
Framingham	  Heart	  Study	  (see	  section	  1.6.1).	  Despite	  these	  guidelines,	  doctors	  may	  
still	   be	   persuaded	   in	   their	   therapeutic	   decisions	   by	   high	   absolute	   values	   of	   total	  
cholesterol	  or	  LDL-­‐C.	  	  
	  
All	   the	   principal	   blood	   lipid	   fractions:	   total	   cholesterol,	   LDL-­‐C,	   HDL-­‐C,	   and	  
triglycerides,	  have	  both	  environmental	  and	  genetic	  determinants,	  with	  a	   reported	  
heritability	   of	   40	   -­‐	   70%	   (Krauss	   2008).	   Recently,	   association	   studies	   using	   whole	  
genome	   and	   dense	   gene-­‐centric	   arrays	   have	   identified	   numerous	   common	   SNPs	  
associated	  with	  these	  four	   lipid	  fractions.	  Each	  SNP	  has	  a	  small	  average	  effect	  but	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any	   individual	   may	   carry	   numerous	   variants	   which,	   collectively,	   have	   a	   more	  
substantial	   influence	   on	   blood	   lipid	   levels	   (Talmud	   et	   al.	   2009).	   Genetic	   variants	  
have	   some	   potential	   advantages	   over	   non-­‐genetic	   risk	   factors	   as	   predictors	   of	  
disease	  risk.	  Genotype	  is	  fixed	  from	  conception	  and	  so	  should	  represent	  long-­‐term	  
differences	  in	  blood	  lipid	  values	  without	  the	  biological	  variation	  that	  affects	  assays	  
of	  blood	  lipids	  themselves.	  Genotyping	  assays	  have	  very	  high	  fidelity	  and	  low	  cost.	  
This	  has	  led	  to	  an	  interest	  in	  the	  potential	  use	  of	  genetic	  information	  for	  evaluation	  
of	  cardiovascular	  risk.	  	  Despite	  lipids	  being	  important	  CHD	  risk	  factors,	  there	  is	  little	  
information	  on	  the	  population	  effect	  of	  multiple	   lipid-­‐associated	  SNPs	  on	  clinically	  
relevant	  healthcare	  outcomes	  such	  as	  estimates	  of	  cardiovascular	  risk,	  prescription	  
of	  lipid-­‐lowering	  drug	  therapies,	  and	  subsequent	  clinical	  events.	  	  
	  
The	  aim	  of	  the	  work	  in	  this	  chapter	  was	  to	  evaluate	  the	  influence	  of	  common	  SNPs	  
associated	   with	   total	   cholesterol,	   LDL-­‐C,	   HDL-­‐C	   and	   triglyceride	   levels	   on	   the	  
following	  outcomes:	  (1)	  being	  identified	  as	  a	  ‘high-­‐risk’	  individual	  as	  determined	  by	  
a	  Framingham	  10	  year	  CVD	  risk	  greater	  than	  20%,	  which	  is	  the	  qualifying	  threshold	  
used	   to	   identify	   such	   individuals	   in	   Britain	   (and	   many	   other	   countries),	   and	   is	   a	  
reference	   against	   which	   many	   other	   methods	   of	   risk	   prediction	   are	   routinely	  
assessed;	  (2)	  receiving	  lipid	  lowering	  treatment,	  since	  guidelines	  encourage	  primary	  
therapeutic	   intervention	   for	   these	   high-­‐risk	   individuals;	   and	   (3)	   coronary	   disease	  
events.	  Analysis	  was	  carried	  out	  in	  two	  British	  cohorts	  (WHII	  and	  BWHHS),	  in	  which	  
prescribing	  decisions	  were	  made	  without	  knowledge	  of	  participants’	  genotype.	  For	  
comparison,	  the	  association	  of	  the	  Framingham	  10	  year	  CVD	  risk	  score	  (Anderson	  et	  
al.	   1991),	  which	   is	   based	   on	   phenotypic	   rather	   than	   genetic	  measurements,	  with	  
the	  odds	  of	  receiving	  lipid	  medication	  and	  CHD	  outcome	  was	  also	  assessed.	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3.2 Materials	  and	  Methods	  
3.2.1 Study	  Populations	  
Data	  from	  the	  WHII	  and	  BWHHS	  cohorts	  were	  used	  for	  this	  analysis,	  both	  of	  which	  
were	   described	   previously	   in	   section	   2.2.1.	   Baseline	   lipid	   and	   CVD	   risk	   factor	  
measurements	   (1991-­‐1993	   in	  WHII,	   and	   1999-­‐2001	   in	   BWHHS)	   were	   used,	   while	  
information	  on	  CHD	  events	  and	  lipid	  medication	  use	  was	  obtained	  from	  the	  2003-­‐
2004	   follow-­‐up	   phase	   (10	   years	   from	   baseline)	   in	   WHII	   and	   the	   2007	   follow-­‐up	  
phase	  (8	  years	  from	  baseline)	  in	  BWHHS.	  
	  
3.2.2 Lipid	  Measurements	  
In	   WHII	   venous	   blood	   samples	   at	   each	   examination	   were	   taken	   after	   at	   least	   5	  
hours	  of	  fasting.	  	  Serum	  obtained	  after	  centrifugation	  was	  refrigerated	  at	  -­‐4°C	  and	  
assayed	  within	  72	  hours	  of	  the	  blood	  draw.	  Total	  cholesterol	  and	  triglycerides	  were	  
measured	  using	  a	  centrifugal	  analyser.	  HDL-­‐C	  levels	  were	  determined	  by	  measuring	  
cholesterol	   in	   the	   supernatant	   fluid	   obtained	   after	   precipitating	   non-­‐HDL-­‐C	   with	  
dextran	   sulfate-­‐magnesium	   chloride	   with	   the	   use	   of	   a	   centrifuge	   (Kivimäki	   et	   al.	  
2008).	   In	   BWHHS,	   total	   cholesterol,	   HDL-­‐C,	   and	   triglycerides	   were	   measured	   on	  
frozen	  serum	  sample	  using	  the	  same	  methods	  used	  in	  WHII.	  In	  both	  studies,	  LDL-­‐C	  
concentration	  was	   estimated	   based	   on	   the	   Friedewald	   formula	   (Friedewald	   et	   al.	  
1972).	   Because	   isolation	   of	   the	   LDL	   fraction	   requires	   ultracentrifugation,	   a	  
technique	  not	  generally	  available	  in	  service	  laboratories,	  the	  concentration	  of	  LDL-­‐C	  
was	  calculated	  by	  this	  formula.	  Individuals	  with	  triglyceride	  levels	  >4.5	  mmol/L	  did	  
not	  have	  their	  LDL-­‐C	  levels	  calculated	  and	  were	  set	  as	  missing,	  since	  calculated	  LDL-­‐
C	   cannot	   be	   accurately	   estimated	   when	   triglyceride	   levels	   exceed	   this	   threshold	  
(Friedewald	  et	  al.	  1972).	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3.2.3 Coronary	  Events	  Data	  Collection	  
In	   WHII,	   questionnaires	   were	   sent	   at	   each	   phase	   of	   data	   collection	   to	   gather	  
information	  on	  self-­‐reported	  non-­‐fatal	  coronary	  events	  (MI	  or	  angina),	  and	  this	  was	  
supplemented	  by	  information	  on	  coronary	  events	  identified	  by	  research	  clinic	  ECGs,	  
and	  through	  verification	  of	  primary	  care	  and	  hospital	   records	   (Marmot	  &	  Brunner	  
2005).	   At	   baseline	   in	   BWHHS,	   women	  were	   recorded	   to	   have	   CHD	   if	   they	   had	   a	  
medical	   record	   of	   an	  MI	   or	   angina,	   or	   if	   they	   self-­‐report	   that	   a	   doctor	   had	   ever	  
diagnosed	  a	  heart	  attack	  or	  angina.	  At	  subsequent	  phases	  in	  BWHHS,	  incident	  (new)	  
cases	   of	   CHD	   were	   collected	   through	   detailed	   medical	   record	   reviews	   and	  
participant	   questionnaires	   and	   by	   linkage	   to	   the	   National	   Health	   Service	   (NHS)	  
Central	  Register	  for	  information	  on	  date	  and	  cause(s)	  of	  all	  deaths	  during	  follow-­‐up.	  	  
	  
3.2.4 Lipid	  Medication	  Use	  Data	  Collection	  
In	  WHII,	  participants	  were	  asked	  to	  name	  any	  medication	  taken	  in	  the	  14	  days	  prior	  
to	   the	   survey	   at	   each	   phase.	   The	   medication	   list	   was	   recoded	   using	   the	   British	  
National	   Formulary	   (BNF)	   codes	   (http://bnf.org/bnf/index.htm)	   and	   participants	  
were	   categorised	   as	   users	   of	   lipid	   lowering	   drug	   therapy	   if	   they	   used	   statins	   or	  
other	   lipid	   lowering	   drugs	   such	   as	   fibrates,	   nicotinic	   acid	   and	   its	   derivatives,	  
cholesterol	  absorption	  inhibitors,	  or	  omega-­‐3	  fatty	  acid	  compounds.	  Baseline	  lipid-­‐
lowering	  drug	  use	  in	  BWHHS	  was	  determined	  by	  face	  to	  face	  interview.	  Participants	  
were	  asked	  to	  bring	  to	  the	  assessment	  their	  repeat	  medication	  slips	  or	  their	  actual	  
medications.	  Data	  on	  all	  medications,	   including	  their	  dosage,	  were	  entered	  onto	  a	  
questionnaire	   sheet	   by	   the	   interviewer.	   For	   women	   who	   forgot	   their	   repeat	  
prescription	   document	   they	  were	   asked	   about	   any	  medications,	   including	   dosage	  
and	  the	  reason	  for	  which	  they	  were	  prescribed	  the	  medication.	  Medications	  were	  
catalogued	   using	   codes	   from	   the	   BNF.	   For	   subsequent	   phases	   in	   BWHHS,	  
information	   on	   medication	   was	   obtained	   from	   self-­‐administered	   postal	  
questionnaire,	   where	   participants	   were	   encouraged	   to	   write	   medication	   details	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direct	   from	  their	   repeat	  prescription	  sheet	  and/or	  mail	  a	   copy	  of	   the	  prescription	  
sheet	  back	  with	  the	  questionnaire.	  	  
	  
3.2.5 Genotyping	  
As	   described	   in	   section	   2.2.4	   both	  WHII	   and	   BWHHS	   individuals	   were	   genotyped	  
using	   the	   Cardiochip	   (Keating	   et	   al.	   2008),	  which	   contains	   ~50,000	   SNPs	   covering	  
~2000	  loci	  that	  are	  known	  to	  be	  involved	  in	  cardiovascular	  pathways.	  After	  quality	  
control	   filters	  (previously	  described	   in	  section	  2.2.4),	  5059	  WHII	  and	  3414	  BWHHS	  
individuals	  with	  genotype	  data	  remained	  for	  analysis.	  	  
	  
3.2.6 Selection	  of	  Lipid-­‐Associated	  SNPs	  
A	   previously	   published	   large-­‐scale	   genetic	   association	   analysis	   of	   SNPs	   on	   the	  
Cardiochip	  genotyping	  platform	  with	  baseline	  measurements	  of	  blood	  lipids	  in	  the	  
5059	  individuals	  from	  WHII	  (Talmud	  et	  al.	  2009)	  reported	  60	  SNPs	  in	  12	  genes	  to	  be	  
associated	  with	   LDL-­‐C,	   73	   SNPs	   in	   10	   genes	   associated	  with	   triglycerides,	   and	   71	  
SNPs	   in	   5	   genes	   associated	   with	   HDL-­‐C	   (Talmud	   et	   al.	   2009),	   all	   passing	   the	  
significance	   threshold	   of	   p-­‐value	   <1x10-­‐05.	   Associations	   with	   total	   cholesterol	   (53	  
SNPs)	  were	  also	  identified,	  though	  not	  published.	  	  
	  
Since	   the	  genotyping	  platform	  used	   is	   a	   gene-­‐centric	   array	  and	  was	  not	  designed	  
using	  a	  tag-­‐SNP	  approach,	  typically	  many	  SNPs	  in	  a	  region	  harbouring	  one	  or	  more	  
causal	  variant(s)	  demonstrate	  univariate	  associations	  with	  the	  traits	  of	  interest,	  but	  
the	  majority	   of	   these	   associations	   are	   indirect	   and	   operate	   through	   LD	   with	   the	  
causal	   site(s).	   In	   the	  study	  by	  Talmud	  et	  al	   (2009),	   the	   lipid-­‐associated	  SNPs	  were	  
therefore	   passed	   through	   a	   stepwise	   variable	   selection	   scheme	  with	   the	   Akaike's	  
Information	   Criterion	   (AIC)	   (Akaike	   1974),	   with	   the	   aim	   of	   removing	   redundant	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associations	   and	   retaining	   the	   best	   predictors	   for	   each	   lipid	   trait	   (Talmud	   et	   al.	  
2009).	  Information	  criteria	  are	  used	  to	  select	  the	  best	  regression	  model	  from	  a	  set	  
of	  possible	  models	  given	  the	  data.	  AIC	  is	  the	  most	  commonly	  used	  criterion.	  The	  AIC	  
value	   reflects	   the	   goodness	   of	   fit	   of	   the	  model,	   but	   also	   includes	   a	   penalty	   that	  
increases	   as	   the	   number	   of	   estimated	   parameters	   increases,	   which	   discourages	  
over-­‐fitting.	   The	   preferred	   model	   is	   the	   one	   with	   the	   minimum	   AIC	   value.	   SNP	  
selection	   was	   carried	   out	   separately	   for	   each	   chromosome	   (since	   independence	  
between	  SNPs	  on	  different	  chromosomes	  is	  expected)	  whereby	  the	  genetic	  model	  
assumed	  an	  additive	  effect.	  Age	  and	  gender	  were	   included	   in	   the	  base	  model	   for	  
the	  variable	  selection	  stage	  for	  all	  three	  lipid	  traits	  (Talmud	  et	  al.	  2009).	  	  
	  
For	  the	  selection	  of	  total	  cholesterol	  and	  LDL-­‐associated	  SNPs,	  the	  APOE	  genotype	  
was	   also	   included	   in	   the	   base	   model	   as	   it	   is	   the	   major	   determinant	   of	   total	  
cholesterol	  and	  LDL-­‐C	  levels	  (see	  section	  1.5.2.3).	  Of	  the	  two	  SNPs	  that	  determine	  
the	  major	  APOE	  isoforms,	  only	  rs7412	  is	  represented	  on	  the	  Cardiochip	  genotyping	  
platform.	  However,	   in	  both	   studies	   the	   two	  SNPs	  had	  been	   separately	  genotyped	  
and	  the	  APOE	  genotype	  determined	  (Abdollahi	  et	  al.	  2006;	  Sabia	  et	  al.	  2010),	  and	  
this	   data	   was	   used	   for	   this	   analysis.	   The	   SNPs	   that	   were	   retained	   after	   variable	  
selection	   included	   21	   SNPs	   (including	   the	   2	  APOE	   SNPs)	   for	   total	   cholesterol,	   23	  
SNPs	   (including	   the	   2	  APOE	   SNPs)	   for	   LDL-­‐C,	   12	   SNPs	   for	  HDL-­‐C,	   and	  16	   SNPs	   for	  
triglycerides	  (Table	  3.1	  -­‐	  Table	  3.4).	  
	  
3.2.7 Calculation	  of	  Lipid	  Genetic	  Risk	  Scores	  
In	  order	  to	  evaluate	  the	  combined	  effects	  of	  the	  common	  lipid-­‐associated	  SNPs,	  a	  
genetic	   risk	   score	  was	   calculated	   for	   each	   lipid	   fraction	   in	   each	   individual,	   which	  
was	  a	  simple	  count	  of	  the	  number	  of	  risk	  alleles	  (for	  HDL-­‐C-­‐associated	  SNPs	  these	  
are	   the	   number	   of	   HDL-­‐C-­‐lowering	   alleles)	   present	   in	   each	   individual.	   The	   score	  
represents	   a	   summary	   of	   the	   genetic	   risk	   from	   the	   different	   variants	   that	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predispose	  an	   individual	   to	   increased	   lipid	   levels	   (in	   the	  case	  of	  HDL-­‐C,	  decreased	  
levels)	  and	  therefore	  increased	  CHD	  risk.	  For	  each	  lipid	  trait,	  genetic	  scores	  for	  each	  
participant	  were	   calculated	   by	   summing	   the	   number	   of	   risk	   alleles	   (0,	   1	   or	   2	   for	  
each	   SNP).	   Based	   on	   prior	   knowledge	   of	   the	   relationship	   between	   the	   APOE	  
genotypes	   and	   LDL-­‐C	   levels	   from	   a	   large	   meta-­‐analysis	   in	   86,067	   healthy	  
participants	   (Bennet	   et	   al.	   2007)	   (refer	   to	   section	   1.5.2.3),	   and	   for	   simplicity,	   the	  
APOE	  risk	  count	  was	  coded	  as	  follows:	  	  ε2	  carriers	  (ε2ε2,	  ε2ε3,	  ε2ε4)	  =	  0,	  ε3ε3	  =	  1	  
and	   ε4	   carriers	   (ε3ε4,	   ε4ε4)	   =	   2,	   and	   included	   in	   the	   LDL-­‐C	   and	   total	   cholesterol	  
score	   calculation.	   The	   genetic	   scores	   were	   calculated	   in	   the	   same	   manner	   for	  
BWHHS	  participants.	  Individuals	  with	  missing	  genotypes	  were	  excluded.	  	  
	  
Where	   per-­‐allele	   effects	   for	   each	   SNP	   are	   similar,	   a	   simple	   risk	   allele	   count	   is	   an	  
easy	  and	  appropriate	  method	  to	  generate	  genetic	  risk	  scores	  since	  it	  assumes	  that	  
each	   risk	  allele	   contributes	  equally	   to	   the	  phenotype.	  However,	   if	   the	  effect	   sizes	  
are	   known	   to	   be	   different	   across	   risk	   alleles,	   then	   a	   weighted	   score	   is	   more	  




ji XGS β1=∑= 	  
where,	   iGS 	  is	  the	  genetic	  score	  for	  the	  ith	  individual,	  m	  is	  the	  number	  of	  SNPs	  used	  
in	  the	  score	  calculation,	  	   ijX 	   is	  the	  risk	  allele	  count	  for	  the	  j-­‐th	  SNP	  in	  individual	   i,	  
and	   jβ 	   is	   the	   per-­‐risk	   allele	   effect	   of	   SNP	   j	   on	   the	   trait	   of	   interest.	   Though	   a	  
weighted	   score	   was	   developed	   in	  WHII	   using	   the	   per	   risk	   allele	   beta-­‐coefficients	  
from	   the	   regression	   of	   lipid	   fractions	   on	   SNPs	   in	   WHII,	   it	   provided	   very	   similar	  
results	  to	  that	  of	  the	  unweighted	  score.	  	  The	  unweighted	  	  	  score	  	  	  is	  	  	  more	  	  	  likely	  	  	  
to	   have	   clinical	   application	   because	   of	   its	   simplicity.	   Therefore,	   for	   ease	   of	  
interpretation,	  only	  the	  results	  from	  the	  unweighted	  scores	  are	  presented	  here.	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3.2.8 Estimation	  of	  the	  10-­‐year	  Absolute	  Risk	  of	  Cardiovascular	  Disease	  
To	   calculate	   the	   Framingham	   10	   year	   risk	   of	   CVD,	   the	   equation	   presented	   by	  
Anderson	  et	  al.	  (1991)	  was	  used,	  which	  uses	  linear	  model	  coefficients	  estimated	  in	  
the	  Framingham	  Heart	  Study	  to	  weight	  each	  risk	  factor	  contribution	  to	  the	  overall	  
risk.	   The	   equation	   incorporates	   information	   on	   gender,	   age,	   diabetes	   mellitus	  
status,	  smoking	  status	  (current),	  systolic	  blood	  pressure,	  total	  cholesterol	  and	  HDL-­‐
C.	  The	   text	  and	  equations	  below,	  extracted	   from	  Anderson	  et	  al.	   (1991),	  describe	  
how	  the	  risk	  of	  a	  CVD	  event	  within	  a	  given	  time	  frame	  can	  be	  calculated.	  
	  	  
A	   parametric	   statistical	   model	   (Anderson	   1991)	   was	   used	   to	   provide	   predicted	  
probabilities	   for	   CVD	   outcome.	   This	   modelling	   is	   based	   on	   risk	   factor	   levels	   and	  
times	  until	  events.	  Let	  T	  denote	  the	  time	  until	  the	  event	  of	  interest,	  and	   1x ,	   2x ...	   kx 	  
represent	   the	   risk	   factor	   measurements	   for	   an	   individual.	   The	   coefficients	  
β0 , 1β , 2β ... kβ ,	   as	   well	   as	   θ	   and	   θ1,	   are	   the	   parameters	   estimated	   from	   the	  
Framingham	   Heart	   Study	   and	   are	   extracted	   from	   Table	   1	   of	   the	   published	  
manuscript	  by	  Anderson	  et	  al.	  (1991).	  The	  model	  assumes	  that	  T	  follows	  a	  Weibull	  
distribution	   (Weibull	   1951),	   and	  θ	  and	  θ1	   are	   the	   scale	   and	   shape	  parameters	   for	  
this	  distribution.	  
Equation	  3.2	  
kk xx βββµ +++= ...110 	  
where,	  µ	  is	  assumed	  to	  be	  a	  linear	  function	  of	  the	  risk	  factors	  and	  log(σ)	  =	  θ	  +	  θ1µ	  is	  
considered	  to	  be	  a	  linear	  function	  of	  µ.	  To	  compute	  the	  probability	  that	  time	  until	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Assume,	  










P(T < t) =1− exp(−exp(u)) 	  
where,	  P(T<t)	  is	  the	  predicted	  probability	  of	  an	  event	  by	  time	  t.	  The	  weights	  for	  the	  
CVD	  risk	  factors	  and	  the	  values	  for	  Θ,	  Θ1	  and	   0β 	  are	  given	  below	  (extracted	  from	  
Anderson	  et	  al.	  (1991)):	  
Θ	   0.6536	  
Θ1	   -­‐0.2402	  
β0	   18.8144	  
Female	   -­‐1.2146	  
loge(age)	   -­‐1.8443	  
loge(age)	  x	  female	   0.3668	  
loge(systolic	  BP)	   -­‐1.4032	  
Smoking	  status	   -­‐0.3899	  
loge(total	  cholesterol/	  HDL-­‐C)	   -­‐0.5390	  
Diabetes	  status	   -­‐0.3036	  
Diabetes	  status	  x	  female	   -­‐0.1697	  
	  
Baseline	   measures	   in	   individuals	   with	   complete	   phenotype	   data	   in	   both	   studies	  
(1991-­‐1993	   in	   WHII,	   and	   1999-­‐2001	   in	   BWHHS)	   were	   used	   for	   calculating	   the	  
Framingham	   10	   year	   CVD	   risk	   score.	   Since	   the	   equation	   incorporates	   total	  
cholesterol	   levels	   and	   is	   designed	   for	   estimating	   risk	   in	   individuals	  without	   heart	  
disease,	  the	  risk	  was	  not	  estimated	  for	  participants	  on	  lipid	  lowering	  medication	  or	  
with	  CHD	  at	  baseline.	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3.2.9 Association	  of	  Genetic	  Scores	  with	  Lipid	  Levels	  
The	  effects	  of	  the	  genetic	  scores	  on	  baseline	  lipid	  concentration	  were	  expressed	  per	  
additional	   risk	   allele	   (equivalent	   to	   a	   unit	   change	   in	   the	   score),	   and	   also	   as	   the	  
difference	  in	  lipid	  value	  between	  participants	  in	  the	  highest	  and	  lowest	  quintile	  of	  
the	   genetic	   score	   distribution.	   Individuals	   on	   lipid	   medication	   at	   baseline	   were	  
excluded	   from	   this	   analysis.	   Linear	   regression	   analysis	  was	  performed	  unadjusted	  
and	  adjusted	  for	  gender	  (only	  in	  WHII)	  and	  age.	  To	  obtain	  a	  normal	  distribution,	  the	  
HDL-­‐C	  and	  triglyceride	  variables	  were	  loge-­‐transformed	  prior	  to	  analysis.	  	  
	  
3.2.10 Association	  of	  Genetic	  Scores	  with	  ‘High-­‐Risk’	  Status	  	  
An	   individual	   with	   Framingham	   10	   year	   risk	   of	   CVD	   greater	   than	   20%	   was	  
considered	  as	  ‘high-­‐risk’,	  since	  this	  is	  the	  cut-­‐off	  that	  has	  been	  used	  for	  therapeutic	  
intervention	   in	   the	   UK.	   	   Using	   logistic	   regression,	   the	   odds	   ratio	   for	   having	   a	  
baseline	  10	  year	  CVD	  risk	  >	  20%	  was	  calculated	  for	  individuals	  in	  the	  top	  quintile	  of	  
each	  lipid	  genetic	  score	  distribution	  with	  reference	  to	  those	  in	  the	  lowest	  quintile,	  
unadjusted	  and	  adjusted	  for	  the	  respective	  lipid	  fraction.	  	  
	   	  	  
3.2.11 Association	  of	  Genetic	  Scores	  with	  Lipid	  Medication	  Use	  
Using	   logistic	   regression	   and	   lipid	   medication	   data	   from	   the	   follow-­‐up	   phases	   in	  
both	  studies,	  the	  odds	  ratios	  for	   lipid	  medication	  use	  for	  primary	  prevention	  were	  
calculated	   for	   individuals	   in	   the	   top	  quintile	  of	   the	  genetic	   score	  distribution	  with	  
reference	   to	   individuals	   in	   the	   lowest	   quintile,	   unadjusted	   and	   adjusted	   for	   the	  
respective	   lipid	   fraction.	   Since	   genotype	   precedes	   outcome,	   both	   incident	   and	  
prevalent	  lipid	  drug	  users	  in	  the	  follow-­‐up	  phases	  were	  considered.	  To	  ensure	  that	  
analysis	   was	   restricted	   to	   subjects	   receiving	   lipid	   lowering	   treatment	   for	   primary	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rather	   than	   secondary	   prevention,	   individuals	   who	   had	   a	   CHD	   event	   prior	   to	  
receiving	   lipid	  medication	  were	   excluded	   from	   this	   analysis.	   For	   comparison,	   the	  
odds	   ratio	   for	   lipid	   medication	   use	   was	   also	   calculated	   for	   individuals	   with	   a	  
Framingham	  10	  year	  CVD	  risk	  greater	  than	  20%	  compared	  to	  those	  with	  lower	  risk.	  
	  
3.2.12 Association	  of	  Genetic	  Scores	  with	  Coronary	  Events	  
Using	  CHD	  event	  data	  at	   the	  follow-­‐up	  phases	   in	  both	  studies,	   the	  odds	  ratios	   for	  
having	   a	   CHD	   event	   for	   those	   in	   the	   top	   quintile	   of	   the	   lipid	   score	   distribution	  
compared	   to	   those	   in	   the	   bottom	  quintile,	   both	   unadjusted	   and	   adjusted	   for	   the	  
relevant	   lipid	   level,	   were	   calculated	   using	   logistic	   regression.	   Since	   genotype	  
precedes	  outcome,	  all	   individuals	  with	  a	  CHD	  event	  by	   the	   follow-­‐up	  phase	   (both	  
incident	   and	   prevalent)	   were	   included	   in	   the	   analysis.	   For	   comparison,	   the	  
unadjusted	   odds	   ratio	   of	   developing	   CHD	   for	   individuals	   with	   high	   baseline	  
Framingham	  10	  year	  CVD	  risk	  (>	  20%)	  compared	  to	  those	  with	  lower	  risk	  was	  also	  
calculated.	  	  
	  
3.2.13 Discriminative	  Ability	  of	  Genetic	  Risk	  Scores	  
To	   evaluate	   the	   potential	   value	   of	   the	   lipid	   genetic	   scores	   for	   discrimination,	   the	  
area	  under	  the	  receiver	  operating	  characteristic	  curve	  (AUROC)	  was	  calculated	  for	  
each	   lipid	   genetic	   score	   for	   distinguishing	   ‘high-­‐risk’	   individuals,	   lipid	   medication	  
usage,	  and	  CHD	  outcome.	  The	  receiver	  operating	  characteristic	  curve	  illustrates	  the	  
performance	  of	  a	  binary	  classifier	  system,	  as	   its	  discrimination	  threshold	   is	  varied,	  
by	   plotting	   the	   proportion	   of	   true	   positives	   (sensitivity)	   versus	   the	   proportion	   of	  
false	   positives	   (specificity),	   at	   various	   threshold	   settings.	   For	   comparison,	   the	  
AUROC	  using	  the	  individual	  lipid	  levels	  as	  predictor	  of	  all	  three	  outcomes	  were	  also	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calculated.	  The	  AUROC	  for	  the	  Framingham	  10	  year	  CVD	  risk	  score	  as	  a	  predictor	  for	  
lipid	  drug	  use	  and	  CHD	  outcome	  were	  also	  calculated.	  
	  
3.2.14 Improvement	  over	  Framingham	  10	  year	  CVD	  Risk	  
To	  determine	  if	  the	  lipid	  genetic	  scores	  improved	  discrimination	  of	  lipid	  drug	  users	  
and	  CHD	  events	  above	  the	  Framingham	  10	  year	  CVD	  risk	  score,	  the	  predicted	  risk	  
for	   each	  outcome	  was	   first	   calculated	  using	   a	   logistic	   regression	  model	  with	   only	  
the	  Framingham	  risk	  score	  as	  a	  predictor	  (the	  baseline	  model),	  followed	  by	  both	  the	  
Framingham	  risk	  score	  and	  each	  lipid	  genetic	  score	  in	  turn	  as	  predictors	  (enhanced	  
model).	   The	   AUROC	   for	   both	   the	   baseline	   and	   enhanced	   models	   for	   each	   lipid	  
genetic	   score	   were	   calculated.	   Analysis	   was	   done	   using	   the	   PredictABEL	   package	  
v1.2.1	  (Kundu	  et	  al.	  2011)	  in	  R	  CRAN	  (R	  Development	  Core	  Team	  2012).	  
	  
3.2.15 Net	  Reclassification	  Improvement	  for	  in	  WHII	  
To	  quantify	  any	  improvement	  in	  classification	  of	  individuals	  with	  and	  without	  CHD	  
when	  the	  lipid	  genetic	  scores	  were	  used	  in	  addition	  to	  the	  Framingham	  10	  year	  CVD	  
risk	   score,	   the	  commonly	  used	  net	   reclassification	   improvement	   (NRI)	   (Pencina	  et	  
al.	  2008)	  was	  calculated	  in	  WHII.	  When	  calculating	  NRI,	  each	  subject	  in	  the	  data	  set	  
has	   two	   risk	   values	   calculated,	   one	   according	   to	   the	   baseline	   model	   and	   one	  
according	   to	   the	   enhanced	   model,	   and	   are	   then	   classified	   into	   pre-­‐defined	   risk	  
categories.	   The	   proportion	   of	   individuals	   that	   are	   reclassified	   into	   a	   different	   risk	  
category	   by	   the	   enhanced	   model	   as	   compared	   with	   the	   baseline	   model	   are	  
determined.	  The	  percentage	  that	  are	  correctly	   reclassified	  are	  CHD	  cases	   that	  are	  
classified	  into	  a	  higher	  risk	  category,	  or	  non-­‐cases	  that	  are	  reclassified	  into	  a	  lower	  
risk	   category,	   in	   the	   enhanced	  model	   compared	   to	   the	   baseline	  model.	   The	   NRI	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summarises	   this	   information	   into	   a	   single	   value	   and	   represents	   the	   difference	   in	  
proportions	  moving	  up	  and	  down	  risk	  categories	  among	  cases	  versus	  controls:	  	  
Equation	  3.5	  
0)]=D|P(down -0)=D|[P(up-1)]=D|P(down -1)=D|[P(up =NRI 	  
where,	  upward	  movement	  (up)	   is	   the	  change	   into	  a	  higher	  category	  based	  on	  the	  
new	   model	   and	   downward	   movement	   (down)	   is	   the	   change	   in	   the	   opposite	  
direction,	   and	  D	  denotes	   the	   event	   indicator	   (cases=1,	   controls=0).	   An	  NRI	   of	   0.1	  
means	   that	   10%	   more	   cases	   were	   appropriately	   moved	   up	   a	   risk	   category	   than	  
down	  compared	  with	  controls.	  NRI	  has	   the	  advantage	  over	   the	  ROC	  curve	   in	   that	  
the	  categories	  can	  be	  formed	  based	  on	  clinically	  important	  risk	  estimates.	  The	  risk	  
of	  a	  CHD	  event	  using	  either	  the	  baseline	  model	  (Framingham	  risk	  as	  the	  predictor)	  
or	  using	  the	  enhanced	  model	  (both	  Framingham	  risk	  and	  the	  lipid	  genetic	  score	  as	  
predictors)	   was	   calculated	   and	   individuals	   classified	   into	   two	   risk	   categories	   (risk	  
<20%	   and	   risk	   >=20%),	   and	   the	   NRI	   calculated.	   Analysis	   was	   done	   using	   the	  
PredictABEL	   package	   v1.2.1	   (Kundu	   et	   al.,	   2011)	   in	   R	   CRAN	   (R	  Development	   Core	  
Team	  2012).	  
	  
3.2.16 Summary	  of	  Phenotypic	  Data	  Used	  
For	  clarification,	  a	  summary	  of	  whether	  baseline	  or	  follow-­‐up	  variables	  were	  used	  in	  
each	  of	  the	  above	  described	  analyses	  is	  shown	  below.	  
Table	  3.5	  A	  summary	  of	  the	  phenotypic	  data	  used	  in	  each	  analysis.	  
Analysis	   WHII	  	   BWHHS	  
Baseline	  measurement	   1991-­‐1993	   1999-­‐2001	  
Follow-­‐up	  measurement	   2003-­‐2004	   2007	  
Collection	  of	  biological	  samples	  for	  DNA	  extraction	   Follow-­‐up	   Baseline	  
Calculation	  of	  Framingham	  10	  year	  CVD	  risk	  	   Baseline	  	   Baseline	  	  
Association	  of	  gene	  scores	  with	  lipid	  levels	   Baseline	  	   Baseline	  	  
Association	  of	  gene	  score	  with	  lipid	  medication	  use	   Follow-­‐up	   Follow	  up	  
Association	  of	  gene	  score	  with	  CHD	   Follow	  up	  	   Follow	  up	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3.3 Results	  
3.3.1 Participant	  Characteristics	  
The	  baseline	  characteristics	  of	  the	  participants	  from	  the	  two	  studies	  are	  shown	  in	  
Table	   3.6.	  WHII	   individuals	   are	   younger	   and	   have	   much	   lower	   baseline	   CVD	   risk	  
compared	   to	   BWHHS	   individuals.	   In	  WHII,	   of	   those	   individuals	   that	   did	   not	   have	  
CHD	   and	  were	   not	   on	   lipid	  medication	   at	   baseline,	   8%	  had	   an	   estimated	   10-­‐year	  
CVD	  risk	  >	  20%.	  On	  follow-­‐up	  (~10yrs	  later)	  32%	  of	  these	  ‘high-­‐risk’	  individuals	  were	  
on	  lipid	  medication,	  while	  only	  7%	  of	   low-­‐risk	  individuals	  (baseline	  CVD	  risk	  ≤20%)	  
were	   on	   lipid	   medication	   at	   follow-­‐up.	   In	   BWHHS,	   49%	   had	   CVD	   risk	   >	   20%	   at	  
baseline,	  of	  which	  34%	  were	  on	  medication	  at	  follow-­‐up	  (~8	  years	  later),	  while	  only	  
8%	  of	  BWHHS	  individuals	  with	  baseline	  CVD	  risk	  ≤20%	  were	  on	  lipid	  medication	  at	  
follow-­‐up.	  	  
Table	  3.6	  Cohort	  characteristics	  for	  WHII	  and	  BWHHS.	  	  
	  
Whitehall	  II	   BWHHS	  
	   Men	  (N=3721)	   Women	  (N=1338)	   Women	  (N=3414)	  
Baseline	   	   	   	  
Age	  (yrs)	   49.1	  (5.9)	   49.6(6.1)	   68.8(5.5)	  
BMI	  (kg/m2)	   25.0	  (3.1)	   25.3(4.7)	   27.6(4.9)	  
%	  Smokers	  (current)	   11	   15	   11	  
%	  Smokers	  (ex/current	  )	   51	   46	   44	  
Diastolic	  BP	  (mmHg)	   80.7	  (8.9)	   76.1(9.3)	   79.4	  (11.7)	  
Systolic	  BP	  (mmHg)	   121.5	  (12.8)	   116.6	  (13.7)	   146.9	  (25.3)	  
Framingham	  10yr	  risk	  (%)	   10.6	  (6.9)	   5.6	  (4.9)	   22.1	  (11.7)	  
Total	  Cholesterol	  (mmol/l)	   6.5	  (1.1)	   6.4	  (1.2)	   6.6	  (1.2)	  
LDL-­‐C	  (mmol/l)	  	   4.4	  (1.0)	   4.2	  (1.1)	   4.2	  (1.1)	  
HDL-­‐C	  (mmol/l)	  	   1.3	  (0.4)	   1.7	  (0.4)	   1.7	  (0.5)	  
Triglyceride	  (mmol/l)	   1.6	  (1.2)	   1.1	  (0.7)	   1.9	  (1.2)	  
	   	   	   	  
Baseline	   	   	   	  
Lipid	  drug	  users	   33	  (0.9%)	   10	  (0.7%)	   204	  (5.9%)	  
CHD	  cases	   96	  (2.6%)	   25	  (1.9%)	   460	  (13.4%)	  
Follow-­‐up	  phase	   	   	   	  
Duration	  from	  baseline	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  ~10yrs	   ~8yrs	  
Lipid	  drug	  users	   426	  (11.4%)	   121	  (9.0%)	   692	  (20.1%)	  
CHD	  cases	   334	  (9.0%)	   87	  (6.5)	   802	  (23.3%)	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3.3.2 Association	  of	  Genetic	  Risk	  Scores	  with	  Blood	  Lipids	  	  
Though	  per	   allele	   effects	   on	   lipid	   values	   are	   small	   (Table	   3.7)	   there	   is	   substantial	  
difference	   in	   mean	   lipid	   levels	   between	   individuals	   in	   the	   highest	   and	   lowest	  
quintile	   of	   the	   genetic	   score	   distribution.	   Individuals	   in	   the	   top	   quintile	   of	   the	  
cholesterol	  genetic	  score	  distribution	  have	  0.96	  (0.85	  –	  1.07)	  mmol/L	  and	  0.62	  (0.46	  
–	  0.78)	  mmol/L	  higher	   total	  cholesterol	   than	  those	   in	   the	  bottom	  quintile	   in	  WHII	  
and	  BWHHS,	   respectively	   (Table	  3.7).	  Those	   in	   the	   top	  quintile	  of	   the	  LDL	  genetic	  
score	  distribution	  had	  0.85	  (0.76	  –	  0.94)	  and	  0.63	  (0.50	  –	  0.76)	  mmol/L	  higher	  LDL-­‐C	  
than	  those	   in	  the	  bottom	  quintile	   in	  WHII	  and	  BWHHS,	  respectively.	  Similarly,	   the	  
mean	  HDL-­‐C	   levels	  were	  substantially	   lower	   (20%	  and	  15%)	  and	  mean	  triglyceride	  
levels	  higher	  (38%	  and	  26%)	  in	  the	  top	  quintile	  compared	  to	  the	  bottom	  quintile	  in	  
WHII	  and	  BWHHS,	  respectively	  (Table	  3.7).	  
	  
3.3.3 Association	  of	  Genetic	  Risk	  Scores	  with	  ‘High-­‐Risk’	  Status	  
Individuals	   in	  the	  top	  quintile	  of	   the	  distributions	  of	  each	  of	   the	  four	   lipid	  genetic	  
scores	  tended	  to	  have	  a	  higher	  odds	  of	  being	  identified	  as	  ‘high-­‐risk’,	  as	  determined	  
by	  the	  Framingham	  10	  year	  CVD	  risk	  >20%	  (Table	  3.8).	  The	  triglyceride	  genetic	  score	  
showed	   the	   strongest	   association,	   with	   individuals	   in	   the	   top	   quintile	   of	   the	  
triglyceride	  score	  distribution	  having	  a	  1.99	  (1.39	  –	  2.85)	  and	  1.56	  (1.22	  –	  2.00)	  fold	  
higher	   odds	   of	   having	   10	   year	   CVD	   risk	   >20%	   compared	   to	   those	   in	   the	   bottom	  
quintile	  in	  WHII	  and	  BWHHS,	  respectively.	  Adjusting	  for	  the	  respective	  baseline	  lipid	  
levels	   completely	   attenuated	   the	   association	   of	   all	   genetics	   scores	   (Table	   3.8).	  	  
None	  of	   the	   lipid	  genetic	   scores	  were	  associated	  with	   risk	   factors	   incorporated	   in	  
the	  Framingham	  risk	  equation	  other	  than	  blood	  lipids	  (shown	  for	  WHII	  in	  Table	  3.9,	  
indicating	   the	   association	   of	   the	   genetic	   scores	   with	   Framingham	   risk	   is	   driven	  
simply	  by	  the	  effect	  of	  genotype	  on	  lipid	  levels.	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3.3.4 Association	  of	  Genetic	  Risk	  Scores	  with	  Lipid	  Medication	  Use	  
Individuals	  in	  the	  top	  quintile	  of	  the	  LDL-­‐C	  genetic	  score	  had	  a	  2.38	  (1.57	  -­‐	  3.59)	  and	  
2.24	   (1.52	   -­‐	  3.29)	   fold	  higher	  odds	  of	   receiving	   lipid	  medication	   than	   those	   in	   the	  
lowest	   quintile	   (Figure	   3.1A)	   in	   WHII	   and	   BWHHS,	   respectively.	   However,	  
adjustment	  for	  LDL-­‐C	  concentration	  completely	  attenuated	  this	  association	  in	  WHII	  
(Figure	   3.1B).	   In	   BWHHS,	   though	   the	   association	   was	   substantially	   reduced,	   it	  
remained	   significant	   (Figure	   3.1B).	   Individuals	   in	   the	   top	   quintile	   of	   the	   total	  
cholesterol	  and	  triglyceride	  genetic	  scores	  were	  more	  likely	  to	  use	  lipid	  medication	  	  
and	   these	   associations	   were	   attenuated	   to	   the	   null	   after	   adjusting	   for	   total	  
cholesterol	   and	   triglyceride	   levels	   (Figure	   3.1).	   The	   HDL-­‐C	   genetic	   score	   was	   not	  
significantly	   associated	   with	   lipid	   medication	   use	   (Figure	   3.1).	   As	   expected,	  
individuals	  with	  an	  estimated	  CVD	  risk	  >20%	  had	  a	  higher	  likelihood	  (WHII	  OR	  =	  4.15	  
(3.04	  –	  5.67);	  BWHHS	  OR	  =	  2.98	  (2.32-­‐3.83))	  of	  receiving	  lipid	  medication	  compared	  
to	  those	  with	  lower	  risk.	  
	  
3.3.5 Association	  of	  Genetic	  Risk	  Scores	  with	  CHD	  Events	  
Individuals	   in	   the	   top	  quintile	   (compared	   to	  bottom	  quintile)	  of	   the	  LDL-­‐C	  genetic	  
score	   distribution	   had	   a	   higher	   risk	   of	   CHD	   (WHII	   OR	   =	   1.43	   (1.02	   –	   2.00)	   and	  
BWHHS	  OR	  =	  1.31	  (0.99	  -­‐	  1.72))	  (Figure	  3.2A).	  After	  adjusting	  for	  LDL-­‐C	  levels,	  this	  
association	   was	   completely	   attenuated	   in	  WHII	   but	   not	   in	   BWHHS	   (Figure	   3.2B).	  
Similar	  associations	  were	  seen	  in	  both	  studies	  for	  the	  total	  cholesterol	  genetic	  score	  
(Figure	   3.2).	   The	   triglyceride	   score	   showed	   association	  with	   higher	   risk	   of	   CHD	   in	  
WHII	  but	  not	   in	  BWHHS	   (Figure	  3.2).	  The	  HDL-­‐C	  genetic	   score	  was	  not	  associated	  
with	  CHD	  outcome.	  By	  comparison,	  individuals	  with	  a	  Framingham	  10	  year	  CVD	  risk	  
>20%	  had	   a	   4.21	   (3.08	   –	   5.75)	   and	  2.49	   (1.80	   –	   3.44)	   fold	   higher	   odds	  of	   CHD	   in	  
WHII	  and	  BWHHS,	  respectively.	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Figure	  3.1	   	  Association	  of	   lipid	  genetic	   scores	  with	   lipid	  medication	  use.	  Odds	   ratio	   (with	  95%	  CI	  
and	   p-­‐value)	   of	   using	   lipid-­‐modifying	   drugs	   in	   top	   vs.	   bottom	   quintiles	   of	   each	   genetic	   score	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Figure	  3.2	  Association	  of	  lipid	  genetic	  scores	  with	  CHD.	  Odds	  ratio	  (with	  95%	  CI	  and	  p-­‐value)	  of	  CHD	  
outcome	   for	   individuals	   in	   the	   top	   quintile	   of	   each	   lipid	   genetic	   score	   distribution	   compared	   to	  
individuals	   in	  the	  bottom	  quintile.	  Odds	  ratios	  and	  p-­‐values	  are	  shown	  for	   (A)	  unadjusted	  analyses	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3.3.6 Comparison	  of	  Genotype-­‐based	  and	  Phenotype-­‐based	  Discrimination	  
Blood	  lipid	  measurements	  performed	  better	  that	  the	  respective	  genetic	  scores	  for	  
discriminating	  high-­‐risk	  individuals,	  lipid	  medication	  use	  and	  CHD	  outcome,	  with	  all	  
AUROC	   in	  WHII	   above	   0.6,	  while	   those	   for	   the	   respective	   genetic	   scores	  were	   all	  
below	   0.6	   (shown	   for	   WHII	   in	   Table	   3.10).	   Total	   cholesterol	   and	   LDL-­‐C	   levels	  
performed	  the	  best	  for	  discriminating	  lipid	  medication,	  exhibiting	  an	  AUROC	  of	  0.79	  
(0.76	  –	  0.81)	  and	  0.78	  (0.75	  –	  0.80),	  while	  HDL-­‐C	  and	  triglyceride	  levels	  performed	  
best	  for	  discriminating	  high-­‐risk	   individuals.	  The	   latter	   is	  not	  surprising,	  since	  both	  
of	  	  these	  	  measures	  	  are	  	  incorporated	  	  into	  	  the	  	  Framingham	  	  risk	  	  calculation.	  	  The	  
Framingham	  10	  year	  CVD	  risk	  score	  performed	  the	  best	  for	  CHD	  discrimination,	  and	  
the	  	  inclusion	  of	  	  the	  lipid	  genetic	  scores	  	  in	  addition	  to	  the	  Framingham	  risk	  score	  in	  
the	  model	  did	  not	  improve	  discrimination	  (Table	  3.11).	  The	  performance	  of	  each	  of	  
the	  lipid	  genetic	  scores	  in	  comparison	  to	  the	  Framingham	  10	  year	  CVD	  risk	  score	  for	  
discriminating	  high-­‐risk	  individuals,	  lipid	  medication	  use	  and	  CHD	  in	  both	  studies	  is	  
shown	  in	  Figure	  3.3.	  
	  
3.3.7 Net	  Reclassification	  for	  Coronary	  Disease	  Events	  in	  WHII	  
There	   was	   no	   significant	   improvement	   in	   classification	   over	   the	   Framingham	   10	  
year	   CVD	   risk	   when	   any	   of	   the	   genetic	   scores	   were	   added	   to	   the	   risk	   prediction	  
model,	  with	  less	  than	  1%	  of	  individuals	  being	  correctly	  reclassified	  in	  the	  enhanced	  
model	   (p-­‐value	  >	  0.13)	   (Table	  3.12).	  Addition	  of	  all	   four	  genetic	   scores	   to	   the	   risk	  
prediction	  model	  also	  did	  not	  improve	  classification	  (0.03%	  correctly	  reclassified,	  p-­‐
value	  =	  0.97).	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Table	  3.10	  Area	  under	  the	  receiver	  operating	  curve	  (AUROC)	  for	  lipid	  levels	  and	  lipid	  genetic	  risk	  
scores	  in	  WHII	  
	  
	  	   AUROC	  
	  	   High-­‐risk	   Lipid	  drug	  use	   CHD	  
Total	  Cholesterol	   0.70	  (0.67	  -­‐	  0.73)	   0.79	  (0.76	  -­‐	  0.81)	   0.61	  (0.58	  -­‐	  0.64)	  
Cholesterol	  genetic	  score	   0.54	  (0.51	  -­‐	  0.57)	   0.60	  (0.57	  -­‐	  0.64)	   0.54	  (0.51	  -­‐	  0.57)	  
	   	   	   	  LDL-­‐C	   0.71	  (0.68	  -­‐	  0.74)	   0.78	  (0.75	  -­‐	  0.80)	   0.62	  (0.59	  -­‐	  0.64)	  
LDL-­‐C	  genetic	  score	   0.54	  (0.50	  -­‐	  0.57)	   0.59	  (0.56	  -­‐	  0.62)	   0.53	  (0.50	  -­‐	  0.56)	  
	   	   	   	  HDL-­‐C	   0.76	  (0.74	  -­‐	  0.79)	   0.59	  (0.56	  -­‐	  0.62)	   0.60	  (0.57	  -­‐	  0.63)	  
HDL-­‐C	  genetic	  score	   0.58	  (0.54	  -­‐	  0.61)	   0.53	  (0.50	  -­‐	  0.57)	   0.52	  (0.49	  -­‐	  0.55)	  
	   	   	   	  Triglycerides	   0.78	  (0.75	  -­‐	  0.80)	   0.71	  (0.68	  -­‐	  0.74)	   0.62	  (0.59	  -­‐	  0.65)	  




Table	  3.11	  Area	  under	  the	  receiver	  operating	  curve	  (AUROC)	  for	  combined	  Framingham	  10yr	  CVD	  
risk	  score	  (FRS)	  and	  lipid	  genetic	  scores	  
	  
Exposure	   Study	   AUROC	  for	  actual	  drug	  use	   AUROC	  for	  CHD	  
FRS	  
WHII	   0.73	  (0.70	  –	  0.76)	   0.71	  (0.67	  –	  0.74)	  
BWHHS	   0.67	  (0.64	  –	  0.70)	   0.65	  (0.61	  –	  0.69)	  
FRS	  +	  cholesterol	  genetic	  
score	  
WHII	   0.74	  (0.71	  –	  0.77)	   0.68	  (0.65	  –	  0.72)	  
BWHHS	   0.68	  (0.65	  –	  0.71)	   0.65	  (0.61	  –	  0.69)	  
FRS	  +LDL	  genetic	  score	  
WHII	   0.74	  (0.71	  –	  0.77)	   0.68	  (0.64	  –	  0.71)	  
BWHHS	   0.68	  (0.65	  –	  0.71)	   0.65	  (0.61	  –	  0.69)	  
FRS	  +HDL	  genetic	  score	  
WHII	   0.71	  (0.67	  –	  0.74)	   0.70	  (0.66	  –	  0.73)	  
BWHHS	   0.67	  (0.64	  –	  0.70)	   0.64	  (0.60	  –	  0.68)	  
FRS	  +triglyceride	  genetic	  
score	  
WHII	   0.72	  (0.69	  –	  0.76)	   0.70	  (0.66	  –	  0.73)	  
BWHHS	   0.67	  (0.64	  –	  0.70)	   0.64	  (0.60	  –	  0.68)	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3.4 Discussion	  
3.4.1 Summary	  of	  Results	  
Individuals	   in	   the	   top	   quintile	   of	   the	   LDL-­‐C	   and	   total	   cholesterol	   genetic	   score	  
distributions,	   calculated	   using	   23	   LDL-­‐C-­‐associated	   and	   21	   total	   cholesterol-­‐
associated	   genetic	   variants,	   respectively,	   tended	   to	   have	   greater	   odds	   of	   having	  
high	   CVD	   risk	   status,	   receiving	   lipid-­‐lowering	  medication	   and	   having	   a	   CHD	  event	  
than	  individuals	  in	  the	  bottom	  quintile,	  in	  two	  UK	  studies	  of	  middle-­‐aged	  men	  and	  
women.	   	  Despite	  predisposing	   to	   lifelong	  differences	   in	   levels	  of	   blood	   lipids,	   the	  
strength	  of	  the	  genetic	  associations	  was	  	  insufficiently	  	  large	  to	  usefully	  discriminate	  
individuals	   likely	   	   to	   	   require	   	   lipid-­‐lowering	   	   treatment	   	   or	   	   develop	   	   CHD.	   The	  
Framingham	   10	   year	   CVD	   risk	   score	   which	   incorporates	   a	   single	   mid-­‐life	  
measurement	   of	   total	   cholesterol	   and	   HDL-­‐C	   as	   well	   as	   other	   non-­‐genetic	   risk	  
factors,	  performed	  better	  than	  genetic	  scores	  for	  CHD	  discrimination,	  and	  addition	  
of	   the	   genetic	   risk	   scores	   to	   the	   Framingham	   10	   year	   CVD	   risk	   did	   not	   improve	  
discrimination	  or	  reclassification.	  
	  
3.4.2 Comparison	  with	  Previous	  Studies	  
Murray	  et	  al	  (2009)	  found	  that	  LDL-­‐C	  and	  triglyceride	  genetic	  scores	  based	  on	  7	  and	  
11	   SNPs	   (identified	   by	   previous	   GWAS),	   respectively,	   were	   associated	   with	   the	  
likelihood	   of	   exceeding	   the	   lipid	   thresholds	   for	   intervention,	   as	   advocated	   by	   US	  
guidelines	   (by	   the	   National	   Institutes	   of	   Health	   Expert	   Panel	   on	   Detection,	  
Evaluation,	  and	  Treatment	  of	  High	  Blood	  Cholesterol	  in	  Adults),	  in	  an	  Italian	  sample	  
of	  1155	   individuals	  over	  65	  years,	  but	   	   that	  a	  score	  based	  on	  9	  HDL-­‐C-­‐	  associated	  
variants	  was	  not	   (Murray	  et	  al.	  2009).	  The	  study	  also	  showed	  that	   the	  HDL-­‐C	  and	  
triglyceride	  risk	  allele	  counts	  were	  associated	  with	  MI.	  This	  study	  did	  not	  examine	  
associations	   with	   estimates	   of	   absolute	   CVD	   risk	   or	   the	   number	   of	   individuals	  
actually	   treated	  with	   lipid-­‐modifying	  drugs.	  Any	   improvement	   in	  discrimination	  or	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reclassification	  over	  commonly	  used	  non-­‐genetic	  risk	  scores	  was	  also	  not	  assessed.	  
For	   the	   analysis	   in	   WHII	   and	   BWHHS,	   the	   genetic	   scores	   were	   based	   on	   SNPs	  
identified	  in	  WHII	  using	  the	  Cardiochip	  (Keating	  et	  al.	  2008),	  which	  has	  denser	  SNP	  
coverage	   of	   many	   of	   the	   loci	   associated	   with	   blood	   lipid	   fractions,	   but	   lesser	  
genome	  coverage	  than	  the	  arrays	  used	  in	  GWAS.	  SNPs	  studied	  by	  Murray	  et	  al	  were	  
either	   present	   or	   had	   proxy	   SNPs	   (based	   on	  HapMap	   CEU	   LD	   estimates;	   R2>	   0.8)	  
present	  on	  the	  Cardiochip,	  which	  allowed	  the	  use	  of	  variable	  selection	  methods	  to	  
identify	  the	  best	  genetic	  predictors	  of	  lipid	  levels	  from	  the	  much	  larger	  number	  of	  
significant	  associations	  observed	  in	  each	  region.	  	  
	  
A	  study	  by	  Kathiresan	  et	  al.	  (2008)	  examined	  the	  utility	  of	  LDL-­‐C	  and	  HDL-­‐C	  genetic	  
scores	  for	  the	  discrimination	  of	  CVD	  events.	  They	  generated	  a	  single	  score	  based	  on	  
a	  smaller	  subset	  of	  11	  SNPs	  in	  9	  genes	  associated	  with	  either	  LDL-­‐C	  or	  HDL-­‐C	  from	  
published	  studies.	  The	  genetic	  score	  was	  associated	  with	  incident	  CVD	  events	  even	  
after	   adjustment	   for	   lipid	   levels.	   They	   found	   that	   a	  model	   that	   incorporated	   the	  
genetic	   score	  did	  not	   improve	   the	  discrimination	  of	  CVD	  events	  but	  did	  modestly	  
improve	   risk	   classification	   in	  193	  CVD	  cases	   (MI,	   ischemic	   stroke,	   and	  death	   from	  
CHD)	   and	   4039	   controls.	   However,	   the	   three	   risk	   categories	   used	   were	   0-­‐10%,	  	  	  	  	  	  	  	  
>10-­‐20%,	   and	  >20%.	   In	   the	   context	   of	  UK	   guidelines	   for	   primary	  CVD	  prevention,	  
there	   would	   be	   no	   alteration	   in	   therapeutic	   intervention	   decisions	   for	   those	  
reclassified	  between	  the	  lowest	  two	  risk	  categories.	  	  
	  
3.4.3 CVD-­‐Associated	  SNPs	  and	  Prediction	  
Since	   this	   analysis,	   new	   variants	   associated	  with	   the	   principal	   lipid	   fractions	   have	  
been	  identified	  by	  large-­‐scale	  association	  analysis	  (Teslovich	  et	  al.	  2010;	  Asselbergs	  
et	   al.	   2012).	   In	   addition,	   GWAS	   have	   also	   identified	   multiple	   variants	   associated	  
with	   CVD	   outcome	   (McPherson	   et	   al.	   2007;	   Samani	   et	   al.	   2007;	   Aulchenko	   et	   al.	  
2009).	  Whether	  these	  additional	  genetic	  variants	  can	  provide	  sufficiently	  accurate	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predictions	  to	  enable	  genetically-­‐informed	   intervention	  decisions	  remains	  unclear.	  
Several	  studies	  have	  explored	  whether	  genetic	  markers	  can	  improve	  risk	  prediction	  
using	  genetic	  risk	  scores,	  but	  the	  results	  from	  these	  studies	  have	  been	  conflicting	  or	  
modest.	  Although	  some	  have	  shown	  that	  genetic	  variants	  are	  associated	  with	  CVD	  
outcome	   independent	   of	   conventional	   risk	   factors,	   only	   one	   study	   was	   able	   to	  
demonstrate	   a	   clinically	   significant	   improvement	   in	   predictive	   ability	   using	   both	  
measures	  of	  risk	  reclassification	  and	  discrimination,	  which	  are	  more	  informative	  for	  
the	  purpose	  of	   risk	  prediction	   (Table	  3.13)	   (Di	  Angelantonio	  &	  Butterworth	  2012).	  
However,	  these	  findings	  need	  to	  be	  considered	  in	  the	  light	  of	  several	  limitations	  of	  
the	   studies.	   Firstly,	   the	  number	  of	  events	   considered	   in	   these	   studies	   is	   relatively	  
small	   and	   therefore	   they	   are	   likely	   to	   be	   underpowered	   to	   detect	   significant	  
improvement	   in	   risk	   prediction.	   Second,	   only	   a	   few	   (typically	   around	   a	   dozen)	  
selected	  genetic	  variants,	  are	  included	  in	  the	  genetic	  risk	  score	  (Di	  Angelantonio	  &	  
Butterworth	  2012).	  	  	  
	  
New	   approaches	   have	   shown	   that	   the	   proportion	   of	   variance	   explained	  when	   all	  
SNPs	   on	   the	   array	   are	   considered	   is	   much	   larger	   than	   that	   explained	   by	   SNPs	  
passing	  a	  preset	  significance	  threshold	  (Yang	  et	  al.	  2010).	  Alternative	  approaches	  to	  
risk	  prediction	  that	  incorporate	  all	  variants	  nominally	  associated	  with	  CVD	  risk	  may	  
provide	   more	   power	   but	   may	   also	   be	   prone	   to	   bias	   and	   non-­‐transferability	   (Di	  
Angelantonio	   &	   Butterworth	   2012).	   The	   selection	   and	   combination	   of	   genetic	  
variants	  is	  essential	  to	  maximise	  the	  potential	  improvement	  in	  risk	  prediction	  over	  
and	  above	  risk	  factors	  currently	  used	  in	  risk	  prediction.	  Recent	  work	  on	  the	  power	  
and	  predictive	  accuracy	  of	  polygenic	  scores	  has	  shown	  that	  very	  large	  sample	  sizes,	  
up	  to	  an	  order	  of	  magnitude	  greater	  than	  currently	  available,	  would	  be	  needed	  for	  
estimating	   predictors	   to	   a	   level	   which	   is	   useful	   for	   prediction	   (Dudbridge	   2013).	  
Therefore,	   as	   sample	   sizes	   begin	   to	   grow,	   prediction	   using	   polygenic	   scores	  may	  
become	  more	  feasible.	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3.4.4 Clinical	  Implications	  
Consistent	   evidence	   from	   this	   and	   other	   studies	   now	   indicates	   that	   prediction	  
based	  on	  phenotype	  outdoes	  prediction	  based	  on	  common	  genotypic	  variation.	  The	  
current	  American	  Heart	  Association	  policy	  on	  the	  use	  of	  common	  genetic	  variants	  
for	   risk	   prediction	   states	   that	   though	   there	   is	   robust	   evidence	   linking	   common	  
variants	   to	   complex	   CVD,	   the	   minor	   improvement	   in	   discrimination	   creates	  
scepticism	   about	   the	   clinical	   utility	   for	   risk	   prediction	   (Ashley	   et	   al.	   2012).	   It	   is	  
currently	   uncertain	   how	   the	   genotype	   results	   can	   or	   should	   influence	   clinical	  
management.	  More	   importantly,	   interpretation	   of	   results	   can	   be	   challenging	   and	  
time	  consuming	  for	  clinicians	  and	  patients,	  which	  is	  likely	  to	  steer	  them	  away	  from	  
the	  use	  of	  genotyping	  for	  CVD	  risk	  prediction	  (Ashley	  et	  al.	  2012).	  There	  is	  a	  lack	  of	  
studies	   informing	   the	   clinical	   benefit	   of	   providing	   such	   genetic	   information	   to	  
patients	  and	  funding	  for	  such	  clinical	  studies	  is	  essential	  to	  build	  an	  evidence	  base	  
for	  the	  field	  (Ashley	  et	  al.	  2012).	  
	  
3.4.5 Limitations	  
Though	  a	  large	  number	  of	  SNPs	  associated	  with	  the	  major	  blood	  lipid	  fractions	  were	  
studied,	  these	  variants	  collectively	  explain	  only	  a	  small	  proportion	  of	  the	  variance	  in	  
blood	  lipid	  levels	  and	  only	  a	  fraction	  of	  the	  heritability	  (Talmud	  et	  al.	  2009).	  Given	  
the	   gene-­‐centric	   design	   of	   the	   array,	   loci	   outside	   known	   cardiovascular	   pathways	  
would	  have	  been	  missed.	  Since	  this	  work	  was	  completed,	  the	  Global	  Lipids	  Genetic	  
Consortium	   (GLGC)	   conducted	   a	   meta-­‐analysis	   of	   GWAS	   involving	   more	   than	  
100,000	   participants,	   and	   together	   with	   the	   recent	   Cardiochip-­‐based	   discovery	  
meta-­‐analysis	  in	  over	  60,000	  individuals,	  the	  list	  of	  loci	  influencing	  the	  major	  blood	  
lipid	  fractions	  has	   increased	  to	  almost	  100	  (Teslovich	  et	  al.	  2010;	  Asselbergs	  et	  al.	  
2012).	   Scores	   based	  on	   a	   larger	   number	   of	   lipid	   related	   SNPs	  will	   likely	   explain	   a	  
larger	  proportion	  of	  the	  variance	  in	  blood	  lipids	  and	  have	  larger	  average	  differences	  
in	  lipid	  concentrations	  in	  individuals	  at	  opposite	  extremes	  of	  the	  score	  distribution.	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However,	   the	   ability	   of	   genetic	   scores	   incorporating	   these	   additional	   SNPs	   to	  
identify	   individuals	   with	   ‘high-­‐risk’	   status	   or	   CHD	   events	   may	   not	   be	  
correspondingly	   large	  because	   the	   effect	   sizes	   of	   additional	   loci	   identified	   in	   very	  
large	   meta-­‐analysis	   tend	   to	   be	   extremely	   small.	   Additionally,	   new	   SNPs	   are	   also	  
distributed	  across	  different	  chromosomes	  and	  inherited	  independently,	  so	  that	  only	  
a	  small	  proportion	  of	   the	  population	  carries	  a	   large	  burden	  of	   lipid	   raising	  alleles.	  
Further	   analysis	   based	   on	   all	   currently	   known	   lipid	   related	   loci	  will	   be	   needed	   to	  
determine	   if	   the	   interpretations	  of	   these	   findings,	  based	  on	   the	  Cardiochip	  array-­‐
derived	   lipid	   genetic	   risk	   scores,	   on	   the	  utility	   of	   lipid	   related	   SNPs	   for	   predicting	  
important	  healthcare	  outcomes	  will	  substantially	  alter.	  It	  is	  important	  to	  note	  that	  
despite	  individuals	  with	  Apoe	  e2e2	  having	  lower	  total-­‐cholesterol	  and	  LDL-­‐C	  levels	  
based	  on	  the	  Bennet	  et	  al	  meta	  analysis,	  the	  relationship	  with	  CHD	  is	  complex	  due	  
to	  its	  causal	  role	  in	  hyperlipoproteinemia.	  However,	  since	  this	  genotype	  is	  rare,	  any	  
impact	  on	  the	  results	  would	  be	  insignificant.	  	  
	  
Ongoing	   efforts	   to	   fine	   map	   causal	   variants	   at	   the	   known	   loci	   may	   increase	   the	  
number	   of	   eligible	   SNPs	   and	   improve	   the	   performance	   of	   lipid	   related	   genetic	  
scores.	   The	   effects	   of	   gene-­‐gene	   and	   gene-­‐environment	   interactions	   were	   not	  
modelled	   and	  may	   also	   contribute	   to	   the	  missing	   phenotype	   variance	   explained.	  
Efforts	  to	  deeply	  re-­‐sequence	  for	  rare	  variants	  at	  the	  relevant	  genomic	  regions	  may	  
also	  identify	  highly	  penetrant	  (albeit	  rare)	  alleles	  with	  a	  larger	  effect	  on	  blood	  lipid	  
levels	   than	   those	   studied	   here,	   and	   incorporating	   these	   into	   genetic	   risk	   score	  
calculations	  may	  improve	  performance.	  	  
	  
The	   associations	   observed	   in	  WHII	   are	   likely	   to	   be	   overestimated	   since	   the	   same	  
data	  was	   used	   both	   for	   SNP	   discovery	   and	   evaluation	   of	   the	   performance	   of	   the	  
allele	   scores.	   However,	   associations	   and	   performance	   estimates	   were	   broadly	  
similar	   in	   BWHHS.	  Given	   the	   strong	   association	   of	   some	   lipid	   genetic	   scores	  with	  
lipid	  drug	  usage,	  individuals	  with	  a	  higher	  number	  of	  risk	  alleles	  are	  more	  likely	  to	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be	   put	   on	   lipid	   medication,	   thus	   reducing	   their	   risk	   of	   an	   event.	   Therefore	   the	  
association	  of	  lipid	  genetic	  scores	  with	  CHD	  outcome	  may	  be	  underestimated.	  This	  
also	   applies	   to	   the	   Framingham	   10	   year	   CVD	   risk	   score,	   whereby	   those	   with	   a	  
baseline	  risk	  >20%	  were	  more	  likely	  to	  be	  put	  on	  lipid	  medication	  and	  the	  exclusion	  
of	   higher-­‐risk	   CHD	   patients	   from	   the	   latter	   analysis	   may	   have	   blunted	   the	   true	  
association	  of	  Framingham	  risk	  with	  CHD	  outcome.	  	  
	  
The	   Framingham	   risk	   equations	   were	   developed	   based	   on	   data	   from	   a	   sample	  
population	   in	   Framingham,	  Massachusetts,	   and	   there	   have	   been	   studies	   showing	  
that	  this	  method	  over-­‐estimates	  risk	  in	  other	  populations	  (Hense	  et	  al.	  2003;	  Kent	  
2002;	  Brindle	  et	  al.	  2003).	  Despite	  this,	  they	  have	  been	  used	  widely	  both	  within	  the	  
UK	   and	   elsewhere.	   The	   QRISK	   cardiovascular	   disease	   risk	   algorithm	   (QRISK2)	  
(Hippisley-­‐Cox	   et	   al.	   2007)	   has	   been	   developed	   to	   provide	   accurate	   estimates	   of	  
cardiovascular	   risk	   in	   patients	   from	  different	   ethnic	   groups	   in	   England	   and	  Wales	  
and	  would	   be	   a	  more	   appropriate	   estimator	   for	   the	   cohorts	   used.	   However,	   the	  
QRISK	   requires	   information	   on	   participant	   post	   codes,	   which	   is	   not	   available	   in	  
WHII,	  and	  also	  the	  equations	  underpinning	  the	  calculation	  are	  not	  freely	  available	  
since	  QRISK	  is	  licensed	  for	  commercial	  or	  healthcare	  use.	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4 Developing	  Genetic	  Instruments	  for	  Lipids	  
4.1 Introduction	  
For	  prognostic	  research,	  all	  factors	  associated	  with	  an	  outcome,	  whether	  causal	  or	  
not,	  are	  of	   interest	  (Sheehan	  et	  al.	  2008).	  Causality	  on	  the	  other	  hand,	   is	  relevant	  
for	   informing	  health	  interventions	  and	  in	  drug	  discovery.	  MR	  analysis	  uses	  genetic	  
variants	   as	   unbiased	   proxies	   for	   modifiable	   risk	   factors	   in	   order	   to	   determine	  
whether	  their	  relationship	  with	  an	  outcome	  is	  causal	  (refer	  to	  section	  1.6.2).	  	  Due	  to	  
the	  random	  assortment	  of	  alleles	  at	  the	  time	  of	  gamete	  formation,	  the	  population	  
distributions	   of	   genetic	   variants	   are	   generally	   independent	   of	   behavioural	   and	  
environmental	   factors	   that	   typically	   confound	   epidemiological	   associations	  
between	   putative	   risk	   factors	   and	   outcome	   (Smith	   &	   Ebrahim	   2004).	   The	  
unidirectional	   flow	  of	  biological	   information	   from	  gene	   through	   to	   risk	   factor	  and	  
then	   to	   disease	   outcome	   avoids	   reverse	   causation,	   since	   the	   disease	   or	   outcome	  
cannot	   change	   the	   inherited	   genetic	   variants	   that	   are	   associated	   with	   the	   risk	  
factor.	  	  
	  
Higher	   LDL-­‐C	   concentration	   is	   associated	   with	   a	   higher	   risk	   of	   CHD,	   and	   the	  
relationship	   is	   considered	   causal	   because	   randomised	   trials	   using	   LDL-­‐C-­‐lowering	  
interventions	  such	  as	  HMG-­‐CoA	  reductase	  inhibitors	  (statins)	  have	  shown	  to	  reduce	  
CHD	   risk	   in	   proportion	   to	   the	   LDL-­‐C	   reduction	   (Baigent	   et	   al.	   2005;	   Baigent	   et	   al.	  
2010).	   Epidemiological	   studies	   have	   shown	   that	   increased	   triglyceride	   levels	   and	  
decreased	  HDL-­‐C	  levels	  are	  both	  associated	  with	  CHD.	  However,	  randomised	  trials	  
of	  drugs	  directed	  at	  HDL-­‐C	  and	  triglycerides	  have	  not	  shown	  consistent	  results	  and	  
have	   therefore	   been	   unable	   to	   confirm	   or	   refute	  whether	   these	   associations	   are	  
causal	   (Cannon	   et	   al.	   2010;	   Ginsberg	   et	   al.	   2010;	   Jun	   et	   al.	   2010;	   NHLBI	  
Communications	  2011).	  There	   is	   therefore	  a	   lot	  of	   interest	   in	  assessing	  the	  causal	  
relationship	   of	   these	   lipid	   fractions	   with	   various	   clinically	   relevant	   outcomes.	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Confirmation	   of	   causality	   would	   determine	   whether	   development	   of	   drugs	  
designed	   to	   raise	   HDL-­‐C	   or	   lower	   triglyceride	   levels	   are	   worth	   pursuing	   for	  
cardiovascular	   disease	   risk	   management.	   Given	   the	   large	   number	   of	   genetic	  
variants	   reported	   to	   be	   associated	   with	   lipid	   levels,	   the	   aim	   of	   this	   work	   is	   to	  
explore	  different	  approaches	   for	   the	  development	  of	  suitable	  genetic	   instruments	  
for	  LDL-­‐C,	  HDL-­‐C	  and	  triglycerides	  to	  use	  in	  MR	  analyses.	  Genotypic	  and	  phenotypic	  
data	   from	   5059	   Caucasian	   individuals	   from	   the	   WHII	   cohort	   were	   used	   for	   lipid	  
instrument	  development.	  
	  
4.2 Materials	  &	  Methods	  
4.2.1 Genotypic	  and	  Phenotypic	  Data	  
The	  development	  of	  genetic	  instruments	  utilised	  genotype	  data	  for	  5059	  Caucasian	  
individuals	   from	   the	  WHII	   cohort	   (see	   section	   2.2.1.3	   for	   cohort	   description)	   that	  
had	  been	  genotyped	  using	   the	   Illumina	  Cardiochip	   (as	  described	   in	   section	  2.2.4),	  
and	  baseline	  (1991-­‐1993)	  lipid	  measurements	  (as	  described	  in	  section	  3.2.2).	  	  
	  
4.2.2 Measuring	  the	  Strength	  of	  a	  Genetic	  Instrument	  
As	  mentioned	  in	  section	  1.6.2.4,	  the	  strength	  of	  an	  instrument	  can	  be	  measured	  by	  
the	   proportion	   of	   the	   total	   phenotypic	   variance	   explained	   by	   the	   instrument,	   R2,	  
also	   known	   as	   the	   coefficient	   of	   determination.	   This	   can	   be	   calculated	   from	   the	  
simple	  linear	  regression	  of	  the	  genetic	  instrument	  with	  the	  exposure	  of	  interest	  as	  
follows:	  
	  
	   	  
Chapter	  4:	  Materials	  &	  Methods	  
	   	   	   	   	   	   	  
	  
139	  
	   	   	  
where,	   	   iy 	   is	   the	   observed	   risk	   factor	   value	   for	   the	   ith	   individual,	   iyˆ is	   the	   fitted	  
value	  for	  the	  ith	  individual	  and	   y 	  is	  the	  mean	  of	  the	  observed	  data.	  The	  numerator	  
is	  the	  residual	  sum	  of	  errors	  (the	  unexplained	  variance)	  and	  the	  denominator	  is	  the	  
total	   sum	   of	   squares	   (the	   total	   variance	   in	   the	   observed	   data).	   The	   F-­‐statistic	   is	  
another	  measure	  of	   instrument	   strength	  and	   is	   related	   to	  R2,	   sample	   size	   (n)	   and	  
number	  of	  instruments	  (k)	  used,	  and	  is	  calculated	  as	  follows:	  	  
	  
	  
	   	   	   	   	  
As	  mentioned	  in	  section	  1.6.2.3,	  the	  causal	  effect	  can	  be	  estimated	  using	  the	  2SLS	  
method.	   In	  the	  presence	  of	  confounding	  between	  the	  exposure	  and	  outcome,	  the	  
casual	   estimate	   from	   a	   2SLS	   regression	   will	   be	   biased	   towards	   this	   confounded	  
association,	  and	  the	  extent	  of	  bias	  is	  inversely	  related	  to	  the	  F-­‐statistic	  (Staiger	  and	  
Stock	  1997).	  Bias	  occurs	  when	  genetic	  variants	  explain	  not	  only	  systematic	  variation	  
in	  the	  risk	  factor	  of	  interest,	  but	  also	  chance	  variation	  in	  the	  confounders	  (Burgess	  
&	  Thompson	  2013).	  As	  R2	  increases,	  the	  F-­‐statistic	  increases	  and	  the	  bias	  decreases.	  
However,	   including	   additional	   instruments	   that	   do	   not	   increase	   the	   first	   stage	   R2	  
results	   in	  a	  decrease	  in	  the	  F-­‐statistic	  (Equation	  4.2),	  and	  hence	  increases	  the	  bias	  
(Palmer	  et	  al.	  2011).	  Therefore,	  weak	  instrument	  bias	  may	  arise	  in	  situations	  where	  
the	  number	  of	   instruments	   is	   large	  and	  sample	  size	  small.	  By	  rule	  of	  thumb,	  an	  F-­‐
statistic	   >10	   is	   usually	   an	   indicator	   of	   a	   strong	   instrument,	   as	   the	   bias	   of	   the	   IV	  
estimator	   is	  10%	  of	  the	  bias	  of	  the	  observational	  estimator	  (Staiger	  &	  Stock	  1997;	  
Lawlor	   et	   al.	   2008).	   However,	   weak	   instrument	   bias	   is	   a	   continuous	   rather	   than	  
binary	   phenomenon,	   and	   such	   application	   of	   F-­‐statistic	   thresholds	   for	   assessing	  
weak	  instruments	  are	  not	  considered	  useful	  by	  some	  (Burgess	  &	  Thompson	  2013).	  
However,	  with	   large	  enough	  sample	  sizes,	  estimates	  using	  a	  weak	   instrument	  will	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when	   comparing	   strength	   of	   different	   IVs,	   since	   the	   latter	   is	   dependent	   on	   the	  
number	  of	  instruments	  used	  as	  well	  as	  sample	  size.	  
	  
4.2.3 Unweighted	  Genetic	  Risk	  Score	  
When	  multiple,	   independent	  SNPs	  are	  associated	  with	   the	  exposure	  of	   interest,	  a	  
simple	  approach	  for	  MR	  analysis	  is	  to	  combine	  them	  into	  a	  single	  genetic	  risk	  score	  
instrument	   (refer	   to	   section	   1.6.2.8).	   This	   approach	   avoids	   the	   problem	   of	   weak	  
instrument	   bias	   that	  may	   potentially	   arise	   in	   the	   presence	   of	   a	   large	   number	   of	  
possible	  instruments.	  Use	  of	  such	  scores	  assumes	  an	  approximately	  additive	  effect	  
on	  phenotype.	   In	   the	   large-­‐scale	   lipid	  association	  analysis	  by	  Talmud	  et	  al	   (2009),	  
SNPs	  that	  passed	  the	  initial	  discovery	  significance	  threshold	  (p-­‐value	  <	  1x10-­‐05;	  with	  
age	   and	   sex	   as	   covariates	   in	   the	   regression	  model)	  were	   entered	   into	   a	   stepwise	  
regression	   step	  using	   the	  AIC	   (Akaike	  1974)	   for	  model	   selection,	   in	  an	  attempt	   to	  
select	   a	   model	   with	   the	   best,	   non-­‐redundant	   genetic	   predictors	   for	   each	   lipid	  
fraction	  (described	  in	  section	  3.2.6).	  The	  set	  of	  SNPs	  retained	  in	  the	  model	  included	  
23	  SNPs	  (including	  the	  2	  SNPs	  making	  up	  the	  APOE	  genotype)	  for	  LDL-­‐C,	  12	  SNPs	  for	  
HDL-­‐C,	  and	  16	  SNPs	  for	  triglycerides	  (refer	  to	  Table	  3.2	  -­‐	  Table	  3.4).	  The	  set	  of	  SNPs	  
selected	  for	  each	  lipid	  fraction	  were	  combined	  into	  a	  genetic	  risk	  score,	  where	  for	  
each	  individual	  this	  was	  the	  sum	  of	  the	  risk	  allele	  counts	  across	  the	  SNPs	  (previously	  
described	  in	  section	  3.2.7).	  To	  explore	  how	  the	  addition	  of	  each	  SNP	  to	  the	  genetic	  
score	  affected	  the	  strength	  of	  the	  instrument,	  the	  following	  steps,	  using	  LDL-­‐C	  as	  an	  
example,	  were	  carried	  out:	  
• Step	   1:	   Genetic	   variants	   were	   ranked	   in	   order	   of	   decreasing	   R2	   (obtained	  
from	  the	  univariate	  linear	  regression	  of	  LDL-­‐C	  on	  each	  genetic	  variant).	  	  
• Step	   2:	   The	   unweighted	   score	   was	   first	   calculated	   for	   the	   single	   genetic	  
variant	   with	   the	   highest	   R2.	   In	   this	   instance	   the	   genetic	   score	   for	   all	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individuals	  was	  either	  0	  (no	  risk	  alleles),	  1	  (heterozygous)	  or	  2	  (homozygous	  
for	  the	  risk	  allele).	  	  
• Step	   3:	   To	   assess	   instrument	   strength,	   the	   R2	   and	   F-­‐statistic	   for	   the	  
unweighted	  score	  were	  obtained	  from	  the	  linear	  regression	  with	  LDL-­‐C.	  	  
• Step	  4:	  To	  assess	  specificity,	  the	  R2	  values	  from	  the	  linear	  regression	  of	  the	  
LDL-­‐C	  unweighted	  score	  with	  the	  other	  (non-­‐specific)	  lipid	  fractions	  and	  CVD	  
risk	   factors	   (systolic	   blood	   pressure	   (SBP),	   diastolic	   blood	   pressure	   (DBP),	  
CRP	  and	  BMI)	  were	  also	  obtained.	  	  
• Step	  5:	  The	  next	  ranking	  SNP	  was	  added	  to	  the	  genetic	  score	  calculation	  and	  
steps	  3	  and	  4	  repeated	  with	  this	  new	  score.	  
• Step	  6:	  Step	  5	  was	   repeated	  until	  all	   SNPs	  had	  been	   incorporated	   into	   the	  
genetic	  score	  calculation.	  	  
For	   simplicity,	   as	   was	   done	   in	   the	   previous	   chapter	   (section	   3.2.7),	   the	   APOE	  
genotype	  was	  coded	  as	  follows:	  ε2	  carriers	  (ε2ε2/	  ε2ε3/	  ε2ε4)	  =	  0,	  ε3ε3	  =	  1	  and	  ε4	  
carriers	   (ε3ε4/ε4ε4)	   =	   2.	   The	   above	   steps	   were	   repeated	   for	   the	   HDL-­‐C	   and	  
triglyceride	   SNPs,	   with	   the	   R2	   and	   F-­‐statistic	   for	   assessing	   instrument	   strength	  
derived	   from	   the	   regression	   with	   loge-­‐transformed	   HDL-­‐C	   and	   loge-­‐transformed	  
triglycerides,	  respectively.	  	  
	  
4.2.4 Multiple	  Instruments	  Approach	  
Multiple	   SNPs	   associated	   with	   the	   exposure	   of	   interest	   can	   also	   be	   used	  
simultaneously	  as	  individual	  IVs	  in	  a	  multiple	  instruments	  approach	  (refer	  to	  section	  
1.6.2.8).	   The	   multiple	   instruments	   approach	   maximises	   power,	   while	   making	   no	  
assumptions	  regarding	  the	  effect	  sizes	  of	  each	  SNP	  (Pierce	  et	  al.	  2010).	  However,	  if	  
a	   large	   number	   of	   SNPs	   are	   used	   as	   individual	   instruments,	   there	   is	   potential	   for	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introducing	  weak	   instrument	  bias.	  As	  was	  done	  with	   the	  unweighted	   score,	   SNPs	  
were	  ranked	  by	  decreasing	  R2	  values,	  and	  for	  each	  successive	  SNP	  addition,	  the	  R2	  
and	   F-­‐statistic	   values	   were	   extracted	   from	   a	   multiple	   regression	   of	   the	   SNPs	   in	  
question	   with	   the	   respective	   lipid	   fraction.	   To	   examine	   specificity,	   the	   R2	   values	  
were	  also	  extracted	  from	  the	  multiple	  regression	  of	   the	  SNPs	  with	  the	  other	  non-­‐
specific	  lipid	  fractions	  and	  CVD	  risk	  factors.	  
	  
4.2.5 Weighted	  Genetic	  Score	  using	  Univariate	  Beta-­‐Coefficients	  
As	  discussed	  in	  section	  3.2.7,	  genetic	  risk	  scores	  can	  also	  be	  weighted	  by	  the	  effect	  
size	  of	   each	   risk	   allele,	  which	   is	  more	   appropriate	  when	  effects	   sizes	  of	   SNPs	   are	  
different.	  The	  beta-­‐coefficients	   from	  the	  univariate	  regression	  of	   the	   lipid	   fraction	  
on	   each	   SNP	   in	  WHII	   were	   used	   as	   weights.	   Though	   it	   was	   possible	   to	   generate	  
weights	  for	  the	  APOE	  genotypes	  from	  the	  WHII	  data,	  a	  previously	  published	  meta-­‐
analysis	   with	   a	   sample	   size	  more	   than	   10	   times	   that	   of	  WHII	   had	   estimated	   the	  
effect	   (in	   mmol/L)	   of	   the	   APOE	   genotype	   on	   LDL-­‐C	   levels	   (Bennet	   et	   al.	   2007)	  
(section	   1.5.2.3).	   	   Based	   on	   this	   study,	  where	   ε3/ε3	   individuals	  were	   used	   as	   the	  
reference	  group,	  the	  APOE	  genotypes	  were	  weighted	  as	  follows:	  	  ε2ε2	  =	  -­‐0.9,	  ε2ε3	  =	  
-­‐0.4,	  ε2ε4	  =	  -­‐0.2,	  ε3/ε3	  =	  0,	  ε3ε4	  =	  0.1	  and	  ε4ε4	  =	  0.2.	  
	  
4.2.6 SNP	  Multicollinearity	  
The	  problem	  of	  multicollinearity	  occurs	  when	  two	  or	  more	  predictor	  variables	  are	  
highly	  correlated	  (Montgomery	  et	  al.	  2012).	  Presence	  of	  correlated	  SNPs	  can	  lead	  to	  
large	   changes	   in	   individual	   effect	   estimates	   when	   other	   predictors	   are	   added	   or	  
removed	   from	   the	  model,	   and	  may	   also	   result	   in	   an	   insignificant	   coefficient	   of	   a	  
predictor	   variable	   in	   a	   multiple	   regression	   analysis,	   despite	   the	   simple	   linear	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regression	   showing	   the	   coefficient	   to	   be	   significantly	   different	   from	   zero	  
(Montgomery	  et	  al.	  2012).	  	  
	  
To	  determine	  the	  presence	  and	  quantify	  the	  degree	  of	  collinearity	  between	  the	  AIC-­‐
selected	   SNPs,	   the	   beta-­‐coefficients	   from	   the	   univariate	   regression	   of	   each	   SNP	  
with	  the	  respective	  lipid	  fraction	  were	  compared	  to	  the	  beta-­‐coefficients	  obtained	  
from	  a	  multiple	  regression	  where	  all	  SNPs	  were	  used	  as	  predictors	  simultaneously.	  
The	   variance	   inflation	   factor	   (VIF)	   was	   also	   calculated	   for	   each	   SNP	   in	   each	   lipid	  
genetic	   score	   using	   the	   vif()	   function	   from	   the	   car	   package	   in	   R	   CRAN	   (R	  
Development	  Core	  Team	  2012).	  The	  VIF	  is	  a	  measure	  of	  how	  much	  the	  variance	  of	  
an	  estimated	  regression	  coefficient	  is	  increased	  due	  to	  collinearity	  and	  is	  calculated	  
using	  Equation	  4.3.	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
where,	   2jR 	  is	  the	  coefficient	  of	  determination	  of	  a	  regression	  of	  predictor	  j	  obtained	  
when	  j	  is	  regressed	  on	  all	  the	  other	  predictors.	  When	  the	  predictor	  j	  is	  uncorrelated	  
2
jR 	  will	  be	  small	  and	  VIF	  close	  to	  1,	  while	  if	  j	  is	  nearly	  linearly	  dependent	  on	  some	  of	  
the	  subset	  of	  the	  remaining	  predictors,	   2jR 	  will	  be	  close	  to	  1	  and	  VIF	  becomes	  very	  
large.	  The	  square	  root	  of	  the	  VIF	  is	  an	  indication	  of	  how	  much	  larger	  the	  standard	  
error	  is,	  compared	  with	  what	  it	  would	  be	  if	  that	  variable	  were	  uncorrelated	  with	  the	  
other	   predictor	   variables	   in	   the	   model	   (Belsey	   et	   al.	   1980)	   e.g	   if	   the	   VIF	   of	   a	  
predictor	   variable	   is	   5,	   the	   standard	   error	   for	   the	   coefficient	   of	   that	   predictor	  
variable	   is	   √5	   =	   2.2	   times	   as	   large	   as	   it	   would	   be	   if	   that	   predictor	   variable	   was	  
uncorrelated	   with	   the	   other	   predictor	   variables.	   VIFs	   exceeding	   5	   are	   commonly	  
considered	  high	  and	  are	  an	  indication	  of	  a	  possible	  multicollinearity	  problem,	  while	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4.2.7 Weighted	  Genetic	  Score	  using	  Bayesian	  Information	  Criterion	  for	  SNP	  
Selection	  followed	  by	  Ridge	  Regression	  
A	   straightforward	   solution	   to	   avoid	   multicollinearity	   would	   be	   to	   simply	   use	   the	  
most	   significantly	   associated	   SNP	   from	  each	   gene	   region	   in	   the	   score	   calculation.	  
However,	  with	  this	  approach	  multiple	  independent	  signals	  in	  a	  single	  gene	  would	  be	  
missed,	   there	   is	   ambiguity	   in	   defining	   gene	   boundaries,	   and	   SNPs	   in	   different	  
(neighbouring)	  genes	  may	  not	  necessarily	  be	  independent	  since	  LD	  blocks	  can	  span	  
several	  genes.	  To	  automate	  SNP	  selection	  and	  allow	  multiple	  SNPs	  in	  a	  gene	  to	  be	  
selected,	   but	   reduce	   the	   multicollinearity	   problem	   between	   selected	   SNPs,	   two	  
measures	  were	  taken:	  
1. Firstly,	   the	   SNPs	   associated	   with	   baseline	   LDL-­‐C,	   HDL-­‐C	   or	   triglycerides	   in	  
WHII	   (p-­‐value	   <	   1x10-­‐05)	   were	   included	   in	   a	   stepwise	   variable	   selection	  
scheme	   with	   a	   more	   stringent	   information	   criterion	   -­‐	   the	   Bayesian	  
Information	   Criterion	   (BIC)	   (Schwarz	   1978),	   using	   the	   step()	   function	   from	  
the	   stats	   package	   in	   R	   CRAN	   (R	   Development	   Core	   Team	   2012).	   The	   BIC	  
imposes	  a	  larger	  penalty	  than	  AIC	  as	  the	  number	  of	  predictors	  in	  the	  model	  
increases,	  and	  therefore	  tends	  to	  choose	  a	  model	  with	  fewer	  SNPs	  than	  AIC.	  
Sex	  and	  age	  were	  included	  in	  the	  baseline	  model,	  and	  for	  selection	  of	  LDL-­‐C	  
SNPs,	  the	  APOE	  genotype	  was	  also	  included	  in	  the	  baseline	  model.	  
2. Secondly,	   the	   beta-­‐coefficients	   used	   to	   weight	   the	   SNP	   risk	   allele	   counts	  
were	  obtained	  from	  a	  Ridge	  regression	  (Brown	  1994).	  The	  Ridge	  regression	  
is	   a	   variant	   of	   ordinary	   multiple	   linear	   regression	   that	   ‘shrinks’	   the	   beta-­‐
coefficients	  of	  redundant	  SNPs,	  thereby	  circumventing	  issues	  that	  may	  arise	  
if	   highly-­‐correlated	   SNPs	   are	   present	   in	   the	  model.	   Though	  OLS	   estimates	  
are	  unbiased,	  the	  presence	  of	  multicollinearity	  results	  in	  large	  variances	  for	  
the	   estimated	   regression	   coefficients.	   Ridge	   regression	   trades	   a	   small	  
amount	   of	   bias	   in	   the	   coefficient	   estimates	   for	   a	   substantial	   reduction	   in	  
coefficient	   sampling	   variance,	   producing	   a	   smaller	   mean-­‐squared	   error	   of	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estimation	  of	  the	  coefficients.	  Ridge	  regression	  requires	  the	  specification	  of	  
a	  Ridge	  constant,	  which	  controls	  the	  extent	  to	  which	  Ridge	  estimates	  differ	  
from	  the	  least-­‐squares	  estimates.	  The	  larger	  the	  Ridge	  constant,	  the	  greater	  
the	   bias	   and	   the	   smaller	   the	   variance	   of	   the	   Ridge	   estimator.	   The	   Ridge	  
regression	   using	   the	   Lawless	   and	   Wang	   estimate	   of	   the	   Ridge	   constant	  
(Lawless	  &	  Wang	  1976)	  was	  carried	  out	  on	  the	  BIC-­‐selected	  SNPs	  using	  the	  
lm.ridge()	  function	  from	  the	  MASS	  package	  in	  R	  CRAN	  (R	  Development	  Core	  
Team	   2012),	   with	   sex	   and	   age	   included	   in	   the	   base	  model.	   For	   the	   LDL-­‐C	  
SNPs,	   the	  APOE	   genotype	   was	   also	   included	   in	   the	   base	  model.	   The	   final	  
weights	  for	  each	  SNP	  were	  the	  beta-­‐coefficients	  from	  the	  Ridge	  regression.	  
For	  the	  APOE	  genotype,	  weights	  were	  derived	  from	  the	  Bennet	  et	  al	  (2007)	  
paper,	  as	  specified	  in	  section	  4.2.5.	  
	  
4.3 Results	  
4.3.1 Comparison	  of	  Instrument	  Strength	  
The	   single	   strongest	   SNP	   instruments	   explained	   5%,	   3%	   and	   2%	   of	   the	   total	  
variation	  in	  LDL-­‐C,	  HDL-­‐C	  and	  triglycerides,	  respectively	  (Figure	  4.1).	  As	  more	  SNPs	  
were	  added,	  either	  to	  the	  genetic	  score	  calculation	  or	  used	  as	  multiple	  instruments,	  
the	  R2	  value	  tended	  to	  increase.	  This	  is	  shown	  for	  the	  AIC-­‐selected	  SNPs	  using	  both	  
the	  unweighted	  genetic	  score	  in	  Figure	  4.1,	  and	  the	  multiple	  instruments	  approach	  
in	   Figure	   4.2.	  When	   all	   SNPs	   (whether	   selected	   using	  AIC	   or	   BIC)	  were	   combined	  
into	  a	  single	  genetic	  risk	  score	  or	  used	  as	  multiple	   instruments,	  the	  final	  R2	  values	  
were	  twice	  as	  large	  as	  that	  of	  the	  single,	  strongest	  SNP	  instrument	  (Table	  4.1).	  For	  
each	  lipid	  fraction,	  three	  approaches	  provided	  the	  best	  instruments	  with	  equivalent	  
strength:	   the	   multiple	   instruments	   approach	   using	   AIC-­‐selected	   SNPs,	   multiple	  
instruments	   approach	   using	   BIC-­‐selected	   SNPs,	   and	   the	   weighted	   genetic	   score	  
based	   on	   BIC-­‐selected	   SNPs	   and	   beta-­‐coefficients	   from	   a	   Ridge	   regression	   as	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weights,	  with	  all	   three	  explaining	  13%,	  7%	  and	  7%	  of	   the	   total	   variation	   in	  LDL-­‐C,	  
HDL-­‐C	   and	   triglycerides,	   respectively	   (Table	   4.1).	   For	   all	   approaches,	   the	   final	   F-­‐
statistics	  were	  much	  larger	  than	  10	  (Table	  4.1).	  As	  the	  number	  of	  SNP	  instruments	  
increased,	   the	   F-­‐statistic	   for	   the	   genetic	   score	   also	   increased,	   while	   that	   for	   the	  
multiple	   instruments	   approach	   decreased.	   As	   SNPs	   with	   very	   small	   effect	   are	  
added,	  the	  R2	  does	  not	  increase	  by	  much,	  and	  since	  the	  F-­‐statistic	  depends	  on	  the	  
R2	  and	  the	  number	  of	  instruments	  used,	  as	  more	  instruments	  with	  small	  effect	  are	  
added,	   the	   F-­‐statistic	   will	   decrease.	   With	   the	   genetic	   risk	   score	   the	   number	   of	  
instruments	  is	  always	  one,	  regardless	  of	  the	  number	  of	  SNPs	  used.	  
	  
4.3.2 Instrument	  Specificity	  
To	  evaluate	  specificity	  of	  the	  instruments,	  the	  R2	  values	  from	  the	  regression	  of	  each	  
instrument	   with	   the	   other,	   non-­‐specific	   lipid	   fractions	   and	   CVD	   risk	   factors	   were	  
extracted.	  Table	  4.2	   shows	   the	  R2	   values	   for	  each	   instrument	   from	   the	   regression	  
with	  the	   lipid	  fraction	  of	   interest,	  as	  well	  as	  the	   largest	  R2	  from	  the	  association	  of	  
the	   instrument	   with	   a	   non-­‐specific	   risk	   factor.	   As	   well	   as	   explaining	   5%	   of	   the	  
variation	   in	   LDL-­‐C,	   the	  APOE	   genotype	   explained	  1%	  of	   the	   total	   variation	   in	   CRP	  
levels.	   As	   more	   SNPs	   were	   added	   to	   the	   genetic	   score,	   the	   strength	   of	   the	  
association	   with	   CRP	   decreased,	   with	   the	   final	   AIC-­‐selected	   unweighted	   genetic	  
score	  explaining	  only	  0.2%	  of	  the	  variation	  in	  CRP.	  Overall,	  the	  LDL-­‐C	  genetic	  scores	  
appeared	  to	  be	  specific	  for	  LDL-­‐C,	  explaining	  less	  than	  0.7%	  of	  the	  variation	  in	  any	  
of	  the	  other	  non-­‐specific	  CVD	  risk	  factors.	  The	  single	  strongest	  SNP	  instruments	  for	  
HDL-­‐C	  and	  triglycerides	  explained	  less	  than	  0.6%	  of	  the	  variation	  in	  any	  of	  the	  other	  
CVD	  risk	  factors.	  However,	  the	  HDL-­‐C	  genetic	  scores	  explained	  1-­‐2%	  of	  the	  variation	  
in	   triglycerides,	  while	   the	   triglyceride	  genetic	  scores	  also	  explained	  between	  1-­‐2%	  
of	   the	   variation	   in	   HDL-­‐C	   (Table	   4.1).	   For	   the	   multiple	   instruments	   approach,	  
whether	   selected	   using	   AIC	   or	   BIC,	   the	   LDL-­‐C	   SNPs	   also	   explained	   	   3%	   	   of	   	   the	  	  
variation	  	  	  in	  	  	  	  HDL-­‐C,	  	  	  the	  	  	  	  HDL-­‐C	  	  	  SNPs	  	  	  explained	  	  	  	  4%	  	  	  	  of	  	  	  	  the	  	  	  variation	  	  	  in	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triglycerides,	   and	   the	   triglyceride	   SNPs	   explained	   2%	   of	   the	   variation	   in	   HDL-­‐C	  
(Figure	  4.2).	  	  
	  
4.3.3 SNP	  Collinearity	  
For	   the	   AIC-­‐selected	   SNPs,	   rather	   than	   a	   continuous	   increase	   in	   R2,	   addition	   of	  
certain	  SNPs	  to	  the	  genetic	  score	  resulted	  in	  a	  drop	  in	  the	  R2	  value	  (Figure	  4.1).	  This	  
was	  due	  to	  the	  presence	  of	  multicollinearity	  between	  some	  SNPs.	  Multicollinearity	  
was	   not	   an	   issue	   in	   the	  multiple	   instruments	   approach	   since	   no	   assumptions	   are	  
required	  regarding	  the	  effect	  size	  for	  each	  SNP	  (Figure	  4.2).	  As	  mentioned	  earlier,	  
presence	   of	   multicollinearity	   can	   result	   in	   unstable	   beta-­‐coefficient	   estimation.	  
Table	   4.3	   compares	   the	   univariate	   beta-­‐coefficients	   with	   those	   obtained	   from	   a	  
multiple	  regression	  of	  the	  AIC-­‐selected	  SNPs	  with	  LDL-­‐C.	  For	  some	  SNPs,	  the	  effect	  
estimate	  from	  the	  multiple	  regression	  analysis	  was	  in	  the	  opposite	  direction	  to	  that	  
of	  the	  univariate	  beta-­‐coefficient,	  in	  others	  the	  estimate	  was	  inflated,	  and	  for	  some	  
the	   association	   with	   LDL-­‐C	   was	   no	   longer	   significant.	   Two	   SNPs	   (rs629301	   and	  
rs12740374),	  both	  in	  the	  CELSR2	  gene,	  had	  inflated	  beta-­‐coefficients,	  and	  both	  had	  
very	   large	   VIFs	   (>	   100).	   For	   rs629301	   the	   effect	   size	   was	   also	   in	   the	   opposite	  
direction	  (Table	  4.3).	  These	  two	  SNPs	  were	  found	  to	  be	  in	  perfect	  LD	  according	  to	  
HapMap	   and	   1000	   Genomes	   data.	   For	   the	   AIC-­‐selected	   HDL-­‐C	   SNPs,	   though	   the	  
multiple	  regression	  p-­‐values	  were	  less	  significant	  than	  the	  univariate	  p-­‐values,	  there	  
were	   no	   large	   differences	   in	   the	   beta-­‐coefficients	   and	   all	   VIFs	   were	   less	   than	   5	  
(Table	  4.4).	  Two	  of	  the	  triglyceride-­‐associated	  SNPs,	  rs331	  and	  rs3916027,	  had	  VIFs	  
>100	   (Table	  4.5).	  These	   two	  SNPs	  were	  also	   in	  perfect	   LD	  based	  on	  HapMap	  and	  
1000	  Genomes	  data.	  In	  addition,	  the	  two	  SNPs	  with	  VIF	  ~6	  were	  also	  in	  LD	  (r2=0.54;	  
D’=1).	  For	  three	  of	  the	  triglyceride-­‐associated	  SNPs,	  the	  beta-­‐coefficients	  from	  the	  
multiple	   regression	   were	   in	   the	   opposite	   direction	   to	   the	   univariate	   beta-­‐
coefficients	  (Table	  4.5).	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4.3.4 BIC-­‐SNP	  Selection	  and	  Ridge	  Regression	  
Variable	  selection	  using	  AIC	  failed	  to	  remove	  all	  highly	  correlated	  SNPs.	  Therefore	  
the	   more	   stringent	   BIC	   was	   used	   for	   model	   selection.	   For	   both	   LDL-­‐C	   and	  
triglycerides,	   stepwise	   regression	   using	   BIC	   retained	   a	   smaller	   number	   of	   genetic	  
predictors	   in	   the	   model	   than	   with	   AIC	   (Table	   4.6).	   None	   of	   the	   triglyceride-­‐
associated	  SNPs	  selected	  by	  the	  BIC	  had	  large	  VIFs.	  Though	  the	  2	  AIC-­‐selected,	  LDL-­‐
C-­‐associated	  SNPs	  with	  very	  large	  VIFs	  were	  retained	  by	  the	  model	  selection	  using	  
BIC,	  applying	  a	  Ridge	  regression	  shrunk	  the	  coefficients	  for	  these	  2	  SNPs	  from	  1.21	  
and	  -­‐1.09	  (from	  the	  multiple	  regression)	  to	  0.23	  and	  -­‐0.068,	  respectively.	  For	  HDL-­‐C,	  
using	  the	  BIC	  selected	  the	  same	  number	  of	  SNPs	  (Table	  4.6)	  (but	  not	  necessarily	  the	  
same	  SNPs)	  as	  AIC.	  
	  
Table	   4.6	   Comparison	  of	   SNP	   selection	  by	  AIC	   and	  BIC.	  The	   table	   compares	   the	  number	   of	   SNPs	  
retained	   after	   variable	   selection	   using	   AIC	   or	   BIC.	   BIC	   selects	   a	   smaller	   number	   of	   LDL-­‐C-­‐	   and	  
triglyceride-­‐associated	  SNPs.	  Presence	  of	  SNPs	  with	  high	  variance	  inflation	  factors	  (VIF	  >5)	  indicates	  
presence	  of	  multicollinearity.	  With	  AIC,	  SNP	  multicollinearity	  is	  an	  issue	  with	  the	  selected	  set	  of	  LDL	  
(2	  SNPs	  with	  VIF>5)	  and	  triglyceride	  SNPs	  (4	  SNPs	  with	  VIF>5).	  Using	  BIC	  overcomes	  this	  problem	  for	  
the	   triglyceride	   SNPs,	   but	   multicollinearity	   remains	   even	   after	   BIC-­‐selection	   of	   LDL-­‐C	   associated	  
SNPs.	  
	  	  
Number	  of	  genetic	  predictors	  
selected	  by	  model	  
Number	  of	  genetic	  predictors	  with	  VIF>5	  
Exposure	   AIC	   BIC	   AIC	   BIC	  
LDL	   22	   16	   2	   2	  
HDL	   12	   12	   0	   0	  
Triglyceride	   16	   13	   4	   0	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4.4 Discussion	  
4.4.1 Summary	  of	  Results	  
Two	   important	  considerations	  when	  performing	  MR	  analysis	  are	   the	  strength	  and	  
specificity	  of	  the	  instrument.	  Based	  on	  the	  SNPs	  associated	  with	  lipid	  levels	  in	  WHII,	  
assessment	  of	  the	  different	  approaches	  to	  instrument	  development	  shows	  that	  the	  
weighted	   genetic	   score	   consisting	   of	   SNPs	   selected	   by	   a	   stepwise	   regression	  
approach	   using	   the	   BIC	   for	  model	   selection	   and	  weighted	   by	   coefficients	   derived	  
from	  a	  Ridge	  regression,	  provide	  the	  best	  instruments	  in	  terms	  of	  both	  strength	  and	  
specificity	  for	  the	  exposure	  of	   interest.	  Though	  the	  multiple	  instruments	  approach	  
was	   equivalent	   in	   strength	   to	   the	   genetic	   score,	   a	   genetic	   score	   instrument	   that	  
combines	  multiple	  SNPs	  into	  a	  single	  IV	  is	  less	  likely	  to	  suffer	  from	  weak-­‐instrument	  
bias	  when	  the	  number	  of	  SNPs	  used	  is	  large	  and/or	  sample	  size	  is	  small.	  	  
	  
4.4.2 Multicollinearity	  
Multicollinearity	   is	  often	  caused	  by	  the	  choice	  of	  model,	  such	  as	  when	  two	  highly	  
correlated	  predictors	  are	  used	   in	   the	  regression	  model	   (Montgomery	  et	  al.	  2012).	  
Stepwise	  regression	  using	  AIC	  for	  model	  selection	  was	  initially	  adopted	  to	  select	  the	  
best	  genetic	  predictors	  of	  each	   lipid	  fraction,	  with	  the	  assumption	  that	  redundant	  
SNPs	  would	  be	  removed.	  However,	  several	  correlated	  SNPs,	  some	  of	  which	  are	   in	  
perfect	   LD,	   were	   retained	   by	   the	   model.	   Re-­‐specifying	   the	   model	   by	   manually	  
removing	   the	   correlated	   SNPs	   can	   overcome	   the	   problem	   of	   multicollinearity.	  
However,	  this	  would	  require	  several	  iterations	  of	  model	  specification	  and	  may	  not	  
be	   a	   satisfactory	   solution	   if	   the	   SNPs	   dropped	   from	   the	   model	   have	   significant	  
explanatory	   power	   (Montgomery	   et	   al.	   2012).	   Presence	   of	   multicollinearity	   may	  
result	  in	  poor	  estimates	  of	  the	  regression	  coefficients,	  and	  subsequently,	  inaccurate	  
weights	   for	   the	   genetic	   score.	   The	   above	   issues	  were	   overcome	  by	   using	   a	  more	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stringent	  model	   selection	   criterion	  which	   excluded	   some	   of	   the	   correlated	   SNPs,	  
followed	  by	  the	  use	  of	  a	  Ridge	  regression	  to	  obtain	  the	  weights	  for	  each	  SNP.	  The	  
latter	  has	  the	  effect	  of	  shrinking	  the	  beta-­‐coefficients	  and	  thus	  the	  contribution	  of	  
redundant	  SNPs	   towards	   zero.	  An	  alternative	   to	   this	  multi-­‐stage	  approach	   to	  SNP	  
selection	   and	   weight	   estimation	   is	   to	   use	   a	   method	   such	   as	   lasso,	   which	   is	   a	  
penalised	   regression	   technique	   that	   carries	   out	   variable	   selection	   and	   estimates	  
coefficients	   of	   the	   selected	   variables,	   shrinking	   estimates	   of	   redundant	   variables	  
towards	   zero.	   The	   lasso	  method	  eliminates	   the	  need	   to	   select	   an	   initial	   subset	  of	  
SNPs	  using	  a	  pre-­‐defined	  association	  p-­‐value	  threshold,	  and	  available	  software	  that	  
implement	  this	  method	  enable	  the	  efficient	  analysis	  of	  a	  very	  large	  number	  of	  SNPs	  
characteristic	  of	  large-­‐scale	  association	  studies.	  
	  
4.4.3 Weak	  Instrument	  Bias	  
The	   F-­‐statistic	   can	   be	   used	   as	   an	   indication	   of	   the	   degree	   of	   bias	   of	   the	   2SLS	  
estimator	   to	   the	  observed	  association	  between	  exposure	  and	  outcome.	  Based	  on	  
previous	  studies,	  where	  the	  F-­‐statistic	  is	  greater	  than	  10,	  the	  bias	  becomes	  typically	  
negligible	  (Pierce	  et	  al.	  2010).	  In	  the	  case	  of	  the	  lipid	  instruments	  considered	  here,	  
whether	   using	   genetic	   scores	   or	   multiple	   instruments,	   all	   F-­‐statistics	  were	   much	  
greater	   than	   10.	   However,	   if	   the	   number	   of	   SNPs	   used	   in	   a	  multiple	   instruments	  
approach	  increases	  with	  little	  increase	  in	  R2,	  this	  may	  create	  weak	  instrument	  bias,	  
since	   the	   F-­‐statistic	   is	   dependent	   on	   R2	   and	   the	   number	   of	   instruments.	   Current	  
genetic	   studies	  usually	  have	   large	  enough	   sample	   sizes	   to	   avoid	  weak	   instrument	  
bias,	  however,	  there	  will	  be	  a	  limit	  to	  the	  number	  of	  lipid-­‐associated	  SNPs	  that	  can	  
be	   used	   with	   the	   multiple	   instruments	   approach.	   On	   the	   other	   hand,	   weak	  
instrument	   bias	   is	   unlikely	   to	   be	   an	   issue	   when	   a	   large	   number	   of	   SNPs	   are	  
combined	  into	  a	  single	  genetic	  score	  instrument.	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4.4.4 Specificity	  
At	  the	  individual	  SNP	  level,	  some	  SNPs	  may	  be	  associated	  with	  more	  than	  one	  lipid	  
fraction	  or	  with	  other	  CVD	  risk	  factors.	  If	  these	  risk	  factors	  are	  downstream	  in	  the	  
same	   biological	   pathway	   (Figure	   4.3A)	   then	   the	   assumption	   that	   the	   instrument	  
only	  affects	  outcome	  via	   the	  exposure	  of	   interest	   is	  not	  violated.	  However,	   this	   is	  
not	  the	  case	  when	  a	  SNP	  exerts	  an	  effect	  on	  outcome	  via	  an	  independent	  pathway	  
to	   the	   exposure	   of	   interest	   (Figure	   4.3B).	   Unfortunately,	   the	   path	   of	   association	  
between	   instrument	   and	   exposure	   of	   interest	   is	   not	   always	   known,	   making	   it	  
difficult	   to	   interpret	   results	   when	   an	   instrument	   is	   associated	   with	   other	   risk	  
factors.	   A	   number	   of	   SNPs	   were	   associated	   with	   both	   triglycerides	   and	   HDL-­‐C.	  
Further	   selection	  of	  SNPs	  associated	  only	  with	   the	   lipid	   fraction	  of	   interest	  would	  
provide	  a	  more	  specific	  instrument	  and	  may	  help	  better	  dissect	  the	  causal	  pathway.	  
Using	   a	   multiple	   instruments	   approach	   appears	   to	   be	   less	   specific	   than	   using	   a	  
weighted	  genetic	  score	  derived	  from	  the	  same	  set	  of	  SNPs,	  which	  may	  suggest	  that	  
when	  combining	  multiple	  SNPs	   into	  a	  single	  score,	  some	  of	  the	  pleiotropic	  effects	  
may	  balance	  out.	  
	  
4.4.5 Limitations	  
The	  major	   limitation	  of	   this	   analysis	   is	   that	   instrument	   strength	  was	  estimated	   in	  
the	   same	   sample	   used	   to	   identify	   the	   SNPs	   and	   estimate	   effect	   sizes.	   Instrument	  
strength	   reported	   here	   will	   therefore	   be	   inflated	   due	   to	   discovery	   bias.	   If	   MR	  
analysis	   is	   also	   carried	   out	   in	   the	   same	   dataset,	   there	   is	   likely	   to	   be	   bias	   due	   to	  
“winner’s	   curse”.	  Recent	  work	  by	  Burgess	  and	  Thompson	   (2013)	   showed	   that	   the	  
use	  of	  variants	  and	  weights	  chosen	  based	  on	  	  the	  strength	  	  of	  their	  	  association	  with	  	  
the	   risk	   factor	   in	   the	   data	   under	   analysis	   gives	   biased	   causal	   estimates	   in	   the	  
direction	  of	  the	  confounded	  association.	  The	  genetic	  instruments	  developed	  in	  one	  
dataset	  should	  therefore	  be	  applied	  in	  an	  MR	  analysis	  in	  an	  independent	  dataset.	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Figure	  4.3	  Association	  of	  a	  variant	   in	  a	  causal	  pathway.	  X	  denotes	   the	  exposure	  of	   interest,	  B	  an	  
additional	  risk	  factor,	  Y	  the	  outcome	  of	  interest	  and	  G	  the	  genetic	  instrument.	  (A)	  Though	  a	  genetic	  
variant	   determining	   the	   exposure	   of	   interest	  may	   also	   be	   associated	  with	   other	   downstream	   risk	  
factors,	  it	  is	  still	  a	  valid	  instrument.	  (B)	  Where	  the	  instrument	  is	  associated	  independently	  with	  both	  














	   	  
	   	  
When	   the	   only	   source	   of	   information	   on	   weights	   is	   the	   data	   under	   analysis,	   an	  
alternative	   approach	   recommended	   by	   Burgess	   and	   Thompson	   is	   to	   use	   a	   ten-­‐
foldcross-­‐validation	  approach	  whereby	  weights	  are	  calculated	  based	  on	  90%	  of	  the	  
data	  and	  the	  ten	  sets	  of	  weights	  are	  applied	  in	  the	  (10%)	  validation	  data	  (Burgess	  &	  
Thompson	   2013).	   In	   this	   way	   the	   correlation	   between	   the	   weights	   and	   the	   data	  
under	  analysis	  is	  removed.	  However,	  large	  enough	  sample	  sizes	  would	  be	  required	  
to	  allow	  sufficient	  numbers	  in	  the	  validation	  data.	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The	  analysis	  carried	  out	   in	  this	  chapter	  assumes	  only	  additive	  effects	  of	  alleles	  for	  
each	  SNP	  and	  no	  gene-­‐gene	  interactions.	  Though	  not	  explored	  in	  this	  work,	  if	  these	  
assumptions	  did	  not	  hold,	  it	  would	  be	  possible	  to	  incorporate	  such	  knowledge	  into	  
the	   model.	   However,	   analysis	   by	   Burgess	   &	   Thompson	   (2013)	   showed	   that	   an	  
unweighted	  allele	  score	  is	  robust	  to	  model	  mis-­‐specification.	  
	  
Since	  this	  analysis,	  the	  GWAS	  meta-­‐analysis	  by	  the	  GLGC	  in	  over	  100,000	  individuals	  
(Teslovich	  et	   al.	   2010)	   and	   the	  more	   recent	   gene-­‐centric	  meta-­‐analysis	   (using	   the	  
Illumina	  Cardiochip)	  in	  around	  66,000	  individuals	  (Asselbergs	  et	  al.	  2012)	  have	  both	  
identified	   a	   large	   number	   of	   novel	   loci	   associated	   with	   each	   of	   the	   three	   lipid	  
fractions.	  The	  SNPs	  and	  regression	  coefficients	  reported	  by	  these	  studies	  could	  be	  
used	   to	   generate	   unbiased	   weighted	   lipid	   genetic	   scores	   for	   MR	   analysis.	   Using	  
more	   than	   one	   genetic	   score	   generated	   from	   SNPs	   and	   weights	   identified	   and	  
estimated	  from	  independent	  datasets	  would	  provide	  evidence	  for	  the	  robustness	  of	  
the	   IV	   estimate,	   as	   independently	   derived	   genetic	   scores	   are	   unlikely	   to	   be	  
influenced	  by	  the	  same	  pleiotropy	  or	  linkage	  disequilibrium-­‐induced	  confounding.	  	  
	  
Since	  the	  study	  by	  Yang	  et	  al	  (2010),	  which	  showed	  that	  when	  all	  SNPs	  on	  the	  GWA	  
platform	  are	   considered	   they	  explain	  a	  much	   larger	  proportion	  of	   the	  phenotypic	  
variation	  than	  those	  chosen	  by	  a	  p-­‐value	  threshold,	  there	  has	  been	  a	  lot	  of	  interest	  
in	  the	  use	  of	  all	  SNPs	  on	  the	  genotyping	  platform	  for	  MR	  instrument	  development.	  
However,	   the	   issue	   of	   specificity	   and	   weak	   instrument	   bias	   would	   need	   to	   be	  
carefully	  considered	  when	  exploring	  such	  an	  approach	  for	  MR	  analysis.	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5 Determining	  the	  Causal	  Relationship	  between	  Blood	  
Lipids	  and	  Carotid-­‐Intima	  Media	  Thickness:	  a	  Mendelian	  
Randomisation	  Analysis	  
5.1 Introduction	  
Higher	   LDL-­‐C	   concentration	   is	   associated	   with	   a	   higher	   risk	   of	   CHD,	   and	   the	  
relationship	   is	   considered	   causal	   because	   randomised	   trials	   using	   LDL-­‐C-­‐lowering	  
interventions	   such	  as	   statins	  have	   shown	   to	   reduce	  CHD	   risk	   in	  proportion	   to	   the	  
degree	  of	  LDL-­‐C	  reduction	  (Baigent	  et	  al.	  2005;	  Baigent	  et	  al.	  2010).	  Interventions	  to	  
elevate	   HDL-­‐C	   or	   reduce	   triglycerides	   might	   also	   confer	   incremental	   protection	  
against	   CHD,	   but	   thus	   far	   randomised	   trials	   of	   drugs	   directed	   at	   these	   two	   lipid	  
fractions	  have	  been	  unable	   to	  confirm	  or	   refute	  such	  effects	   (Cannon	  et	  al.	  2010;	  
Forrest	   et	   al.	   2008;	  Ginsberg	   et	   al.	   2010;	   Jun	   et	   al.	   2010;	  NHLBI	   Communications	  
2011).	  	  
	  
Conclusive	   demonstration	   of	   the	   benefit	   and	   safety	   of	   new	   lipid-­‐modifying	  
interventions	   requires	   evaluation	   in	   large,	   expensive	   randomised	   trials	   with	   hard	  
clinical	  end	  points	   in	  people	  already	  receiving	  effective	  drugs	   for	  CHD	  prevention.	  
Approaches	   that	   help	   validate	   treatment	   targets	   ahead	   of	   such	   trials	   may	   help	  
reduce	  the	  risk	  of	  late-­‐stage	  failures	  in	  drug	  development.	  One	  approach	  has	  been	  
to	  use	  a	  non-­‐invasive	  measure	  of	  atherosclerosis,	  CIMT,	  as	  a	  surrogate	  end-­‐point.	  
CIMT	  is	  considered	  to	  be	  a	  subclinical	  measure	  of	  atherosclerosis,	  which	  is	  strongly	  
associated	  with	  risk	  of	  CHD	  (O’Leary	  et	  al.	  1999;	  Chambless	  et	  al.	  1997).	  Statin	  drugs	  
that	  are	  effective	  in	  reducing	  CHD	  also	  reduced	  progression	  of	  CIMT	  in	  proportion	  
to	  the	  degree	  of	  LDL-­‐C-­‐lowering	  (Bedi	  et	  al.	  2010;	  Espeland	  et	  al.	  2005;	  Kastelein	  et	  
al.	  2003).	  However,	  interventions	  developed	  so	  far	  that	  reduce	  triglycerides	  or	  raise	  
HDL-­‐C	   have	   shown	   inconsistent	   effects	   on	   CIMT	   (Bots	   et	   al.	   2007;	   Hiukka	   et	   al.	  
2008;	   Taylor	   et	   al.	   2009),	   making	   it	   uncertain	   whether	   the	   specific	   agents	   are	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ineffective	  for	  CHD	  prevention,	  whether	  these	  two	  lipid	  fractions	  in	  general	  are	  not	  
causally	   related	   to	   CHD	   and	   therefore	   invalid	   targets,	   or	   whether	   CIMT	   is	   an	  
inadequate	   marker	   of	   HDL-­‐C	   or	   triglyceride-­‐mediated	   effects	   on	   CHD	   risk.	   MR,	  
described	   in	   section	   1.6.2,	   provides	   a	   means	   of	   evaluating	   and	   quantifying	   the	  
extent	   to	   which	   associations	   between	   a	   putative	   risk	   factor	   (e.g.	   HDL-­‐C	   or	  
triglycerides)	  and	  an	  outcome,	  such	  as	  CHD	  or	  CIMT,	  are	  causal	  (Ebrahim	  &	  Smith,	  
2008).	  	  
	  
Using	   large-­‐scale	   genotyping	   arrays,	   many	   SNPs	   influencing	   LDL-­‐C,	   HDL-­‐C	   and	  
triglycerides	   have	   recently	   been	   identified	   (Talmud	   et	   al.	   2009;	   Teslovich	   et	   al.	  
2010;	   Asselbergs	   et	   al.	   2012),	   and	   these	   provide	   potential	   instruments	   for	   MR	  
analyses.	   The	   aim	   of	   the	   work	   in	   this	   chapter	   was	   to	   determine	   the	   casual	  
relationship	   between	   these	   three	   lipid	   fractions	   and	   common	   CIMT	   using	   MR	  
analysis.	   The	   LDL-­‐C,	   HDL-­‐C	   and	   triglyceride	  weighted	   genetic	   scores	   developed	   in	  
the	  previous	  chapter,	  based	  on	  lipid-­‐associated	  SNPs	  on	  the	  Cardiochip	  and	  weights	  
estimated	   in	   WHII,	   were	   used	   as	   instruments	   for	   the	   three	   lipid	   fractions	   to	  
estimate	   their	   causal	   association	  with	   common	  CIMT	   in	   around	  3000	  participants	  
from	   the	   WHIII	   study	   (Marmot	   &	   	   Brunner	   2005)	   and	   also	   in	   around	   3400	  
individuals	  from	  the	  IMT	  Progression	  as	  Predictors	  of	  Vascular	  Events	  in	  a	  High	  Risk	  
European	   Population	   (IMPROVE)	   study	   (Baldassarre	   et	   al.	   2010)	   using	   the	   2SLS	  
approach	   for	   instrumental	   variable	   analysis	   (described	   in	   section	   1.6.2.3).	   In	  
addition,	  the	  causal	  association	  was	  also	  determined	  in	  both	  studies	  using	  weighted	  
genetic	   scores	   based	   on	   the	   independently	   identified	   lipid-­‐associated	   SNPs	   and	  	  
effect	  sizes	  reported	  by	  the	  GLGC	  GWAS	  meta-­‐analysis	   in	  over	  100,000	  individuals	  
(Teslovich	  et	  al.	  2010).	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5.2 Materials	  &	  Methods	   	  
5.2.1 Study	  Cohorts	  
The	  WHII	  cohort	  has	  been	  described	  in	  section	  2.2.1.3.	  	  The	  IMPROVE	  longitudinal	  
study	   (Baldassarre	   et	   al.	   2010)	   recruited	   a	   total	   of	   3711	   individuals	   (48%	   men)	  
between	  March	  2004	  and	  April	  2005	  from	  7	  centres	  in	  5	  European	  countries,	  with	  a	  
median	  age	  of	  64.4	  years.	  Eligibility	  criteria	   included	  age	  between	  55	  to	  79	  years,	  
presence	   of	   at	   least	   three	   vascular	   risk	   factors,	   and	   absence	   of	   symptoms	   of	  
cardiovascular	   diseases	   and	   any	   conditions	   that	   might	   limit	   longevity	   or	  
visualisation	  of	  the	  carotid	  intima.	  The	  study	  was	  designed	  in	  accordance	  with	  the	  
rules	   of	   Good	   Clinical	   Practice,	   and	   with	   the	   ethical	   principles	   established	   in	   the	  
Declaration	   of	   Helsinki.	   Informed	   consent	   was	   obtained	   from	   all	   participants.	  
Baseline	  data	  from	  the	  IMPROVE	  data	  was	  used	  in	  analysis.	  
	  
5.2.2 CIMT	  Measurement	  
In	  WHII,	  ultrasound	  vascular	  measurements	  were	  taken	  in	  the	  2003-­‐2004	  follow-­‐up	  
phase.	  Participants	  were	  examined	  in	  a	  supine	  position,	  with	  the	  head	  turned	  to	  a	  
45	   degree	   angle	   away	   from	   the	   side	   to	   be	   scanned.	   The	   far	  walls	   of	   the	   left	   and	  
right	  common	  carotid	  artery	  were	  visualised	  in	  the	  lateral	  projection.	  The	  common	  
CIMT	   was	   measured	   at	   its	   thickest	   part,	   1	   cm	   proximal	   to	   the	   bifurcation.	   A	  
measurement	  was	   taken	   between	   the	   leading	   edge	   of	   the	   intima	   and	   the	  media	  
adventitia	  on	  three	  separate	  images	  on	  each	  side	  using	  electronic	  callipers,	  and	  the	  
mean	  of	  the	  six	  measures	  was	  used	  for	  analysis.	  The	  overall	  coefficient	  of	  variation	  
(defined	  as	  the	  ratio	  of	  the	  standard	  deviation	  	  to	  the	  mean)	  for	  repeated	  measures	  
of	  CIMT	  was	  4.7%	  (N	  =	  89),	  indicating	  high	  reproducibility	  (Kivimäki	  et	  al.	  2008).	  For	  
all	  analyses,	  the	  CIMT	  variable	  was	  loge-­‐transformed.	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In	   IMPROVE,	   the	   far	   walls	   of	   the	   left	   and	   right	   common	   carotid	   artery	   were	  
visualised	   in	   the	   lateral	   projection	   and	   recorded	   on	   sVHS	   videotapes.	  
Measurements	  were	  taken	  at	  the	  thickest	  part	  of	  common	  carotids,	  1	  cm	  proximal	  
to	  the	  bifurcation.	  The	  far	  walls	  of	  the	  common	  carotids	  in	  their	  entire	  length	  were	  
measured	  in	  at	  least	  three	  different	  images	  on	  each	  side	  using	  dedicated	  software	  
able	   to	   automatically	   recognise	   the	   leading	   edge	   of	   the	   intima	   and	   the	   media	  
adventitia.	   For	   each	   segment	   the	   mean	   of	   the	   six	   measures	   was	   used	   for	   the	  
analysis.	   The	   overall	   coefficient	   of	   variation	   for	   repeated	  measures	   of	   CIMT	   was	  
3.9%	   (N	   =	   121)	   (Baldassarre	   et	   al.	   2010).	   In	   both	   studies,	   to	   obtain	   a	   normal	  
distribution,	  the	  CIMT	  variable	  was	  loge-­‐transformed.	  
	  
5.2.3 Lipid	  Measurements	  
For	  WHII,	  baseline	   lipid	  measurements	  were	  used	   for	   the	  analysis,	   since	  very	   few	  
individuals	   were	   on	   lipid-­‐lowering	   therapy	   at	   baseline	   (previously	   described	   in	  
section	   3.2.2).	   In	   the	   IMPROVE	   study,	   blood	   sampling	   for	   laboratory	   tests	   was	  
performed	  after	  an	  overnight	  fast.	  Serum	  was	  frozen	  at	  –80oC	  prior	  to	  shipment	  for	  
centralised	  biochemical	  analyses	  and	  biobanking	  in	  Stockholm	  (Karolinska	  Institute	  
Stockholm,	   Sweden).	   Serum	   concentrations	   of	   total	   cholesterol,	   HDL-­‐C	   and	  
triglycerides	   were	   analysed	   in	   a	   centralised	   laboratory.	   LDL-­‐C	   concentration	   was	  
calculated	   using	   the	   Friedewald	   (Friedewald	   et	   al.	   1972).	   HDL-­‐C	   and	   triglyceride	  
variables	  were	  loge-­‐transformed	  for	  all	  analyses.	  
	  
5.2.4 Genotyping	  
As	  described	   in	  section	  2.2.4,	  DNA	  was	  extracted	  from	  whole	  blood	  samples	   from	  
WHII	   participants	   between	   2003	   and	   2004,	   and	   genotyping	   on	   a	   total	   of	   5592	  
samples	  using	  the	  Illumina	  Cardiochip	  (Keating	  et	  al.	  2008)	  was	  completed	  in	  2008.	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At	   the	   beginning	   of	   2012,	   genotyping	   of	   3413	  WHII	   samples	  was	   also	   completed	  
using	  the	  Illumina	  Metabochip	  platform	  (Voight	  et	  al.	  2012).	  In	  the	  IMPROVE	  study,	  
3695	  samples	  were	  genotyped	  using	  the	  Metabochip.	  The	  Metabochip	  is	  a	  custom	  
genotyping	   array	   that	   provides	   cost-­‐effective	   genotyping	   of	   nearly	   200,000	   SNPs	  
chosen	   based	   on	   GWAS	   results	   from	   meta-­‐analyses	   of	   23	   traits	   that	   include	  
cardiovascular	   disease	   outcomes	   (CAD,	   type	   2	   diabetes	   (T2D)	   and	   MI),	   and	   risk	  
factors	   (fasting	   glucose,	   fasting	   insulin,	   2-­‐hour	   glucose,	   glycated	   haemoglobin	  
(HbA1c),	  T2D	  age	  of	  diagnosis,	  LDL-­‐C,	  HDL-­‐C	  triglycerides,	  total	  cholesterol,	  systolic	  
and	  diastolic	  blood	  pressure,	  QT	  interval,	  BMI,	  waist-­‐to-­‐hip	  ratio	  adjusted	  for	  BMI,	  
waist	  circumference	  adjusted	  for	  BMI,	  height,	  body	  fat	  percentage,	  platelet	  count,	  
mean	  platelet	  volume,	  and	  white	  blood	  cell	  count).	  	  
	  
After	  applying	  quality	  control	  steps	  (refer	  to	  section	  2.2.4)	  (filtering	  for	  duplicates,	  
cryptic	   relatedness,	   ambiguous	   gender,	   self-­‐reported	   non-­‐Caucasians,	   outliers	  
based	   on	   the	   genome-­‐wide	   identity-­‐by-­‐state	   analysis	   implemented	   in	   PLINK,	  	  
sample	  call	  rate	  <80%	  and	  SNP	  call	  rate	  <98%),	  5059	  Cardiochip	  genotyped	  samples	  
and	   3126	   Metabochip	   genotyped	   samples	   from	   WHII	   were	   available	   for	   the	  
analysis.	   In	   the	   IMPROVE	   study,	   after	   quality	   control	   (SNP	   and	   sample	   call	   rate	  
<95%,	   removing	   individuals	   for	   relatedness	   (confirmed	   or	   cryptic),	   reported	   non-­‐
European	   descent,	   outliers	   identified	   by	  multi-­‐dimensional	   scaling,	   and	  mismatch	  
between	   recorded	   and	   genotype-­‐determined	   sex),	   3430	   individuals	   remained	   for	  
analysis.	  
	  
5.2.5 Generating	  Lipid	  Genetic	  Score	  Instruments	  
Two	  lipid	  genetic	  scores	  were	  derived:	  one	  based	  on	  an	  internal	  analysis	  in	  the	  WHII	  
study	   using	   SNPs	   present	   on	   the	   Cardiochip	   and	   one	   based	   on	   lipid-­‐associated	  
variants	  reported	  by	  the	  GLGC	  (Teslovich	  et	  al.	  2010),	  as	  described	  below.	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5.2.5.1 Cardiochip	  Genetic	  Scores	  
The	  SNPs	  and	  weights	  used	  for	  calculating	  the	  Cardiochip	  genetic	  scores	  for	  LDL-­‐C,	  
HDL-­‐C	   and	   triglycerides	   in	   both	   WHII	   and	   IMPROVE	   were	   derived	   using	   variable	  
selection	  with	  BIC	  and	  Ridge	  regression	  in	  WHII	  (Table	  5.1	  -­‐	  Table	  5.3),	  as	  described	  
in	   the	   previous	   chapter	   (section	   4.3.7).	   SNPs	   not	   present	   in	   the	   IMPROVE	   data	  
(because	   they	   were	   not	   represented	   on	   the	  Metabochip	   genotyping	   platform	   or	  
failed	   quality	   control)	  were	   excluded	   from	   the	   genetic	   score	   calculations.	   In	   both	  
studies,	   individuals	   with	   any	   missing	   genotypes	   for	   the	   SNPs	   used	   in	   the	   score	  
calculation	  were	  excluded	  from	  the	  analysis.	  
	  
5.2.5.2 GLGC	  Genetic	  Scores	  
In	   the	  published	  GLGC	  meta-­‐analysis,	   an	   association	  p-­‐value	  <5×10−8	  was	  used	   to	  
denote	  significant	  association	  between	  SNPs	  and	  lipid	  traits	  (Teslovich	  et	  al.	  2010).	  
For	  the	  purpose	  of	  the	  genetic	  score	  calculation	  only	  the	  lead	  SNP	  from	  each	  locus	  
was	  selected,	  and	  if	  a	  SNP	  was	  associated	  with	  more	  than	  one	  lipid	  fraction	  it	  was	  
only	  used	   in	  the	  genetic	  score	  calculation	  for	  the	  trait	  with	  which	   it	  had	  the	  most	  
significant	  association	  p-­‐value	  (primary	  trait	  association).	  These	  are	  the	  SNPs	  listed	  
in	   the	   primary	   tables	   of	   the	   GLGC	   publication	   (Teslovich	   et	   al.	   2010).	   Since	   the	  
design	  of	  the	  Metabochip	  was	  based	  on	  GWAS	  results,	  a	  large	  number	  of	  the	  lipid-­‐
associated	   SNPs	   reported	   by	   the	   GLGC	   meta-­‐analysis	   were	   present	   on	   the	  
Metabochip	   platform.	   Risk	   allele	   counts	   were	   therefore	   calculated	   in	   WHII	   and	  
IMPROVE	  using	   the	  Metabochip	   genotype	   data.	   Risk	   allele	   counts	  were	  weighted	  
using	  the	  univariate	  beta-­‐coefficients	  reported	  by	  the	  GLGC	  discovery	  meta-­‐analysis	  
(Table	   5.1	   -­‐	   Table	   5.3).	   The	   GLGC	   reports	   a	   strong	   association	   of	   rs4420638	   on	  
chromosome	  19	  with	  LDL-­‐C	  levels,	  but	  this	  SNP	  is	  not	  independent	  of	  the	  APOE	  SNP	  
rs429358.	   Therefore,	   as	   was	   done	   for	   the	   Cardiochip	   scores,	   the	  weighted	  APOE	  
genotypes	  were	  used	   in	   the	   calculation	  of	   the	   LDL-­‐C	   genetic	   score	   instead	  of	   the	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GLGC-­‐reported	   SNP.	   Since	   the	   discovery	   of	   the	  GLGC	   SNPs	  was	   carried	   out	   in	   an	  
independent	  dataset	  and	  only	  a	  single	  SNP	  was	  selected	  at	  each	  locus,	  the	  issues	  of	  
discovery	  bias	  and	  multicollinearity	  due	  to	  LD	  were	  minimised.	  SNPs	  not	  present	  in	  
the	  data	  (because	  they	  were	  not	  represented	  on	  the	  genotyping	  platform	  or	  failed	  
quality	  control)	  were	  excluded	  from	  the	  genetic	  score	  calculations.	  Individuals	  with	  
missing	  data	  for	  SNPs	  used	  in	  the	  score	  calculation	  were	  excluded.	  
	  
Table	  5.1 SNPs contributing to the LDL-C genetic scores. 
	  














rs4299376	   ABCG8	   yes	   yes	   G	   T	   0.12	   0.071	  
rs2072560	   APOA5	   yes	   no	   T	   C	   0.21	   -­‐	  
rs1367117	   APOB	   no	   yes	   A	   G	   -­‐	   0.1	  
rs562338	   APOB	   yes	   no	   G	   A	   0.14	   -­‐	  
rs934197	   APOB	   yes	   no	   A	   G	   0.094	   -­‐	  
rs12721109	   APOC4	   yes	   no	   G	   A	   0.26	   -­‐	  
rs10402271	   BCAM/PVRL2	   yes	   no	   G	   T	   0.062	   -­‐	  
rs12740374	   CELSR2	   yes	   no	   G	   T	   0.23	   -­‐	  
rs629301	   CELSR2	   yes	   yes	   T	   G	   -­‐0.068	   0.15	  
rs17231506	   CETP	   yes	   no	   C	   T	   0.1	   -­‐	  
rs1800562	   HFE	   no	   yes	   G	   A	   -­‐	   0.057	  
rs12916	   HMGCR	   yes	   no	   C	   T	   0.11	   -­‐	  
rs8017377	   KIAA1305	   no	   yes	   A	   G	   -­‐	   0.029	  
rs6511720	   LDLR	   no	   yes	   G	   T	   -­‐	   0.18	  
rs17248720	   LDLR	   yes	   no	   C	   T	   0.43	   -­‐	  
rs2228671	   LDLR	   yes	   no	   C	   T	   -­‐0.21	   -­‐	  
rs8110695	   LDLR	   yes	   no	   T	   A	   0.066	   -­‐	  
rs3757354	   MYLIP	   no	   yes	   C	   T	   -­‐	   0.037	  
rs2479409	   PCSK9	   no	   yes	   G	   A	   -­‐	   0.052	  
rs11591147	   PCSK9	   yes	   no	   G	   T	   0.52	   -­‐	  
rs283813	   PVRL2	   yes	   no	   T	   A	   0.14	   -­‐	  
rs1564348	   SLC22A1	   no	   yes	   T	   C	   -­‐	   0.014	  
rs11220462	   ST3GAL4	   no	   yes	   A	   G	   -­‐	   0.05	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Table	  5.2	  SNPs	  contributing	  to	  HDL-­‐C	  genetic	  scores	  














rs1883025	   ABCA1	   no	   yes	   T	   C	   -­‐	   0.024	  
rs4148008	   ABCA8	   no	   yes	   G	   C	   -­‐	   0.011	  
rs2923084	   AMPD3	   no	   yes	   G	   A	   -­‐	   0.011	  
rs2072560	   APOA5	   yes	   no	   T	   C	   0.064	   -­‐	  
rs6450176	   ARL15	   no	   yes	   A	   G	   -­‐	   0.013	  
rs11820589	   BUD13	   yes	   no	   A	   G	   0.054	   -­‐	  
rs2814944	   C6orf106	   no	   yes	   A	   G	   -­‐	   0.013	  
rs581080	   C9orf52	   no	   yes	   G	   T	   -­‐	   0.017	  
rs3764261	   CETP	   no	   yes	   C	   A	   -­‐	   0.088	  
rs12708967	   CETP	   yes	   no	   C	   T	   0.031	   -­‐	  
rs17231506	   CETP	   yes	   no	   C	   T	   0.041	   -­‐	  
rs5880	   CETP	   yes	   no	   C	   G	   0.04	   -­‐	  
rs5883	   CETP	   yes	   no	   C	   T	   0.091	   -­‐	  
rs711752	   CETP	   yes	   no	   G	   A	   0.023	   -­‐	  
rs9989419	   CETP	   yes	   no	   A	   G	   0.016	   -­‐	  
rs2925979	   CMIP	   no	   yes	   T	   C	   -­‐	   0.012	  
rs737337	   DOCK6	   no	   yes	   C	   T	   -­‐	   0.017	  
rs3136441	   F2	   no	   yes	   T	   C	   -­‐	   0.02	  
rs4846914	   GALNT2	   no	   yes	   G	   A	   -­‐	   0.016	  
rs1800961	   HNF4A	   no	   yes	   T	   C	   -­‐	   0.049	  
rs4731702	   KLF14	   no	   yes	   C	   T	   -­‐	   0.015	  
rs2652834	   LACTB	   no	   yes	   A	   G	   -­‐	   0.01	  
rs386000	   LILRA3	   no	   yes	   G	   C	   -­‐	   0.021	  
rs1532085	   LIPC	   no	   yes	   G	   A	   -­‐	   0.037	  
rs261342	   LIPC	   yes	   no	   C	   G	   0.036	   -­‐	  
rs4775041	   LIPC	   yes	   no	   G	   C	   0.028	   -­‐	  
rs17410962	   LPL	   yes	   no	   G	   A	   0.027	   -­‐	  
rs301	   LPL	   yes	   no	   T	   C	   0.027	   -­‐	  
rs12967135	   MC4R	   no	   yes	   A	   G	   -­‐	   0.011	  
rs4660293	   PABPC4	   no	   yes	   G	   A	   -­‐	   0.012	  
rs7134375	   PDE3A	   no	   yes	   C	   A	   -­‐	   0.01	  
rs4129767	   PGS1	   no	   yes	   G	   T	   -­‐	   0.01	  
rs6065906	   PLTP	   no	   yes	   C	   T	   -­‐	   0.024	  
rs9987289	   PPP1R3B	   no	   yes	   A	   G	   -­‐	   0.031	  
rs16942887	   PSKH1	   no	   yes	   G	   A	   -­‐	   0.033	  
rs838880	   SCARB1	   no	   yes	   T	   C	   -­‐	   0.016	  
rs13107325	   SLC39A8	   no	   yes	   T	   C	   -­‐	   0.022	  
rs11869286	   STARD3	   no	   yes	   G	   C	   -­‐	   0.012	  
rs2293889	   TRPS1	   no	   yes	   T	   G	   -­‐	   0.011	  
rs181362	   UBE2L3	   no	   yes	   T	   C	   -­‐	   0.012	  
rs1689800	   ZNF648	   no	   yes	   G	   A	   -­‐	   0.012	  
	  Total	  	   	  	   12	   29	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Table	  5.3	  SNPs	  contributing	  to	  Triglyceride	  genetic	  scores	  















rs442177	   AFF1	   no	   yes	   T	   G	   -­‐	   0.025	  
rs10750097	   APOA5	   yes	   no	   G	   A	   0.042	   -­‐	  
rs651821	   APOA5	   yes	   no	   C	   T	   0.22	   -­‐	  
rs33989105	   APOC3	   yes	   no	   T	   C	   0.038	   -­‐	  
rs17145713	   BAZ1B	   yes	   no	   C	   T	   0.085	   -­‐	  
rs10195252	   COBLL1	   no	   yes	   T	   C	   	   0.023	  
rs2068888	   CyP26A1	   no	   yes	   G	   A	   -­‐	   0.026	  
rs2131925	   DOCK7	   no	   yes	   T	   G	   -­‐	   0.058	  
rs174546	   FADS1	   no	   yes	   T	   C	   -­‐	   0.043	  
rs2412710	   GANC/CAPN3	   no	   yes	   A	   G	   -­‐	   0.079	  
rs1260326	   GCKR	   yes	   yes	   T	   C	   0.05	   0.099	  
rs2304128	   GMIP	   yes	   no	   G	   T	   0.086	   -­‐	  
rs17108993	   GPR120	   yes	   no	   G	   C	   0.11	   -­‐	  
rs12678919	   LPL	   no	   yes	   A	   G	   -­‐	   0.15	  
rs10503669	   LPL	   yes	   no	   C	   A	   0.047	   -­‐	  
rs285	   LPL	   yes	   no	   C	   T	   0.051	   -­‐	  
rs3289	   LPL	   Yes	   no	   C	   T	   0.15	   -­‐	  
rs331	   LPL	   Yes	   no	   G	   A	   0.032	   -­‐	  
rs9686661	   MAP3K1	   No	   yes	   T	   C	   -­‐	   0.029	  
rs645040	   MSL2L1	   No	   yes	   T	   G	   -­‐	   0.025	  
rs11776767	   PINX1	   No	   yes	   C	   G	   -­‐	   0.023	  
rs5756931	   PLA2G6	   No	   yes	   T	   C	   -­‐	   0.017	  
rs11613352	   R3HDM2	   No	   yes	   C	   T	   -­‐	   0.03	  
rs17145738	   TBL2	   No	   yes	   C	   T	   -­‐	   0.11	  
rs2954029	   TRIB1	   No	   yes	   A	   T	   -­‐	   0.064	  
rs17321515	   TRIB1	   Yes	   no	   A	   G	   0.048	   -­‐	  
rs13238203	   TYW1B	   No	   yes	   C	   T	   -­‐	   0.089	  
rs12286037	   ZNF259	   Yes	   no	   T	   C	   0.18	   -­‐	  
Total	  	   	  	   13	   16	   	  	   	   	   	  
	  
	  
5.2.6 Association	  of	  Genetic	  Scores	  with	  Lipid	  Levels	  
Linear	   regression	   was	   used	   to	   evaluate	   the	   association	   of	   lipid	   levels	   with	   their	  
respective	  genetic	  scores,	  without	  any	  adjustment	  for	  covariates.	  For	  comparison	  of	  
effect	  sizes	  across	  the	  different	  lipid	  traits,	  regression	  analysis	  was	  also	  performed	  
on	  standardised	  variables	  (Z-­‐scores).	  The	  proportion	  of	  variance	  explained	  (R2)	  and	  
the	   F-­‐statistic	   derived	   from	   the	   regression	   were	   reported	   as	   measures	   of	   the	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strength	  of	  each	  genetic	  score	  as	  an	  instrument.	  The	  R2	  values	  from	  the	  regression	  
of	  each	  genetic	  score	  with	  the	  non-­‐indexed	  lipid	  fractions	  were	  also	  reported	  as	  an	  
indication	  of	  instrument	  specificity.	  	  
	  
5.2.7 Observed	  Association	  between	  Lipids	  and	  CIMT	  
Association	  of	  CIMT	  with	   lipid	   levels	  was	  determined	  using	   linear	   regression,	  with	  
and	  without	  adjustment	  for	  sex,	  age,	  smoking	  (current	  status),	  diabetes	  status	  and	  
statin	  use.	  For	  comparison	  of	  effect	  sizes	  across	  traits,	  regression	  analysis	  was	  also	  
performed	  on	  standardised	  variables.	  
	  
5.2.8 Direct	  Association	  between	  Lipid	  Genetic	  Scores	  and	  CIMT	  
Direct	  association	  between	  the	  genetic	  scores	  and	  CIMT	  using	  linear	  regression	  was	  
carried	   out	   unadjusted	   for	   any	   covariates,	   and	   adjusted	   for	   the	   first	   three	  
dimensions	   from	  multidimensional	   scaling	   (refer	   to	   section	   2.2.4).	   To	   ensure	   that	  
any	  association	  with	  CIMT	  was	  only	  through	  the	  effect	  of	  the	  genetic	  scores	  on	  the	  
relevant	   lipid	   fraction,	  analysis	  was	  also	  repeated	  adjusted	   for	   the	  other	   two	   lipid	  
fractions.	  
	  
5.2.9 Causal	  Effect	  Estimate	  using	  2SLS	  
To	  estimate	  the	  causal	  effect	  of	  each	  lipid	  fraction	  with	  CIMT,	  instrumental	  variable	  
analysis	  using	  2SLS	  was	  carried	  out	  without	  any	  adjustment	  for	  covariates,	  using	  the	  
ivreg()	   command	   from	   the	   AER	   package	   (Kleiber	   &	   Zeileis	   2010)	   in	   R	   CRAN	   (R	  
Development	  Core	   Team	  2012).	  A	  meta-­‐analysis	   of	   the	   effect	   estimates	   from	   the	  
two	   studies	  was	   also	   carried	   out	   using	   a	   fixed	   effect	  model,	  where	   the	   summary	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estimate	   was	   the	   weighted	   (by	   the	   inverse	   of	   the	   study	   variance)	   mean	   of	   the	  
study-­‐specific	   effects.	   The	   analysis	  was	   then	   repeated	   using	   lipid	   levels	   corrected	  
for	  statin	  use	  by	  applying	  multiplicative	  correction	  factors	  derived	  from	  an	  analysis	  
of	  repeatedly	  measured	   lipid	   levels	   in	  WHII,	   including	   levels	  measured	  before	  and	  
after	   lipid-­‐lowering	   treatment.	   This	   method	   was	   reported	   in	   a	   recent	   large-­‐scale	  
genetic	  meta-­‐analysis	   (Asselbergs	  et	  al.	   2012).	   For	   statin	  users,	   the	   recorded	   lipid	  
values	   were	   multiplied	   by	   a	   constant:	   LDL-­‐C	   by	   1.352;	   HDL-­‐C	   by	   0.949,	   and	  
triglycerides	  by	  1.210	  (Asselbergs	  et	  al.	  2012).	  For	  comparison	  of	  effect	  sizes	  across	  
lipid	  traits,	  regression	  analysis	  was	  also	  performed	  on	  standardised	  variables.	  
	  
5.3 Results	  
5.3.1 Study	  Characteristics	  
Population	   characteristics	   and	   sample	   sizes	   with	   both	   genotype	   and	   phenotype	  
data	  are	   shown	   in	  Table	  5.4.	   The	  mean	  age	  of	  WHII	  participants	   at	   the	   follow-­‐up	  
phase	  when	  CIMT	  measurements	  were	  taken	  was	  60.9	  (SD	  =	  6.0)	  years,	  similar	  to	  
the	  mean	  age	  of	  64.2	  (SD	  =	  5.4)	  years	  for	  the	  IMPROVE	  participants.	  Mean	  CIMT	  in	  
WHII	  and	  IMPROVE	  was	  0.8	  mm	  (SD	  =	  0.2)	  and	  1.2	  mm	  (SD	  =	  0.3),	  respectively.	  The	  
mean	  baseline	  LDL-­‐C	  level	  in	  WHII	  was	  4.4	  mmol/L	  (SD	  =	  1.0).	  The	  lower	  mean	  LDL-­‐
C	   level	   in	   IMPROVE	   (3.6	   mmol/L;	   SD=1.0)	   may	   partly	   be	   explained	   by	   the	   larger	  
proportion	  of	   participants	  on	   statin	  medication	   at	   the	   time	  of	   lipid	  measurement	  
(0.9%	  in	  WHII	  versus	  40%	  in	  IMPROVE).	  The	  distributions	  and	  range	  of	  lipid	  values	  in	  
the	   two	   studies	   were	   comparable	   (Figure	   5.1).	   The	   range	   of	   CIMT	   values	   in	  
IMPROVE	   was	   larger	   than	   in	   WHII,	   with	   101	   individuals	   having	   CIMT	   >	   2mm	   in	  
IMPROVE	  but	  none	  in	  WHII	  (Figure	  5.1).	  
	  
	  	  
Chapter	  5:	  Results	  
	   	   	   	   	   	   	  
	  
172	  





























































































   
   
















   
   











































































































































































































































   
Chapter	  5:	  Results	  
	   	   	   	   	   	   	  
	  
173	  



































































            (B
) 
   
   
   
   
   
   
 
Chapter	  5:	  Results	  
	   	   	   	   	   	   	  
	  
174	  
	   	   	  
5.3.2 Cardiochip	  Lipid	  Genetic	  Scores	  
Seventeen	  SNPs	   (including	   the	  2	  APOE	   SNPs)	   contributed	   to	   the	  Cardiochip	   LDL-­‐C	  
genetic	  score	  (Table	  5.1),	  and	  12	  and	  13	  SNPs,	  respectively,	  to	  the	  HDL-­‐C	  (Table	  5.2)	  
and	  triglyceride	  (Table	  5.3)	  genetic	  scores.	  After	  applying	  quality	  control	  filters,	  all	  
SNPs	   for	   each	   lipid	   score	   were	   available	   in	   the	   WHII	   dataset.	   In	   the	   IMPROVE	  
dataset	  13	  of	  17	  LDL-­‐C	  SNPs	  (including	  2	  APOE	  SNPs),	  11	  of	  12	  HDL-­‐C	  SNPs,	  and	  9	  of	  
13	  triglyceride	  SNPs	  were	  available	  for	  the	  score	  calculation.	  	  
	  
5.3.3 GLGC	  Lipid	  Genetic	  Scores	  
Of	   the	   lead	   SNPs	   reported	   by	   the	   GLGC	  meta-­‐analysis,	   12	   (including	   the	   2	  APOE	  
SNPs),	  29	  and	  16	  SNPs	  associated	  with	  LDL-­‐C,	  HDL-­‐C	  and	  triglycerides,	  respectively,	  
were	   present	   on	   the	  Metabochip	   (Table	   5.1	   -­‐	   Table	   5.3)	   and	   contributed	   to	   the	  
genetic	   scores.	   In	  WHII,	   all	   LDL-­‐C	   SNPs,	   28	   of	   29	   HDL-­‐C	   SNPs	   and	   all	   triglyceride	  
SNPs	  were	  present.	  In	  IMPROVE,	  10	  of	  12	  LDL-­‐C	  SNPs	  (including	  the	  2	  APOE	  SNPs),	  
28	  of	  29	  HDL-­‐C	  SNPs,	  and	  all	  triglyceride	  SNPs	  were	  available	  for	  score	  calculation.	  
	  
5.3.4 Association	  of	  Lipid	  Levels	  with	  Lipid	  Genetic	  Scores	  
A	  1	  SD	  higher	  Cardiochip	  LDL-­‐C	  genetic	  score	  was	  associated	  with	  0.37	  mmol/L	  (95%	  
CI	  =	  0.34	  –	  0.39)	  and	  0.16	  mmol/L	  (95%	  CI	  =	  0.13	  –	  0.20)	  higher	  LDL-­‐C	  in	  WHII	  and	  
IMPROVE,	  respectively.	  A	  1	  SD	  higher	  HDL-­‐C	  genetic	  score	  was	  associated	  with	  8%	  
(beta	   (95%	  CI)	  =	   -­‐0.08	   (-­‐0.09,	   -­‐0.07))	  and	  6%	   (beta	   (95%	  CI)	  =	   -­‐0.06	   (-­‐0.07,	   -­‐0.05))	  
lower	  HDL-­‐C	  in	  WHII	  and	  IMPROVE,	  respectively.	  A	  1	  SD	  higher	  triglyceride	  genetic	  
score	   was	   associated	   with	   14%	   (beta	   (95%	   CI)	   =	   0.14	   (0.13,	   0.16))	   and	   13%	  	  	  	  	  	  	  	  	  	  
(beta	  	  (95%	  	  CI)	  	  =	  	  0.13	  (0.11,	  0.14))	  	  higher	  	  triglycerides	  	  in	  	  WHII	  and	  	  IMPROVE,	  
respectively.	   For	   comparison	   of	   effect	   sizes,	   Figure	   5.2	   shows	   the	   standardised	  	  
beta-­‐coefficients	  	  	  which	  	  represent	  	  the	  	  SD	  	  change	  	  in	  	  lipids	  per	  	  1	  	  SD	  	  change	  	  in	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Figure	  5.2	  Association	  of	  lipid	  genetic	  scores	  with	  lipid	  levels	  in	  WHII	  and	  IMPROVE.	  Effect	  sizes	  are	  
shown	  for	  standardised	  variables:	  standard	  deviation	  change	  in	  LDL-­‐C,	   loge-­‐transformed	  HDL-­‐C	  and	  
loge-­‐transformed	  triglycerides	  per	  1	  SD	  change	  in	  the	  respective	  (A)	  Cardiochip	  genetic	  score	  and	  (B)	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genetic	   score.	   Differences	   in	   lipid	   levels	   associated	  with	   the	   GLGC	   genetic	   scores	  
were	   in	   the	   same	   direction	   but	  were	   slightly	   lower	   in	  magnitude	   in	   both	   studies	  
(Figure	  5.2B)	  
	  
5.3.5 Lipid	  Genetic	  Score	  Instrument	  Strength	  
The	  Cardiochip	  genetic	  scores	  explained	  13%	  and	  3%	  of	  the	  total	  variance	  in	  LDL-­‐C,	  
7%	  and	  5%	  of	  the	  variance	  in	  HDL-­‐C,	  and	  7%	  and	  4%	  of	  the	  variance	  in	  triglycerides	  
in	  WHII	  and	  IMPROVE,	  respectively.	  The	  GLGC	  genetic	  scores	  explained	  11%	  and	  2%	  
of	  the	  total	  variance	  in	  LDL-­‐C,	  4%	  and	  5%	  of	  the	  variation	  in	  loge(HDL-­‐C),	  and	  2%	  and	  
2%	  of	  the	  variation	  in	   loge(triglycerides)	   in	  WHII	  and	  IMPROVE,	  respectively	  (Table	  
5.5).	  All	  genetic	  scores	  had	  very	  large	  F-­‐statistics	  (F	  >	  70)	  (Table	  5.5).	  	  
	  
Table	  5.5	  Strength	  of	  genetic	  instruments.	  R2	  and	  F-­‐statistic	  obtained	  from	  the	  first	  stage	  regression	  
between	  lipid	  levels	  and	  the	  respective	  genetic	  scores	  
	  
	  	   	   R2	   F-­‐statistic	   Sample	  Size	  
	  Genetic	  Scores	   	   WHII	   IMPROVE	   WHII	   IMPROVE	   WHII	   IMPROVE	  
Cardiochip	  	   	  
	   	   	   	   	   	  LDL-­‐C	   	   0.13	   0.03	   697	   90	   4635	   3354	  
HDL-­‐C	   	   0.07	   0.05	   371	   181	   4745	   3410	  
Triglycerides	   	   0.07	   0.04	   259	   137	   4760	   3414	  
	  
	  
	   	   	   	   	   	  GLGC	  	   	  
	   	   	   	   	   	  LDL-­‐C	   	   0.11	   0.02	   366	   75	   3005	   3352	  
HDL-­‐C	   	   0.04	   0.05	   143	   194	   3052	   3342	  




Chapter	  5:	  Results	  
	   	   	   	   	   	   	  
	  
177	  
	   	   	  
In	  WHII,	  R2	  and	  F-­‐statistics	  for	  the	  Cardiochip	  scores	  were	  much	  higher	  than	  those	  
in	  IMPROVE	  due	  to	  discovery	  bias	  and	  larger	  sample	  size	  in	  WHII.	  The	  considerably	  
lower	   R2	   values	   for	   the	   LDL-­‐C	   genetic	   score	   in	   IMPROVE	   also	   reflects	   the	   large	  
number	   of	   individuals	   on	   statins.	   For	   individuals	   not	   on	   statin	   medication,	   the	  
Cardiochip	   and	   GLGC	   LDL-­‐C	   genetic	   explained	   7.5%	   and	   6%,	   respectively,	   of	   the	  
total	   variation	   in	   LDL-­‐C	   in	   IMPROVE.	   The	   R2	   values	   from	   the	   association	   of	   each	  
genetic	  score	  with	  all	   three	   lipid	   fractions	  are	  shown	   in	  Figure	  5.3	  and	  Figure	  5.4.	  
Though	  there	  is	  association	  between	  the	  triglyceride	  score	  and	  HDL-­‐C,	  and	  the	  HDL-­‐
C	   score	   and	   triglyceride	   levels,	   the	   scores	   are	  much	   stronger	   instruments	   for	   the	  
lipid	  fraction	  in	  question.	  
	  
5.3.6 Association	  of	  Lipid	  Fractions	  and	  CIMT	  
After	  adjustment	  for	  age,	  sex,	  smoking,	  diabetes	  mellitus	  status	  and	  statin	  use,	  only	  
LDL-­‐C	   and	   HDL-­‐C	  were	   associated	  with	   CIMT	   in	   both	   studies.	   A	   1	  mmol/L	   higher	  
LDL-­‐C	  was	  associated	  with	  0.01	  mm	  (95%	  CI	  =	  0.006	  –	  0.02)	  and	  0.02	  mm	  (95%	  CI	  =	  
0.005	   –	   0.03)	   higher	   CIMT	   in	   WHII	   and	   IMPROVE,	   respectively.	   Associations	   of	  
standardised	  measures,	  unadjusted	  and	  adjusted	  for	  covariates	  are	  shown	  in	  Table	  
5.6.	  	  
	  
5.3.7 Direct	  Association	  of	  Lipid	  Genetic	  Scores	  and	  CIMT	  
Only	   the	   Cardiochip	   and	   GLGC	   LDL-­‐C	   genetic	   scores	   were	   significantly	   associated	  
with	  CIMT	   in	  both	  studies,	  and	   this	   remained	   the	  case	  after	  adjustment	   for	  other	  
lipid	  fractions	  and	  the	  first	  three	  dimensions	  from	  MDS	  (Figure	  5.5).	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Table	  5.6	  Associations	  of	   the	   lipid	   fractions	  with	  CIMT	   in	   the	  WHII	   and	   IMPROVE	   studies.	  Effect	  
sizes	  are	  shown	  as	  SD	  change	  in	  loge-­‐transformed	  CIMT	  per	  1	  SD	  change	  in	  LDL-­‐C,	  loge-­‐transformed	  
HDL-­‐C	   and	   loge-­‐transformed	   triglycerides.	   Association	   is	   shown	   for	   the	   unadjusted	   analysis	   and	  
adjusted	  for	  sex,	  age,	  smoking,	  diabetes	  status	  and	  statin	  use.	  
	  
	  	   	  	   Unadjusted	  
Adjusted	  for	  sex,	  age,	  
smoking,	  diabetes	  status	  
and	  statin	  use	  
Lipid	  Phenotype	   Study	   Beta	  (95%	  CI)	   P	   Beta	  (95%	  CI)	   P	  
Standardised	  LDL-­‐C	  	  
WHII	   0.14	  (0.10	  –	  0.17)	   9x10-­‐14	   0.07	  (0.03,	  0.10)	   0.0002	  
IMPROVE	   0.01	  (-­‐0.02,	  0.04)	   0.54	   0.06	  (0.02,	  0.09)	   0.002	  
	   	   	   	   	   	  
	  	  Standardised	  	  
loge	  (HDL-­‐C)	  
WHII	   -­‐0.07	  (-­‐0.10,	  -­‐0.03)	   0.0003	   -­‐0.06	  (-­‐0.10,	  -­‐0.03)	   0.001	  
IMPROVE	   -­‐0.09	  (-­‐0.12,	  -­‐0.06))	   5.2x10-­‐08	   -­‐0.06	  (-­‐0.09,	  -­‐0.02)	   0.002	  
	   	   	   	   	   	  
	  	  Standardised	  
	  loge(triglycerides)	  
WHII	   0.09	  (0.06,	  0.13)	   1.4x10-­‐07	   0.05	  (0.01,	  0.08)	   0.007	  
IMPROVE	   -­‐0.02	  (-­‐0.05,	  0.02)	   0.36	   -­‐0.02	  (-­‐0.05,	  0.01)	   0.24	  
	  
5.3.8 Causal	  Effect	  Estimation	  using	  2SLS	  
Based	   on	   the	  meta-­‐analysis	   of	   the	   estimates	   derived	   from	   the	   2SLS	   instrumental	  
variable	  analysis,	  a	  1	  mmol/L	  higher	  LDL-­‐C	  was	  associated	  with	  a	  3%	  (beta	  (95%	  CI)	  
=	  0.03	  (0.02	  –	  0.05))	  	  and	  4%	  (beta	  (95%	  CI)	  =	  0.04	  (0.02	  –	  0.06))	  	  higher	  CIMT,	  when	  
using	   the	  Cardiochip	  and	  GLGC	  LDL-­‐C	  genetic	   scores,	   respectively,	  as	   instruments.	  
Taking	  the	  mean	  CIMT	  in	  the	  two	  studies	  (0.8	  mm	  and	  1.2	  mm),	  this	  would	  translate	  
into	   a	   0.02	  –	  0.05	  mm	  difference	   in	  CIMT	  per	  mmol/L	  difference	   in	   LDL-­‐C.	  HDL-­‐C	  
and	   triglycerides	   were	   not	   found	   to	   be	   associated	   with	   CIMT	   using	   instrumental	  
variable	  analysis.	  For	  comparison,	  results	  using	  standardised	  variables	  are	  shown	  in	  
Figure	  5.6.	  There	  was	  no	  change	   in	  the	  overall	   IV	  estimate	  when	  using	   lipid	   levels	  
corrected	  for	  statin	  use	  (Figure	  5.7).	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Figure	  5.5	  Association	  of	   LDL-­‐C,	  HDL-­‐C	  and	   triglyceride	  genetic	   scores	  with	  CIMT.	   (A)	  Unadjusted	  
for	  covariates	  (B)	  adjusted	  for	  first	  three	  principal	  components	  (C)	  adjusted	  for	  the	  first	  3	  dimensions	  
from	   MDS	   and	   non-­‐index	   lipid	   fractions.	   Beta-­‐coefficients	   are	   shown	   as	   SD	   change	   in	   loge-­‐
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Figure	   5.6	   Two-­‐stage	   least	   squares	   regression	   analysis.	   Association	   of	   lipid	   fractions	   with	   CIMT	  
obtained	  from	  the	  instrumental	  variable	  analysis	  in	  which	  lipid	  genetic	  scores	  act	  as	  instruments	  for	  
the	  non-­‐confounded	  effect	  of	  each	   lipid	  fraction.	  Effect	  sizes	  and	  95%	  confidence	   intervals	   in	  each	  
study	  and	  summary	  estimates	  from	  a	  fixed-­‐effect	  model	  are	  shown	  as	  SD	  change	  in	  loge-­‐transformed	  
CIMT	  per	  1	  SD	  change	  in	  LDL-­‐C,	  loge-­‐transformed	  HDL-­‐C	  and	  loge-­‐transformed	  triglycerides.	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Figure	  5.7	  Instrumental	  variable	  analysis	  using	  lipid	  levels	  corrected	  for	  statin	  use.	  Effect	  sizes	  and	  
95%	  confidence	  intervals	  in	  each	  study	  and	  summary	  estimates	  from	  a	  fixed-­‐effect	  model	  are	  shown	  
as	  SD	  change	  in	  loge-­‐transformed	  CIMT	  per	  1	  standard	  deviation	  change	  in	  LDL-­‐C,	  loge-­‐transformed	  
HDL-­‐C	  and	  loge-­‐transformed	  triglycerides.	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5.4 Discussion	  
5.4.1 Summary	  of	  Results	  
LDL-­‐C,	  HDL-­‐C	  and	  triglyceride	  genetic	  scores	  were	  used	  in	  an	  MR	  analysis	  to	  assess	  
the	  causal	  relationship	  between	  each	  lipid	  fraction	  and	  CIMT.	  Though	  there	  was	  a	  
positive	   association	   between	   directly	   measured	   LDL-­‐C	   and	   common	   CIMT	   and	   a	  
negative	  association	  between	  directly	  measured	  HDL-­‐C	  and	  CIMT,	  the	  results	  from	  
the	  MR	  analysis	  support	  a	  causal	  association	  with	  LDL-­‐C	  only.	  Despite	  differences	  in	  
cohort	   characteristics	   (i.e.	   healthier	   individuals	   and	   much	   smaller	   proportion	   on	  
lipid-­‐lowering	  medication	   in	  WHII	   compared	   to	   IMPROVE),	   the	   different	   effect	   of	  
genetic	  score	  on	  lipid	  levels	  (smaller	  in	  the	  IMPROVE	  study)	  and	  the	  different	  SNPS	  
used	   in	   the	   two	   genetic	   scores	   (Cardiochip	   versus	   GLGC),	   the	   causal	   association	  
between	  LDL-­‐C	  and	  CIMT	  was	   found	  to	  be	  consistent	   in	  both	  studies	   for	  both	  the	  
Cardiochip	   and	   GLGC	   genetic	   score	   instruments.	   Although	   the	   HDL-­‐C	   and	  
triglyceride	   genetic	   scores	   explained	   a	   similar	   proportion	   of	   the	   variation	   in	   the	  
index	   trait	   to	   the	   LDL-­‐C	   score	   (not	   taking	   into	   account	   the	   R2	   for	   the	   Cardiochip	  
genetic	  score	  in	  WHII	  which	  was	  inflated	  due	  to	  discovery	  bias),	  there	  was	  a	  lack	  of	  
significant	   effect	   on	   CIMT	   for	   these	   two	   lipid	   fractions.	   The	   findings	   suggest	   that	  
CIMT	   is	   likely	   to	  be	  a	   reliable	   surrogate	  outcome	  measure	   in	   randomised	   trials	  of	  
LDL-­‐lowering	   therapy.	   However,	   due	   to	   the	   lack	   of	   evidence	   in	   the	   genetic	  
association	  between	  HDL-­‐C,	   triglycerides	   and	  CIMT,	   the	   findings	   from	   the	   current	  
analysis	  cast	  doubt	  on	  the	  use	  of	  CIMT	  as	  a	  surrogate	  outcome	  measure	  in	  trials	  of	  
HDL-­‐C	  and	  triglyceride-­‐modifying	  therapies.	  
	  
One	  criterion	  for	  causality	  is	  the	  magnitude	  of	  effect.	  Taking	  the	  mean	  CIMT	  in	  the	  
two	  studies	  (0.8	  mm	  and	  1.2	  mm),	  the	  IV	  beta-­‐coefficients	  estimated	  from	  the	  two	  
genetic	  scores	  would	   translate	   into	  approximately	  a	  0.02	  –	  0.05	  mm	  difference	   in	  
CIMT	   per	   mmol/L	   difference	   in	   LDL-­‐C.	   To	   contextualise	   these	   findings,	   a	   meta-­‐
analysis	  of	  11	  statin	  trials	  (Bedi	  et	  al.	  2010)	  found	  that	  after	  treatment	  with	  statins	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(mean	  treatment	  duration	  of	  25.6	  months),	  there	  was	  a	  significant	  reduction	  in	  the	  
mean	   LDL-­‐C	   (pre-­‐treatment:	   4.36	   ±	   0.85	   mmol/L,	   post-­‐treatment:	   2.64	   ±	   0.72	  
mmol/L,	   P<0.05,	  N=2132)	   and	  also	   a	  0.04	  mm	   (95%	  CI=0.028-­‐0.052)	  difference	   in	  
mean	  CIMT	  between	  statin	  therapy	  arm	  and	  placebo	  arm	  (Bedi	  et	  al.,	  2010).	  This	  is	  
roughly	  equivalent	   to	  a	  0.02mm	  decrease	   in	  CIMT	  per	  mmol/L	  decrease	   in	   LDL-­‐C,	  
and	   therefore	   reasonably	   concordant	   with	   the	   genetically-­‐inferred	   casual	  
association	  from	  the	  current	  analysis.	  
	  
5.4.2 CIMT	  as	  a	  Surrogate	  Marker	  
Randomised	  controlled	  drug	  trials	  with	  hard	  clinical	  end	  points	  require	  a	  very	  large	  
number	  of	  participants	  and	  follow-­‐up	  over	  a	   long	  period,	  making	  them	  technically	  
and	   financially	   challenging.	   As	   a	   result,	   surrogate	   endpoints	   are	   frequently	  
employed	   in	   earlier	   phase	   studies	   to	   inform	   the	   decision	   to	   undertake	   a	   larger	  
outcome	  trial.	  CIMT	  has	  been	  used	  as	  a	  surrogate	  end-­‐point	  in	  many	  trials	  of	  lipid-­‐
modifying	   drugs	   (Crouse	   et	   al.	   2007;	  MacMahon	   et	   al.	   1998;	   Smilde	   et	   al.	   2001;	  
Taylor	   et	   al.	   2004).	   However,	   the	   suitability	   of	   CIMT	   as	   a	   surrogate	   marker	   in	  
cardiovascular	   drug	   trials	   is	   controversial	   (Lorenz	   et	   al.	   2012).	   The	   underlying	  
assumption	  in	  trials	  using	  CIMT	  as	  a	  surrogate	  marker	  is	  that	  the	  rate	  of	  change	  in	  
CIMT	   over	   time	   in	   response	   to	   drug	   therapies	   reflects	   the	   change	   in	   the	   risk	   of	  
cardiovascular	  outcomes.	  The	  majority	  of	  CIMT	  trials,	  however,	  have	  short	  follow-­‐
up	   periods	   and	   modest	   sample	   sizes	   and	   therefore	   lack	   power	   to	   identify	  
associations	   with	   cardiovascular	   outcomes.	   Rather,	   they	   are	   designed	   to	   provide	  
inferences	  on	   cardiovascular	  outcomes	  based	  on	  a	  presumed	   inverse	   relationship	  
between	   atherosclerosis	   progression	   and	   cardiovascular	   benefit	   (Taylor	   et	   al.,	  
2011).	  
	  
A	   recent	   large-­‐scale	   meta-­‐analysis	   of	   41	   randomised	   trials	   assessing	   CIMT	   at	  
baseline	  and	   follow-­‐up	  after	   treatment	   (Costanzo	  et	  al.	  2010),	   including	  a	   total	  of	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18,307	  participants,	   concluded	   that	   regression	  of	  CIMT	   induced	  by	   cardiovascular	  
drug	   therapies	   was	   not	   associated	   with	   a	   reduction	   in	   cardiovascular	   events.	  
Though	   the	   meta-­‐analysis	   was	   technically	   sound,	   the	   heterogeneity	   in	   the	  
interventions	   evaluated,	   the	  methods	   used	   for	   CIMT	  measurement,	   the	   outcome	  
definition,	  study	  design,	  population	  characteristics	  and	  follow-­‐up	  time	  between	  the	  
41	  trials	  may	  have	  reduced	  the	  ability	  to	  detect	  an	  association	  between	  carotid	  IMT	  
and	  cardiovascular	  event	  reductions	  in	  such	  trials.	  On	  the	  other	  hand,	  the	  ACCORD	  
Lipid	   trial	   (Ginsberg	  et	  al.	  2010)	  aimed	  to	   test	  whether	   treatment	  of	  T2D	  patients	  
with	   fenofibrate,	   to	   increase	   plasma	   HDL-­‐C	   and	   reduce	   triglyceride	   levels,	   would	  
result	   in	   additional	   cardiovascular	   benefit	   compared	   with	   simvastatin	   (LDL-­‐
lowering)	   therapy	   alone.	   Though	   the	   addition	   of	   fenofibrates	   to	   statin	   treatment	  
did	   not	   show	   any	   significant	   reduction	   in	   clinical	   events	   in	   the	   placebo	   versus	  
treatment	   groups,	   sub-­‐group	   (defined	  by	  baseline	   lipid	   levels)	   analyses	   suggested	  
benefits	  of	   fenofibrate	   therapy	   in	  mixed	  dyslipidemia	   individuals	   (individuals	  with	  
triglyceride	   levels	   in	   the	   upper	   tertile	   and	   HDL-­‐C	   levels	   in	   the	   lower	   tertile	   at	  
baseline).	   Therefore,	   a	   MR	   analysis	   to	   determine	   causality	   between	   HDL-­‐C,	  
triglycerides	   and	   CIMT	   in	   a	   sufficiently	   large	   mixed	   dyslipidemia	   sample	   may	   be	  
worthwhile.	  
	  
5.4.3 Previous	  Mendelian	  Randomisation	  Studies	  of	  Lipids	  and	  CIMT	  
To	   date	   there	   have	   been	   very	   few	   Mendelian	   randomisation	   studies	   addressing	  
association	  of	  lipids	  with	  CIMT	  or	  CHD.	  A	  study	  by	  Aulchenko	  et	  al	  (Aulchenko	  et	  al.	  
2009)	  generated	  genetic	  scores	  for	  total	  cholesterol	  (11	  SNPS),	  LDL-­‐C	  (8	  SNPs),	  HDL-­‐
C	  (8	  SNPs)	  and	  triglycerides	  (11	  SNPs)	  based	  on	  SNPs	  identified	  in	  a	  meta-­‐analysis	  in	  
around	   20,000	   European	   individuals.	   They	   looked	   at	   the	   direct	   association	   of	   the	  
genetic	  scores	  with	  CIMT	  in	  the	  Rotterdam	  study	  (~5700	  individuals	  over	  the	  age	  of	  
55)	  and	  found	  only	  the	  total	  cholesterol	  genetic	  score	  and	  a	  combined	  score	  with	  all	  
lipid	   SNPs	   to	   be	   associated	  with	   CIMT.	   The	   scores	   explained	   less	   than	   5%	   of	   the	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variation	   in	   each	   of	   the	   respective	   lipid	   fractions.	   However,	   they	   did	   not	   use	   an	  
instrumental	  variable	  approach	  to	  quantify	  the	  causal	  effect.	  	  	  
	  
5.4.4 Previous	  Mendelian	  Randomisation	  Studies	  of	  Lipids	  and	  CVD	  Events	  
Four	  SNPs	  that	  were	  associated	  with	  either	  HDL-­‐C	  or	  triglycerides,	  but	  not	  with	  LDL-­‐
C	  in	  the	  GLGC	  meta-­‐analysis,	  were	  also	  associated	  with	  CAD	  (Teslovich	  et	  al.	  2010).	  
However,	  one	  of	  the	  SNPs	  in	  the	  IRS1	  locus	  was	  also	  associated	  with	  increased	  risk	  
of	  type	  2	  diabetes	  mellitus,	  insulin	  resistance	  and	  hyperinsulinemia.	  Therefore,	  the	  
genes	   in	   these	   loci	  may	  have	  pleiotropic	  effects	  on	  non-­‐lipid	  parameters	   that	   are	  
causal	   for	   CAD	   risk	   reduction	   (Teslovich	   et	   al.	   2010).	   The	   Triglyceride	   Coronary	  
Disease	  Genetics	  Consortium	  and	  Emerging	  Risk	  Factor	  Collaboration	  compared	  the	  
risk	   of	   genetically	   elevated	   triglycerides	   levels	   based	   on	   a	   single	   SNP	   (the	  APOA5	  
SNP	   rs662799)	   among	   over	   20,000	   CHD	   cases	   and	   35,000	   controls	   (Sarwar	   et	   al.	  
2010).	   They	   concluded	   that	   there	   was	   a	   causal	   role	   for	   triglycerides-­‐mediated	  
pathway(s)	   in	   CHD.	   However,	   the	  APOA5	   variant	  was	   also	   associated	  with	   HDL-­‐C	  
levels.	  The	  association	  of	  genetically	  determined	  triglycerides	   levels	  with	  CHD	  was	  
also	  attenuated	   to	   the	  null	  after	  adjusting	  not	  only	   for	  HDL,	  but	  also	   for	  non-­‐HDL	  
cholesterol	   and	   other	   variables.	   Since	   the	   effect	   of	   the	   rs662799	   SNP	   is	   not	  
exclusive	   to	   triglycerides,	   this	   compromises	   one	   key	   assumption	   for	   a	   valid	   MR	  
analysis	  and	  complicates	  the	  inference	  on	  the	  potential	  causal	  role	  of	  triglycerides	  
in	  CHD.	  A	  study	  by	  Voight	  et	  al	  (Voight	  et	  al.	  2012b)	  used	  a	  genetic	  score	  consisting	  
of	   14	   common	   SNPs	   selected	   for	   a	   predominant	   effect	   on	  HDL-­‐C	   and	   tested	   this	  
score	   in	   up	   to	   12,482	   cases	   of	   myocardial	   infarction	   and	   41,331	   controls.	   As	   a	  
positive	   control,	   they	   also	   tested	   a	   genetic	   score	   of	   13	   common	   SNPs	   exclusively	  
associated	  with	  LDL-­‐C.	  They	  found	  no	  casual	  association	  of	  HDL-­‐C	  with	  MI	  but	  were	  
able	  to	  confirm	  an	  association	  of	  LDL-­‐C	  with	  MI.	  A	  study	  currently	  under	  review	  (Do	  
et	  al.	  2013)	  found	  that	  triglycerides	  may	  causally	  effect	  risk	  of	  CAD	  even	  after	  taking	  
into	  account	  any	  pleiotropic	  effects	  of	  triglyceride-­‐associated	  SNPs	  with	  other	  lipid	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fractions,	   and	   therefore	   novel	   therapeutic	   approaches	   to	   triglyceride-­‐rich	  
lipoproteins	   might	   be	   expected	   to	   reduce	   CAD	   risk.	   This	   would	   suggest	   that	  
previous	  failed	  trials	  of	  drugs	  targeting	  triglycerides	  could	  have	  been	  related	  to	  the	  
specific	  drug	  or	  drug	  target,	  or	  the	  use	  of	  an	  unsuitable	  surrogate	  marker	  (i.e.	  CIMT)	  
for	  CVD	  risk.	  
	  
5.4.5 Limitations	  
5.4.5.1 Validity	  of	  Instruments	  
Validity	   of	   any	  MR	   analysis	   may	   be	   compromised	   by	   a)	   population	   stratification,	  
where	  allele	  frequencies	  and	  disease	  rates	  differ	  between	  population	  subgroups;	  b)	  
pleiotropy,	  where	  genetic	   instruments	  affect	  the	  outcome	  through	  more	  than	  one	  
intermediate	   risk	   factor;	   and	   c)	   linkage	   disequilibrium,	   where	   another	  
polymorphism	   in	   close	   proximity	   (and	   in	   linkage	   disequilibrium)	   to	   the	   variant	   of	  
interest,	  is	  causing	  disease	  through	  another	  pathway;	  and	  d)	  weak	  instrument	  bias.	  	  
	  
Analysis	  in	  the	  WHII	  was	  restricted	  to	  Caucasians	  and	  MDS	  revealed	  no	  substantial	  
population	   stratification	   after	   quality	   control	   analysis.	   In	   the	   IMPROVE	   study,	  
though	   all	   individuals	   were	   Caucasians	   there	   was	   population	   stratification	   that	  
reflected	   the	   geographical	   location	   from	   which	   the	   samples	   were	   obtained	  
(Baldassarre	   et	   al.	   2010).	   However,	   the	   SNPs	   used	   to	   generate	   the	   GLGC	   genetic	  
scores	   were	   also	   discovered	   in	   individuals	   of	   European	   descent	   from	   the	   United	  
States,	   Europe	   or	   Australia.	   Therefore,	   the	   scores	   should	   be	   applicable	   to	   the	  
general	  European	  population	  and	  stratification	  is	  less	  likely	  to	  be	  an	  issue	  in	  this	  MR	  
analysis.	   Also,	   adjusting	   for	   population	   stratification	   did	   not	   alter	   the	   overall	  
conclusions	  made	  from	  the	  analysis.	  
	  
Often,	   genes	   act	   on	   multiple	   pathways	   and	   may	   therefore	   be	   associated	   with	  
multiple	  intermediate	  phenotypes,	  especially	  those	  that	  act	  as	  transcription	  factors	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for	  other	  genes.	  Some	  SNPs	  included	  in	  the	  score	  may	  be	  independently	  associated	  
with	   other	   cardiovascular	   risk	   factors	   and	   so	   individually	   they	  would	   not	   be	   valid	  
instruments.	   By	   combining	   these	   multiple	   SNPs	   into	   one	   score	   the	   issue	   of	  
pleiotropy	   can	   be	   addressed.	   This	   was	   demonstrated	   in	   chapter	   4,	   where	   the	  
difference	  in	  the	  proportion	  of	  variance	  explained	  by	  the	  genetic	  score	  in	  the	  index	  
and	   non-­‐index	   traits	  was	  much	   larger	   than	   that	   for	   a	   single	   SNP,	   suggesting	   that	  
when	  a	  large	  number	  of	  genetic	  variants	  are	  combined	  into	  a	  single	  genetic	  score,	  
pleiotropic	  effects	  may	  be	  expected	   to	  balance	  out.	  An	  alternative	   to	  overcoming	  
non-­‐specificity	  would	  be	  to	  only	  use	  SNPs	  associated	  with	  the	  exposure	  of	  interest	  
for	  generating	  the	  genetic	  risk	  score.	  This	  approach	  has	  been	  used	  by	  recent	  work	  
currently	   under	   review	   (Do	   et	   al.	   2013),	   whereby	   a	   genetic	   risk	   score	   for	  
triglycerides	   was	   generated	   using	   SNPs	   that	   showed	   large	   effect	   on	   triglyceride	  
levels	   but	   minimal	   effect	   on	   LDL-­‐C.	   Another	   approach	   used	   in	   this	   study	   to	  
overcome	  pleiotropic	  effects	  of	  SNPs	  was	  to	  use	  the	  residuals	  from	  the	  regression	  
of	  the	  exposure	  of	  interest	  on	  the	  non-­‐specific	  risk	  factors,	  so	  that	  any	  SNP	  effects	  
on	  the	  non-­‐specific	  risk	  factors	  were	  accounted	  for.	  Therefore,	  several	  approaches	  
can	   be	   adopted	   to	   ensure	   that	   the	   problem	   of	   specificity	   of	   the	   instrument	   is	  
appropriately	  addressed.	  
	  
Association	  of	  an	  outcome	  with	  one	  polymorphism	  could	  have	  arisen	  by	  chance	  or	  
confounding	   due	   to	   LD,	   but	   associations	   with	   more	   than	   one	   polymorphism	   in	  
different	   genes	   marking	   the	   same	   exposure	   are	   unlikely	   unless	   the	   exposure	   is	  
causal	  (Lewis	  2010).	  Given	  the	  large	  number	  of	  lipid	  genetic	  variants	  that	  have	  been	  
identified	   by	   different	   studies,	   it	   is	   possible	   to	   generate	   many	   independent	  
combinations	   of	   such	   variants,	   and	   from	   these	   many	   independent	   instrumental	  
variable	  estimates	  of	  the	  causal	  effect	  of	  exposure	  of	  interest	  on	  outcome.	  Both	  the	  
Cardiochip	  and	  GLGC	  genetic	  scores,	  which	  used	  only	  partially	  overlapping	  SNP	  sets,	  
supported	   the	   causal	   association	   of	   LDL-­‐C	   with	   CIMT	   in	   each	   study.	   Using	   two	  
different	  scores	  containing	  only	  partially	  overlapping	  SNPs	  provides	  confidence	  that	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the	  results	  are	  not	  biased	  by	  the	  SNP	  set	  used,	  as	  the	  two	  instruments	  are	  unlikely	  
to	  be	  influenced	  by	  the	  same	  pleiotropy	  or	  LD-­‐induced	  confounding.	  
	  
Though	   the	   instrument	   strength	   of	   the	   Cardiochip	   genetic	   scores	   in	   WHII	   are	  
inflated	   due	   to	   discovery	   bias,	   it	   is	   important	   to	   note	   that	   all	   genetic	   scores	   had	  
comparable	   instrument	   strength	   in	   the	   IMPROVE	   study,	   and	   despite	   the	   HDL-­‐C	  
genetic	   scores	   being	   the	   strongest	   instruments	   in	   this	   cohort,	   causality	   was	   only	  
observed	  for	  LDL-­‐C.	  MR	  analysis	  in	  a	  much	  larger	  sample	  size	  sizes	  would	  be	  needed	  
to	  confirm	  or	  refute	  the	  findings	  for	  HDL-­‐C	  and	  triglycerides	  from	  this	  study.	  
	  
Our	   method	   for	   generating	   genetic	   scores	   makes	   several	   assumptions:	   additive	  
effects	  of	   alleles,	   no	  gene-­‐gene	   interactions	  and	  a	   linear	  effect	  of	   lipids	  on	  CIMT.	  
Though	  not	  explored	   in	   this	  work,	   if	   these	  assumptions	  did	  not	  hold,	   it	  would	  be	  
possible	   to	   incorporate	   such	   knowledge	   into	   the	  model.	   However,	   previous	  work	  
has	   shown	   that	   genetic	   scores	   are	   robust	   even	   in	   the	   presence	   of	   a	   different	  
underlying	  genetic	  model.	  	  
	  
5.4.5.2 Refinement	  of	  Instruments	  
It	  remains	  to	  be	  seen	  whether	  the	  addition	  of	  more	  SNPs	  that	   increase	  the	  HDL-­‐C	  
and	   triglyceride	   instrument	   strength	   will	   alter	   the	   conclusions	   based	   on	   this	  
analysis.	  However,	   the	  effect	   sizes	  of	  additional	   loci	   identified	   in	  very	   large	  meta-­‐
analysis	   tend	   to	   be	   extremely	   small,	   therefore	   addition	   of	   these	   may	   not	  
significantly	  improve	  instrument	  strength.	  	  
	  
Conventional	   laboratory	   measures	   of	   LDL-­‐C,	   HDL-­‐C,	   total	   cholesterol	   and	  
triglycerides	   sum	  up	   the	   lipids	   carried	   in	   lipoprotein	  particles	  of	   various	   sizes	  and	  
composition	   (Tukiainen	   et	   al.	   2012).	   Recent	   developments	   in	   high-­‐throughput	  
analytical	   technologies	   such	   as	   nuclear	   magnetic	   resonance	   (NMR)	   and	   mass	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spectrometry	  allows	  more	  refined	  metabolic	  profiling,	  including	  measurement	  of	  a	  
broader	   range	   of	   lipoprotein	   subclasses.	   Large-­‐scale	   metabolomics	   studies	   have	  
provided	   examples	   of	   SNPs	   associated	   with	   HDL-­‐C	   showing	   associations	   in	   the	  
opposite	   direction	   with	   larger	   and	   smaller	   HDL	   particles	   for	   the	   same	   allele	  
(Tukiainen	   et	   al.	   2012).	   Therefore,	   the	   observed	   heterogeneity	   in	   the	   biological	  
effects	  of	  HDL-­‐C	  and	  triglycerides	  may	  mask	  the	  detection	  of	  any	  true	  association	  
with	  CIMT	  to	  CHD.	  Metabolomic	  studies	  have	  also	  shown	  that	  SNPs	  show	  stronger	  
association	   with,	   and	   explain	   a	   greater	   proportion	   of	   the	   variance	   of	   lipoprotein	  
subclasses	   compared	   to	   enzymatic	   lipid	  measures	   (Tukiainen	  et	   al.	   2012).	   Several	  
studies	   have	   shown	   that	   HDL	   subclasses	   differ	   in	   their	   relationship	   to	   CHD,	   with	  
larger	  HDL	   particles	   thought	   to	   be	  more	   anti-­‐atherogenic	   than	   smaller	   ones	   (Ala-­‐
Korpela	   2008;	   Krauss	   2010;	  Morgan	  et	   al.	   2004).	  MR	   studies	  using	   genetic	   scores	  
representative	   of	   the	   specific	   lipoprotein	   subclasses	  would	   therefore	   be	   a	   logical	  
future	  direction.	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6 Discussion	  
The	  key	  aim	  of	  cardiovascular	  disease	  genetics	  has	  been	  to	  correlate	  genotype	  with	  
phenotype	  in	  order	  to	  identify	  the	  genes	  and	  sequence	  changes	  contributing	  to	  trait	  
variation	  and	  disease	  susceptibility	  in	  humans	  and,	  in	  doing	  so,	  provide	  insight	  into	  
the	   biological	   mechanisms	   involved	   in	   disease	   development	   (Kathiresan	   &	  
Srivastava	  2012).	  Large-­‐scale	  association	  studies	  have	  identified	  numerous	  common	  
genetic	   variants	   associated	   with	   CVD	   traits	   and	   risk	   factors.	   Some	   of	   the	   better	  
studied	   traits	   include	   lipids,	   blood	   pressure,	   CAD,	  MI	   and	   stroke.	   However,	   there	  
are	   still	  many	   important	  CVD	   risk	   factors	   that	   have	  not	   been	  extensively	   studied,	  
and	  large-­‐scale	  genetic	  discovery	  has	  the	  potential	  to	  provide	  new	  insight	  into	  the	  
biological	  pathways	  responsible	  for	  variation	  in	  these	  traits.	  For	  risk	  factors	  where	  a	  
large	   number	   of	   genetic	   variants	   have	   already	   been	   identified,	   there	   is	   great	  
interest	  in	  exploring	  how	  these	  can	  be	  applied,	  not	  only	  for	  disease	  risk	  prediction	  
but	  also	  for	  assessing	  causal	  disease	  pathways.	  The	  aims	  of	  the	  work	  in	  this	  thesis	  
were	  therefore	  two-­‐fold:	  first,	  discovery	  of	  genetic	  variants	  influencing	  variation	  in	  
left	   ventricular	  mass,	   an	   important	   CVD	   risk	   factor	   for	   which	   the	   few	   large-­‐scale	  
association	   studies	   that	   have	   previously	   been	   carried	   out	   have	   not	   been	   very	  
successful,	  and	  second,	  investigating	  the	  application	  of	  prior	  knowledge	  of	  the	  large	  
number	   of	   genetic	   variants	   associated	   with	   well-­‐studied	   lipid	   traits	   for	   risk	  
prediction	  and	  Mendelian	  randomisation	  analysis.	  
	  
In	  chapter	  2,	  I	  presented	  the	  results	  from	  an	  association	  analysis	  with	  ECG-­‐derived	  
LV	   mass,	   a	   convenient	   clinical	   measure	   of	   LVH.	   Genetic	   variants	   in	   four	   genes	  
(SCN5A,	  IGF1R,	  PTGES3	  and	  NMB)	  were	  robustly	  associated	  with	  one	  or	  more	  of	  the	  
ECG	  LV	  mass	  indices.	  Other	  plausible	  loci,	  such	  as	  SNPs	  in	  sarcomeric	  genes,	  showed	  
suggestive	   association,	   and	   larger	   studies	   would	   be	   needed	   to	   confirm	   or	   refute	  
these	  associations.	  There	  is	  some	  evidence	  based	  on	  ENCODE	  data	  that	  some	  of	  the	  
identified	   variants	   are	   within	   regulatory	   regions.	   However,	   a	   variant	   can	   have	   a	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direct	  effect	  on	  gene	  expression	  in	  human	  tissues	  or	  be	  functional	  in	  another	  way,	  
without	   necessarily	   having	   a	   causal	   effect	   on	   the	   trait	   (Kathiresan	   &	   Srivastava	  
2012).	  	  
	  
A	  combination	  of	  fine-­‐mapping	  of	  the	  identified	  loci,	  either	  through	  imputation	  or	  
sequencing,	  and	  functional	  experiments	  would	  be	  required	  to	  identify	  (1)	  the	  causal	  
gene	  (2)	  the	  causal	  variant	  (3)	  the	  mechanism	  by	  which	  the	  variant	  affects	  the	  gene	  
and	  (4)	  the	  mechanism	  by	  which	  the	  gene	  affects	  phenotype,	  making	  the	  road	  from	  
genotype	   to	   phenotype	   a	   potentially	   long	   and	   arduous	   one.	   The	   chromosome	  
9p21.3	   locus	  which	  was	   first	   associated	  with	   CAD	   and	  MI	   in	   2007	   (Samani	   et	   al.	  
2007;	  McPherson	  et	  al.	  2007;	  Helgadottir	  et	  al.	  2007)	  provides	  an	  extreme	  example	  
of	   the	   difficulties	   that	   may	   be	   encountered	   partly	   perhaps	   because	   the	   most	  
strongly	  associated	  SNPs	  are	  non-­‐coding	  and	  over	  100	  kilobases	  downstream	  of	  the	  
nearest	  protein-­‐coding	  genes	  CDKN2A	  and	  CDKN2B	   (both	  cyclin-­‐dependent	  kinase	  
inhibitors	   with	   a	   role	   in	   cell-­‐cycle	   regulation).	   Re-­‐sequencing	   and	   fine-­‐mapping	  
studies	   in	   this	   region	  were	   unable	   to	   identify	   a	   causal	   variant	   (Shea	   et	   al.	   2011).	  
Alteration	   of	   a	   non-­‐coding	   RNA	   (antisense	   non-­‐coding	   RNA	   in	   the	   INK4	   locus	  
(ANRIL)),	   and	   disruption	   of	   binding	   of	   the	   STAT1	   transcription	   factor	   binding	  
(Harismendy	   et	   al.	   2011;	   Holdt	   &	   Teupser	   2012)	   have	   both	   been	   explored	   as	  
potential	  mechanisms	  by	  which	  the	  non-­‐coding	  variants	  may	  alter	  susceptibility	  to	  
CAD,	   but	   no	   definitive	   answers	   have	   yet	   emerged.	   Variants	   in	   this	   region	   have	  
shown	   to	   be	   independently	   associated	  with	   expression	   of	  CDKN2A,	   CDKN2B,	   and	  
ANRIL,	  with	   individual	  SNPs	   influencing	  ANRIL	  and	  CDKN2B	  expression	   in	  opposite	  
directions,	   suggesting	   that	   modulation	   of	   ANRIL	   expression	   may	   mediate	  
susceptibility	   to	   disease	   (Cunnington	   et	   al.	   2010).	   A	   recent	   eQTL	   study	   found	   the	  
9p21	   locus	   to	   be	   associated	   with	   the	   expression	   of	   multiple	   genes	   enriched	   for	  
biomarkers	   of	   myocardial	   infarction,	   response	   to	   wounding	   and	   inflammatory	  
processes.	  However,	   none	  of	   the	   genes	   identified	   as	  having	   altered	  expression	   in	  
association	   with	   the	   9p21.3	   risk	   allele	   remained	   significant	   after	   correction	   for	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multiple	  comparisons	  (Pilbrow	  et	  al.	  2012).	  An	  independent	  study	  showed	  that	  the	  
locus	   had	   no	   effect	   on	   a	   wide	   range	   of	   known	   and	   putative	   CVD	   biomarkers	  
(Angelakopoulou	  et	  al.	  2012).	  Six	  years	  on,	   the	   functional	   relevance	  of	   this	   region	  
for	  CAD	  is	  therefore	  yet	  to	  be	  determined.	  	  	  
	  
Genetic	   association	   studies	   have	   identified	   over	   100	   loci	   associated	   with	   one	   or	  
more	  of	  the	  major	  lipid	  fractions,	  providing	  substantial	  biological	  insights	  into	  lipid	  
biology.	  However,	  as	  was	  shown	   in	  chapter	  3,	   their	  performance	   in	  discriminating	  
individuals	  with	   high	   absolute	   risk	   of	   CVD,	   those	   that	   require	   lipid	  medication	   to	  
manage	   CVD	   risk	   and	   those	   that	   develop	   CHD	   is	   poor,	   offering	   no	   improvement	  
over	   non-­‐genetic	   factors.	   This	  may	   reflect	   the	   fact	   that	   the	   proportion	   of	   overall	  
phenotypic	   variance	   explained	   by	   the	   combined	   effects	   of	   the	   variants	   used	   is	  
relatively	   small.	   	   In	   addition,	   the	   distribution	   of	   CVD	   risk	   alleles	   in	   the	   general	  
population	  is	  normal,	  therefore,	  more	  disease	  events	  are	  observed	  among	  the	  large	  
majority	  who	  have	  intermediate	  numbers	  of	  risk	  alleles	  than	  the	  minority	  who	  have	  
a	   large	   number	   of	   risk	   alleles	   and	   are	   therefore	   considered	   to	   be	   at	   high	   risk	   of	  
disease	  —	   the	   prevention	   paradox	   (Rose	   1985).	  More	   recent	  methodologies	   that	  
analyse	   all	   SNPs	   simultaneously	   have	   shown	   that	   the	   SNPs	   on	   the	   genotyping	  
platform	  explain	  a	  much	   larger	  proportion	  of	   the	  phenotypic	  variance	   (Yang	  et	  al.	  
2010)	   than	   is	   estimated	   from	   SNPs	   selected	   based	   on	   some	   significance	   criteria.	  
Extending	   such	   methodology	   to	   risk	   prediction	   may	   improve	   predictive	  
performance.	   A	   recent	   study	   assessing	   the	   performance	   of	   risk	   prediction	   by	  
polygenic	   models	   showed	   that	   the	   predictive	   ability	   depends	   on	   both	   the	   total	  
heritability	   of	   phenotype	   as	   well	   as	   the	   underlying	   effect-­‐size	   distributions	  
(Chatterjee	   et	   al.	   2013).	   They	   show	   that	   under	   the	   most	   likely	   effect-­‐size	  
distributions,	   the	   optimal	   significance	   threshold	   for	   selecting	   SNPs	   for	   prediction	  
models	   in	   large	   GWAS	   can	   be	   much	   less	   stringent	   than	   the	   standard	   (p-­‐value	   <	  
5x10-­‐08)	  used	  in	  discovery	  association	  analyses.	  They	  also	  concluded	  that	  the	  effect-­‐
size	  distributions	  of	  genetic	  variants	  from	  large	  GWAS	  suggest	  that	  though	  increase	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in	  total	  sample	  size	  of	  the	  training	  dataset	  will	  improve	  risk	  prediction	  models,	  the	  
improvement	  will	  be	  slow	  and	  modest	  even	  when	  common	  SNPs	  account	  for	  large	  
proportion	  of	  heritability	  of	   the	  underlying	   traits	   (Chatterjee	  et	   al.	   2013).	   Though	  
such	   polygenic	   models	   may	   not	   achieve	   high	   discriminatory	   power,	   it	   is	   worth	  
noting	  that	  even	  models	  with	  modest	  discriminatory	  power	  may	  provide	  important	  
stratification	   for	   absolute	   risk	   (Chatterjee	   et	   al.	   2013).	   Development	   of	   robust	  
prediction	  models	  in	  the	  future	  will	  need	  to	  consider	  integrating	  both	  common	  and	  
rare	  alleles	  as	  well	  as	  other	  non-­‐genetic	  CVD	  risk	  factors.	  	  
	  
More	   recently,	   there	  has	  been	  a	   lot	  of	   interest	   in	   identifying	  suitable	   instruments	  
that	   can	   be	   used	   to	   distinguish	   causal	   from	   non-­‐causal	   biomarkers	   of	   disease.	  
Though	  both	  types	  are	  useful	  for	  predicting	  disease	  risk,	  only	  causal	  biomarkers	  are	  
a	   suitable	  as	   therapeutic	   targets.	   In	   chapter	  4,	   I	   explored	  different	  approaches	   to	  
instrument	   development	   for	   LDL-­‐C,	   HDL-­‐C	   and	   triglycerides,	   all	   of	   which	   are	  
polygenic	  traits	  with	  multiple	  associated	  SNPs.	  A	  weighted	  genetic	  score	  based	  on	  
SNPs	  selected	  using	  variable	   selection	  with	   the	  Bayesian	   Information	  Criterion	   for	  
model	   selection	   and	   Ridge	   regression	   for	   shrinkage	   of	   beta	   coefficients	   provided	  
the	   best	   instrument	   in	   terms	   of	   strength	   and	   specificity.	   These	   lipid	   instruments	  
were	  then	  applied	  in	  an	  MR	  analysis	  to	  assess	  the	  causal	  relationship	  between	  the	  
three	  lipid	  fractions	  and	  CIMT	  in	  two	  cohorts	  (chapter	  5).	  Completely	  independent	  
weighted	  genetic	  scores	  based	  on	  SNPs	  and	  beta-­‐coefficients	  identified	  by	  the	  GLGC	  
meta-­‐analysis	  were	  also	  used	  as	  instruments.	  LDL-­‐C	  was	  found	  to	  be	  a	  casual	  factor	  
in	   both	   studies	   regardless	   of	   which	   genetic	   score	   instrument	   was	   used,	   but	   no	  
robust	   causal	   association	   was	   found	   with	   HDL-­‐C	   and	   triglycerides.	   This	   would	  
suggest	  that	  for	  trials	  of	  therapeutic	  interventions	  targeting	  HDL-­‐C	  and	  triglycerides	  
levels,	   CIMT	  may	  not	  be	   a	   suitable	   surrogate	  marker	   for	   assessing	   the	  efficacy	  of	  
such	   drugs	   in	   reducing	   CHD	   risk.	   However,	   larger	   studies	   are	   needed	   to	   confirm	  
these	  findings.	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It	  still	  remains	  to	  be	  confirmed	  whether	  these	  two	  lipid	  fractions	  are	  causal	  for	  CHD.	  
Two	   clinical	   trials	   involving	   therapeutic	   elevations	   of	   HDL-­‐C	   on	   patients	   on	   statin	  
therapy	   were	   prematurely	   terminated	   based	   on	   the	   failure	   to	   improve	  
cardiovascular	  outcomes,	   including	  MI	  and	  stroke.	  The	  AIM-­‐HIGH	  study	   (Boden	  et	  
al.	  2011)	  was	  conducted	  with	  niacin,	  the	  most	  effective	  HDL-­‐C-­‐raising	  drug	  currently	  
on	   the	   market;	   the	   dal-­‐OUTCOMES	   study	   (Schwartz	   et	   al.	   2009)	   involved	  
dalcetrapib,	   a	   drug	   in	   development	   that	   partially	   inhibits	   CETP,	   which	   transfers	  
cholesterol	  from	  HDL	  to	  VLDL	  or	  LDL.	  A	  recent	  MR	  analysis	  used	  a	  single	  SNP	  as	  well	  
as	   a	   14-­‐SNP	   genetic	   score	   as	   an	   instrument	   for	   HDL-­‐C	   and	   found	   no	   casual	  
association	   with	   risk	   of	   MI	   in	   around	   12,500	   cases	   and	   over	   41,000	   controls,	  
challenging	  the	  concept	  that	  therapeutic	  interventions	  that	  specifically	  raise	  plasma	  
HDL-­‐C	  will	  translate	  into	  reductions	  in	  risk	  of	  MI	  (Voight	  et	  al.	  2012).	  These	  would	  
suggest	   that	   HDL-­‐C	   may	   simply	   be	   a	   risk	   marker	   and	   not	   a	   causal	   risk	   mediator	  
(Rader	   &	   Tall	   2012).	   However,	   a	   small	   study	   recently	   published	   results	   on	   the	  
effects	   of	   niacin	   on	   HDL	   function.	   They	   assessed	   functional	   properties	   using	   two	  
tests	  -­‐	  cholesterol	  efflux	  capacity	  (a	  measure	  of	  how	  well	  HDL	  removes	  cholesterol	  
from	   lipid-­‐loaded	   cells)	   and	   the	   HDL	   inflammatory	   index	   (which	   quantifies	   the	  
antioxidant	   properties	   as	   it	   relates	   to	   preventing	   the	   oxidation	   of	   LDL).	   Though	  
treatment	   of	   patients	   on	   statins	   with	   niacin	   increased	   HDL-­‐C	   levels	   by	   29%	  
compared	   to	   only	   a	   2%	   increase	   in	   those	  without	   niacin,	   they	   saw	   no	   significant	  
changes	   in	   HDL	   function.	   Another	   MR	   analysis	   found	   non-­‐fasting	   remnant	  
cholesterol	   to	   be	   causally	   associated	   with	   ischemic	   heart	   disease	   (Varbo	   et	   al.	  
2011).	   Remnant	   cholesterol	   is	   the	   cholesterol	   content	   of	   triglyceride-­‐rich	  
lipoproteins,	  composed	  of	  very	  low-­‐density	  lipoproteins	  and	  chylomicron	  remnants	  
in	  the	  nonfasting	  state.	  This	  study	  suggests	  that	  the	  elevated	  cholesterol	  content	  of	  
triglyceride-­‐rich	  lipoprotein	  particles	  causes	  ischemic	  heart	  disease.	  However,	  given	  
the	  pleiotropic	  effects	  of	  the	  genetic	  variants	  studied,	  these	  findings	  would	  need	  to	  
be	   confirmed	   using	   additional	   genetic	   variants	   and/or	   randomized	   intervention	  
trials	  (Varbo	  et	  al.	  2013).	  In	  light	  of	  these	  new	  studies,	  it	  has	  become	  apparent	  that	  
Discussion	  
	   	   	   	   	   	   	  
	  
197	  
	   	   	  
shifting	   focus	   from	   HDL-­‐C	   levels	   to	   HDL	   function	   or	   other	   lipid	   and	   lipoprotein	  
subclasses	   will	   be	   imminent	   in	   future	   research	   on	   lipids	   in	   relation	   to	   CVD.	   The	  
mechanism	  by	  which	  HDL-­‐C	   is	   elevated	  may	  be	  equally	   important	   and	  drugs	   that	  
raise	  HDL-­‐C	  through	  alternative	  mechanisms	  may	  still	  be	  useful.	  With	  enhances	   in	  
high-­‐throughput	  analytical	  technologies	  such	  as	  mass	  spectrometry,	  it	  has	  become	  
feasible	   to	   measure	   a	   much	   broader	   range	   of	   	   lipoprotein	   subclasses	   in	   large	  
cohorts	   (Tukiainen	  et	   al.	   2012).	  Already,	   several	  UK	  population	   cohorts	   (including	  
WHII	  and	  BWHHS)	  have	  begun	  metabolic	  profiling	  of	  individuals,	  with	  the	  potential	  
to	  further	  dissect	  the	  lipid	  metabolic	  pathway	  in	  relation	  to	  CVD	  outcome	  and	  drug	  
development	  strategies.	  
	  
In	   the	   future,	   larger	   collaborations;	   newer	   analytical	   methods;	   analysis	   of	   other	  
types	  of	  genetic	  variants	  (rare	  variants	  and	  CNVs);	   integration	  of	  genetic,	  genomic	  
and	   metabolomic	   data;	   functional	   experiments;	   and	   the	   availability	   of	   more	  
affordable	   next-­‐generation	   sequencing	   technology	   will	   all	   ensure	   continued	  
progression	   in	   biological	   discovery	   and	   research	   into	   the	   utility	   of	   genetic	   risk	  
factors	  for	  complex	  CVD	  traits.	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